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ABSTRACT
The current treatment methods in cancer are associated with toxicity in healthy 
tissues, partial therapeutic response, drug resistance and finally recurrence of the disease. 
The cancer drugs are challenged by non-specific binding, undesired toxicity in healthy 
cells, low therapeutic index and finally poor therapeutic outcome. In this work, a 
targeted nanoscale therapeutic system Antibody Drug Nanoparticle (ADN) was 
engineered to selectively inhibit the breast cancer cell growth with reduced toxicity in 
healthy cells. The ADNs were designed by synthesizing rod shaped nanoparticles using 
pure chemotherapeutic drug and covalently conjugating a therapeutic monoclonal 
antibody (mAb) on the surface of the drug nanorods. The rod shaped nanosized 
formulation of ADNs significantly enhanced the aqueous phase stability and therapeutic 
payload of the system while the conjugated mAb was utilized for specific targeting of 
breast cancer cells. The designed ADN was effective for active targeting and synergistic 
inhibition of breast cancer cells. The mechanisms of actions of ADN was investigated at 
the cellular, molecular and genetic levels in cancer cells. The engineered ADN 
synergistically inhibited the growth of >80% of the human epidermal growth factor 
receptor 2 (HER2) - positive breast cancer cells in vitro. The cell cycle and protein 
expression analysis showed that ADN arrested the cellular growth for a prolonged time 
and induced a programmed cell death mechanism in HER2-positive breast cancer cells in 
vitro. Finally, the gene regulatory analysis showed the genetic mechanisms of 
programmed cell death regulation induced by ADN in breast cancer cell lines.
v
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1.1. NANOTECHNOLOGY IN CANCER
In 2020, cancer is still the second leading cause of death in the United States. It 
was estimated that in 2019, close to 1.8 million new cases of cancer were expected to be 
diagnosed in the U.S. and over 0.6 million people would die from the disease1. The 
conventional treatment methods in cancer are still associated with poor diagnostics, 
toxicity to the normal cells and drug resistance. The limitations in conventional 
therapeutic methods promoted the use of nanoparticles as cancer therapeutics for safer 
and more efficacious treatment 2. The term “Nanotechnology” is defined as the 
“intentional design, characterization, production, and applications of materials, structures, 
devices, and systems by controlling their size and shape in the nanoscale range” 3,4 The 
concept of nanotechnology in cancer has shifted the paradigm of developing cancer 
drugs. The cancer nanomedicine field aims to utilize the multifunctional novel physical 
characteristics of nanosized materials for the diagnostic and therapeutic application at the 
molecular level 5. In cancer treatment, nanomaterials are being engineered to enhance the 
transport property of therapeutic agents and diagnostic tools through the complex 
biological barriers and to aid the interaction with biomolecules. The unique 
characteristics of nanomaterials, for example, high surface area to volume ratio, surface 
physical and chemical characteristics depending on variable sizes or shapes, tunable 
optical, magnetic and electronic properties have made the use of nanomedicine more 
appealing in cancer treatment than the contemporary atomic or macroscale materials 6,7 
These characteristics of nanomaterials are potentially being applied in drug delivery,
diagnosis of early-stage cancer, imaging and tracking the progression of tumor 
formation, development of anti-cancer nano-vaccine therapeutics. The current Food and 
Drug Administration (FDA) approved and clinically used nanomaterials with size ranging 
from 1-100 nm for cancer treatment shown in Figure 1.1 can be categorized into 
inorganic and organic nanoparticle platforms 5’8,9.
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Figure 1.1. Inorganic and organic nanomaterials used in cancer therapy 5
The inorganic nanoparticles comprises mostly carbon nanotubes, fullerenes, 
quantum dots and multifunctional metal nanoparticles 5. A combination of materials 
integrating a wide range of physical and chemical properties into a single system has 
enabled the design of novel inorganic materials for cancer treatment. The organic 
nanomaterials include polymers, lipids, micelles, dendrimers, small protein molecules
and nucleic acid based nano assemblies 8. The hydrophilic surface and biocompatibility 
of organic nanomaterials have made them highly potential therapeutics for cancer 
treatment.
1.2. CURRENT TREATMENT METHODS IN CANCER
1.2.1. Surgery. Surgery is conducted to diagnose, characterize and treat cancer. A 
revolution in cancer surgery arose in 1957 marking the beginning of cancer surgery based 
on laboratory research and clinical trial outcomes 10. The studies showed that the 
bloodstream plays a major role in the dissemination of cancer and regional surgical 
therapies are not enough for improving the survival of patients 11. A scientific basis of 
cancer surgery was established and the studies justified less radical surgery and systemic 
therapy after surgery 10. Currently, surgeries are conducted in cancer treatment in 
combination with other treatment strategies e.g., radiation therapy, chemotherapy at 
different stages of cancer treatment. Initially, surgical biopsies are performed by taking 
out a tissue sample from the possibly affected organ and checking the sample under a 
microscope or by performing necessary pathological tests on the sample. After an initial 
positive diagnosis of cancer, staging surgery may be performed to investigate the extent 
of cancer cell dissemination in the primary organ or to the distant secondary sites (known 
as metastasis). Curative surgeries are operated in order to remove the tumor that has 
spread in a confined area. If the cancer has spread covering a lot of areas and is very 
close to sensitive organs then surgery is conducted to debulk a portion of the affected site 
known as debulking surgery. The rest of the cancer cells are treated by radiation or 
chemotherapy. In ovarian cancer and some lymphoma, debulking is a common surgical
3
procedure. Palliative surgery helps the patients get rid of any form of side effects of 
cancer treatment and to continue with the ongoing treatment.
1.2.2. Radiation Therapy. Radiation therapy involves high energy particles or 
waves to damage or destroy the cancer cells. The therapy might involve delivery of 
radioactive particles or substances, engineered nanomaterials accumulating in the tumor 
site and consequent ablation of substances by radiation to exert therapeutic effect 10,12-15. 
In the U.S. about 60% of the cancer patients receive radiation treatment at some point of 
the systemic cancer treatment 16. Radiation damages the DNA of the cancer cells and 
inhibit the growth 16-18. The therapy also affects the normal cells but most of the slow 
growing normal cells are able to fix the damage and go back to their normal functioning. 
As the cancer cells are rapidly dividing cells and replicate their DNA more often than the 
normal cells, the toxic effect is more dominant on the cancer cells upon DNA damage.
The radiation therapy is conducted in a confined tumor area. The objective of the 
radiation therapy in cancer treatment is to eradicate maximally possible cancer cells while 
minimal killing of normal cells 19. The precise removal of tumor cells with minimally 
affecting the normal tissues is achieved by the advancements in the radiation treatment 
technologies such as intensity modulated radiation therapy (IMRT)20, image guided 
radiation therapy (IGRT) 21, stereotactic body radiation therapy (SBRT)22 and Delta4 
Discoverer16. These technologies offer precise and controlled damage of tumor site 
leaving a large portion of normal cells. Moreover, advancement in imaging technologies 
such as positron emission tomography-computed tomography (PET-CT)23,24, MRI 25,26 
and pretreatment CT enhanced the efficacy of radiation therapy 27 Radiation therapy is 
used in combination with surgery or chemotherapy to treat cancer patients.
4
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1.2.3. Chemotherapy. While surgery and radiation therapy can treat localized 
tumors spreading over a smaller area and are unable to treat metastasized tumors, 
chemotherapy can reach to every organ in the body in an effort to cure cancer. 
Chemotherapy is the major form of treatment method for both the localized and 
metastasized cancer across all cancer types28. Conventional chemotherapeutic drugs are 
associated with poor aqueous phase solubility, non-specificity and multi drug resistance. 
Because of the lack of solubility the chemotherapeutics are required to administer with 
solvents causing severe toxicity. The non-selective chemo drugs affect the fast growing 
healthy cells in the body and cause poor survival rate following the treatment. Moreover, 
multi drug resistance mechanism causes transport of the drug molecules out of the cancer 
cells through enhanced activity of efflux pump molecules such as P-glycoproteins in 
cancer cell membrane which causes partial therapeutic response or cancer recurrence. 
Despite the therapeutic limitations and severe toxicity chemotherapeutic drugs are being 
used ubiquitously in cancer treatment as a first line of defense and in some cancers non 
targeted chemo drugs are the only treatment option because of lacking of any targetable 
surface biomarker. For example, in triple negative breast cancer non targeted 
chemotherapy is still the sole option for treatment 29. Several chemotherapeutic drugs 
have been approved by FDA and are being used clinically either alone or in combination 
with another chemotherapeutic drug. Chemotherapeutic drugs have wide range of 
mechanisms of action. The alkylating agent drug class impair cancer cell growth by 
alkylating specific sites on protein molecules, DNA and RNA30. Their activity mostly 
depends on the relatively fast duplication rate of the cancer cells. The common clinically 
used alkylating agent drugs include nitrogen mustards, platinum complexes (Cisplatin,
Carboplatin), nitrosoureas and many others 31. Hyperactive DNA repair mechanism and 
efficient glutathione conjugation in cancer cells cause resistance to alkylating agent 
drugs32. The antimetabolites, for example, 5- fluorouracil interfere with the DNA 
synthesis and inhibit the cancer cell growth 33. Bleomycin, a member of antitumor 
antibiotics drug class intercalates DNA, forms free oxygen radicals causing DNA breaks 
and cell growth inhibition34,35. The anthracycline antibiotics such as Doxorubicin cause 
intercalation between the base pairs of DNA and specifically inhibit the DNA 
topoisomerases I and II resulting in cell growth arrest 36. The epipodophyllotoxin drugs 
inhibit the cell growth by stabilizing the DNA topoisomerase II complex37. Vinca 
alkaloid chemo drugs dissemble the microtubule assembly and block the polymerization 
of microtubules resulting in cell growth inhibition38. In contrast to the mechanisms of 
vinca alkaloids which cause microtubule disassembly, Taxanes such as Paclitaxel and 
Docetaxel promote microtubule assembly and stabilization resulting in cell growth arrest 
in mitosis phase 39,40. Alkaloid camptothecin semi-synthetic analogs such as Irinotecan 
and Topotecan cause interruption in DNA replication elongation phase and inhibit 
topoisomerase I resulting in cell growth inhibition 41,42.
1.2.4. Cancer Immunotherapy. Cancer immunotherapy is a relatively recent 
therapeutic strategy that involves activating, boosting or engineering the immune cells to 
recognize malignant tumor cells and fight them43. Immune cells are programmed to kill 
any malignant cells or foreign they encounter. However, as the cancer cells evolve from 
normal cell phenotype of our own body, the immune system cannot see them as foreign 
or malignant. Sometimes the cancer cells impose a brake on the activity of these immune 
cells. Moreover, the aggressive form of cancer tissue surpasses the capability of immune
6
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cells to fight them. Several strategies have been adopted over the years to stimulate the 
activity of immune cells to fight against cancer. The checkpoint inhibitor 
immunotherapeutic drugs (e.g., anti-PD1/PDL1, anti-CTLA4) take the brakes off the 
immune cells and help them recognize and attack the cancer cells44-47. In chimeric antigen 
receptor (CAR)-T cell therapy, cytotoxic T cells from patients’ blood are drawn, 
modified in the laboratory condition to recognize specific marker on the malignant cell 
surface and reintroduced into the individual again. The modified T cells now attack only 
the malignant cells that they were trained to attack43. However, the CAR-T therapy is 
currently not therapeutically effective in treatment of solid tumors and limited to 
refractory hematological malignancies48. There are drugs that boost the immune cells to 
fight against cancers known as immunomodulatory drugs, are widely used in cancer 
treatment. Targeted therapeutic mAb e.g., Trastuzumab recognize a specific antigen or 
biomarker and inhibit the growth of cancer cells49. Therapeutics involving cancer 
vaccines, oncolytic viruses, and cytokine delivery are also novel immunotherapeutic 
strategies to fight cancer50.
1.3. NANOPARTICLE BASED THERAPEUTICS IN CANCER TREATMENT
Therapeutic molecules including small molecule drugs, chemotherapeutic drugs, 
RNA interference molecules are being integrated with nanosized drug delivery vehicle 
systems and utilized for cancer treatment. The drug encapsulated nanocarriers facilitate 
the entry of therapeutics into the tumor tissue by providing with improved solubility in 
physiological conditions inside the blood vessel, enhanced bio-availability and bio­
distribution. The selective targeting of cancer tissue with minimal effect on the healthy
cells can be achieved by utilizing the concepts of “passive” and “active” targeting 
principles of cancer therapeutics (Figure 1.2).
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Figure 1.2. A representation of passive and active targeting of nanoparticle based
cancer therapeutics 51
• Passive targeting and EPR effect: In passive targeting approach, nanocarriers 
utilize the defective “leaky” tumor blood vessels and poor lymphatic drainage system in 
the vicinity of solid tumor. These characteristics of the tumor microenvironment allow 
the preferential accumulation of nanoparticles in the tumor site, a phenomenon known as 
enhanced permeability and retention (EPR) effect 52.
• Advantages and limitations of passive targeting: The nanocarriers used in drug 
formulation provide the system with a better pharmacokinetics profile, enhanced 
solubility of drugs, improved toxicological profile. For example, the polymeric 
nanoparticle formulations used in clinically approved drugs showed the characteristics of 
water solubility, non-toxicity and biodegradability. Moreover, the EPR mechanism
allowed the formulation to selectively accumulate in the cancer site. Polymeric micelles 
have been proven to be a suitable carrier of the water insoluble drug. The self-assembling 
system is easy to modify, biocompatible, biodegradable and has a good targeting 
potential. Liposomes are another class of cancer drug nanocarrier having a self­
assembling colloidal structure composed of lipid bilayers. The drug nanocarrier system is 
biocompatible, easier for surface modification and has good potential for selective 
targeting of tumor cells. Dendrimers nanocarriers can provide high ligand density, 
tunable pharmacokinetics and bio-distribution profile. The system is convenient to 
functionalize and has high structural and chemical homogeneity. Taken together, 
integration of nanotechnology in the drug delivery system has shifted the paradigm of 
cancer drug design and development. However, only 15 passively targeted nanoparticle 
based drugs were in clinical practice till 2018. Instability in circulation, premature drug 
release, toxicity to normal cells, poor oral bioavailability, insufficient accumulation of 
drugs at the cancer site have caused hindrances in clinical translation of nanoparticle 
based cancer therapeutics. Moreover, the understanding is limited by the poorly known 
mechanisms of complex nano-bio interactions in the tumor microenvironment. The other 
potential causes limiting the therapeutic efficacy of nanoparticle based drugs can largely 
be attributed to the heterogeneity in permeability in tumor blood vessels, poor tumor 
penetration, hypoxia and angiogenesis, and poor intracellular endosomal escape 
capability of the drug. In addition to that, a major portion of the nanoparticle therapeutics 
are cleared by the phagocytic systems, hepatocytes, kupffer cells while some physically 
cannot get through the sinusoids of the liver.
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• Current passively targeted nanoparticle based therapeutics: Till November, 
2018, only 15 passively targeted drugs got approval for cancer treatment 53. Doxil 
(PEGylated liposomal doxorubicin, liposomal system), approved in 1995 by FDA is the 
first clinically used passively targeted nanoparticle based drug for cancer treatment 54 
The promising characteristics of the drug formulation include prolonged blood circulation 
time, avoidance of reticuloendothelial system (RES) or phagocytic elimination and high 
doxorubicin loading 54 Other examples of clinically approved passively targeted 
nanoparticle based drugs include Abraxane 55,56(albumin-taxol, polymer drug conjugate 
system), Marqibo 57(vincristine sulfate, liposomal system), DaunoXome 58(liposomal 
daunorubicin, liposomal system), Onivyde 59,60(irinotecan, liposomal system), Vyxeos 61( 
cytarabinee-daunorubicin combination, liposomal system), Myocet 62,63(Non, PEGylated 
liposomal doxorubicin, liposomal system), Mepact 64,65( mifamurtide, liposomal system) , 
Genexol-PM 66( PEG-PLA-taxol, polymeric micelles system), and SMANCS 67,68( 
neocarzinostatin, polymer drug conjugate system). While most of the formulations 
mainly focus on improving the drug pharmacokinetics, drug solubility and toxicological 
profile, some nanoparticle based cancer drug formulations have enhanced therapeutic 
response in patients and improved the overall survival percentage compared to the 
standard non-formulated chemo drugs. For example, Abraxane (albumin-Paclitaxel) 
polymer drug conjugate formulation significantly enhanced the therapeutic response in 
metastatic breast cancer patients in phase III clinical trial compared to the standard 
Paclitaxel treatment 55,69.
• Active targeting: The “active” targeting involves binding of affinity ligands 
functionalized on the nanocarrier surface to the specific overexpressed biomarkers or
receptors on the target cells improving selective tissue homing and enhanced retention 
at the tumor vicinity 70. The targeted biomarker enhances the internalization of 
nanoparticles upon binding with nanoparticle surface functionalized ligands.
• Advantages and limitations of active targeting: Actively targeted nanoparticle 
based drugs showed greater potential in cancer treatment by utilizing the enhanced tumor 
localization and most crucially by the selective inhibition of cancer cells minimizing the 
side effects in cancer treatment 71,72. In fact, integration of actively targeting mechanism 
with optimization in nanocarrier design will allow for the design of a more efficacious 
nanotherapeutic platform for cancer treatment 73. Ligands employed on the actively 
targeted nanocarrier surface enhance the nanoparticle accumulation in the intravascular 
tumor cells or endothelial cells of tumor blood vessels70,74. Moreover, the internalization 
of ligand functionalized targeted drug nanoparticle can be mediated through a specific 
pathway by a specific antigen overexpressing tumor cells and the intracellular 
accumulation can be increased 75. However, the greater potential is associated with more 
complex challenges. The first barrier comes with the transport process of the nano-drug 
delivery systems. The protein coating formed around the surface of the nanoparticles, 
known as the “protein corona” limits the blood circulation time of the particles by 
altering the stability and surface architecture of the particle76-79 though longer blood 
circulation time for nanoparticles might not be so crucial considering a high pressure 
blood flow in the tumor microenvironment blood vessels53. The protein coating alters the 
pharmacokinetics and helps elimination by immune systems of the delivery system 80.
The protein corona also hinders the receptor targeting, intracellular uptake, intracellular 
trafficking of the actively targeted nanoparticle based drugs77. The challenge also remains
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in predicting the correlations between nanoparticle size and the binding affinity or 
tissue specific accumulation of drugs. Such a mechanistic model predicts that the 
nanoparticle size >50 nm does not enhance the accumulation of drugs at the malignant 
tumor site when compared to the non-targeted nanotherapeutic system81. Endosomal 
escape into the cytosol is one of the major barriers of the actively targeted nanoparticle 
based drug delivery systems. Nanoparticles internalized or uptaken by the tumor cells in 
clatherin mediated endocytic pathway enter the endosomes and are subsequently 
degraded in lysosomes by a intracellular degradative mechanism often driven by the pH 
of these subcellular compartments82. One of the ingenious mechanisms to enhance 
endosomal escape efficiency is “proton sponge effect” that utilizes the pH buffering 
substances for endosomal escape83. Exocytosis, the cellular recycling process is another 
major limitation for actively targeted nanoparticle based drugs. It has been demonstrated 
that 70% of the uptaken endosomal siRNA encapsulated lipid nanoparticle were rejected 
by the tumor cells through exocytosis84. The current drug delivery vehicles targeting a 
single biomarker or mechanism of action often develop tumor resistance and promotes 
tumor relapse because of the partial and non-sustainable therapeutic outcome85.
Moreover, the choice of specific biomarker ligands, conjugation of ligands with 
nanoparticle and complex manufacturing process impose great hindrance on the efficacy 
of actively targeted nanoparticle based therapeutic drug delivery vehicles 2.
• Current actively targeted nanoparticle based cancer therapeutics: None of 
the actively targeted therapeutics have been approved for clinical use in cancer treatment 
till November, 20 1 8 53. However, a number of drugs have entered in clinical trials. Table
12
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1.1 summarizes the all intravenous actively targeted nanoparticle based cancer 
therapeutics that are in different stages of clinical trials as of August 2019 86.
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MCC-465 being the first actively targeted nanoparticle based drug showed 
selective accumulation in stomach cancer tissues over the normal cells 87 SGT-53, a 
transferrin receptor targeted and p53 plasmid DNA encapsulating cationic liposome 
nanocarrier has been shown to sensitize cancer cells to the subsequent treatment with 
radiation therapy and systemic chemotherapy88,89. The first polymer based targeted 
nanotherapeutic drug to enter the clinical trial is CALAA-01 which encapsulates small 
interfering RNA molecule (siRNA), has shown RNA interfering mechanisms in patients 
and also showed enhanced accumulation in tumor cells intracellularly 75. These examples 
show promising insights towards future clinical success of actively targeted nanoparticle 
based cancer drugs.
1.4. COMBINATION THERAPY TO OVERCOME THE THERAPEUTIC 
RESISTANCE IN CANCER TREATMENT
Treatment with a single drug often causes partial response in cancer treatment.
The cancer cells often acquire resistance to the treatment and hence cause disease 
recurrence. Old age chemotherapeutic drugs, mAb-based targeted drugs, small molecule 
kinase inhibitors have been proven to improve the therapeutic response in cancer patients 
when used in combination with other suitable drugs90,91. In fact, the combination therapy 
is the key treatment strategy for most cancer treatments now 92. For example,
Trastuzumab is used to treat early stage HER2- positive breast cancer as a first line of 
treatment. However, the complete response of the treatment is not achieved in 20-60% 
cases of the HER2- positive and HER2-enriched breast cancer patients93. The treatment is 
also associated with the risk of therapeutic resistance and tumor recurrence after a certain 
period of the treatment. The lower risk of tumor recurrence and better outcome can be
expected when Trastuzumab is administered with another chemotherapeutic drug in 
combination94,95. Till 2013, four phase III clinical trials involving more than 8,000 
patients showed that the risk of recurrence was decreased by 50% in when Trastuzumab 
was administered with or after chemotherapy in combination91,96-99. The American 
Society of Clinical Oncology (ASCO) guideline updated in 2018, recommended anti 
HER2 therapy in combination with chemotherapy or a taxane (Paclitaxel and Docetaxel 
are most common in practice) as a first line of treatment for metastatic HER2-positive 
breast cancer. Trastuzumab treatment has been shown to sensitize the breast cancer cells 
to the microtubulin polymerization agent especially to the taxols and the drugs synergize 
improving the therapeutic outcome in vivo 100-102. Combination therapy with Paclitaxel 
and Trastuzumab for adjuvant HER2- positive breast showed promising long term 
clinical outcome in recent years. In 2015, after a median follow up period of 4 yr, 
adjuvant Paclitaxel and Trastuzumab combination treatment trial involving 406 node 
negative HER2-positive breast cancer patients reported the 3 yr disease free survival rate 
(DFS) to be 98.7%103. In 2019, after 7 yr follow up period, the DFS was 93% with an 
overall survival rate (OS) of 95% 104
1.5. ANTIBODY DRUG CONJUGATES
Antibody Drug Conjugates (ADCs) are the combination therapeutic system 
consisting small molecule cytotoxic drugs covalently bound to the mAb via a stable 
linker (Figure 1.3).
The coupled antibody directs towards a specific antigen that is highly expressed
15
on the cancer cell surface.
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Figure 1.3. Schematic structure of ADC 105
Antigen binding initiates downstream signaling pathways to inhibit the cancer cell 
growth. Eventually, the antibody is internalized in the intracellular endosomes with the 
conjugated therapeutic drug molecule through a clathrin or caveolae mediated 
endocytosis 106 and pinocytosis pathway 107 . The endosomes containing the ADC 
subsequently mature into lysosomes 108,109. In the lysosome, the linker is cleaved and the 
drug molecule released in the cytosol exerts the therapeutic effect following reaching to 


















Figure 1.4. Antigen binding and intracellular trafficking of ADC 105
1.5.1. Advantages and Challenges Associated with ADCs. ADCs have the 
novel advantages of utilizing mAb to specifically target cancer tissue site while also 
delivering cytotoxic potential anti-cancer drug molecule. The system can potentially 
enhance the tumor site specific accumulation of drugs with low or no cytotoxic effects on 
the normal cells111,112. There are major limitations involved along with the ingenuity of 
the ADC combination therapeutic system. Selection of target antigens, drug 
hydrophobicity, insufficiently low therapeutic payload, off target toxicity due to unstable 
linker conjugation in physiological system, drug efflux and multidrug resistance 
constitute the major limitations of ADC therapeutic system113-118. Till 2017, the two third 
of the cytotoxic small molecule drugs in the ADC systems that were on clinical trials 
came from only auristatins and maytansinoids family which inhibit the tubulin
assembly119. This suggests that there still lies limitations keeping from using 
diversified drug molecules in ADC system. High susceptibility to multi drug resistance is 
a common barrier in successful formulation of ADCs. Cancer cells often become 
resistant to multiple drugs through enhanced drug efflux mechanism. The upregulation of 
multidrug resistance protein encoding genes including MDR1, MRP1 and MRP3 promote 
the efflux transporter activity in cancer cells and result in drug resistance 120. In vitro 
therapeutic efficacy of Mylotarg drug on acute myeloid leukemia (AML) cell lines 
showed that P-glycoprotein expression significantly altered the therapeutic potency of the 
drug molecule and treatment with efflux transporter inhibitor restored the potency of the 
payload 121. An ADC system AVE9633 comprising the anti CD33 linked with a 
cytotoxic maytansine analog molecule DM4 has also been shown to be dependent on P- 
glycoprotein expression level for its therapeutic efficacy in vitro 122. Hydrophobic nature 
of ADC reduces the pharmacokinetics and therapeutic index of the system. 
Hydrophobicity also induce antibody aggregation causing small shelf life and clearance 
by immune cells 112. Moreover, the conventional drug to antibody ratio (DAR) in ADC 
system is 3.5-4.0 106,113. The in vitro therapeutic efficacy of ADC system increases with 
increasing DAR value113. Site specific highly loaded ADC system showed enhanced in 
vivo therapeutic efficacy in a system with low antigen expression at the target site 123. In 
the same system, no or low therapeutic effect was observed when treated with similarly 
loaded conventional molecule or with the similar ADC having low payload. This 
suggests that a conventional therapeutic payload might not be sufficient for achieving 
satisfactory outcome while targeting cancer cells with lower abundance in antigen 
expression 124 However, high DAR value has been showed to positively correlate with
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enhanced ADC plasma clearance resulting in reduced in vivo efficacy 125. So, 
balancing between the enhanced payload and best achievable therapeutic index in the 
conventional ADC platform is both a dilemma and a compromise 126. Again, lower 
abundance of target antigens on the tumor cell surface results in further therapeutic 
inefficacy, often causing treatment resistance. These limitations have hindered the 
clinical success of methotrexate, doxorubicin and alkaloid based ADCs119,127. 
Optimization in linker conjugation and stability is another challenge in developing ADCs. 
Premature release of drug molecule in the blood circulation cause toxicity to normal 
tissue and poor therapeutic index. Hydrophobic linker molecule has been showed to 
promote enhanced efflux transporter activity in cancer cells resulting in drug resistance. 
Non polar linker molecule in maytansinoid-based ADC system showed low potency in 
MDR1 overexpressed cancer cells in vitro due to enhanced transport of hydrophobic 
molecule by MDR1 activity 113. Moreover, majority of the ADCs have maleimide type 
conjugation chemistry and often undergo deconjugation, causing off target toxicity 113.
1.5.2. Strategies for Developing Efficacious ADCs. Diversification in the drug 
selection, linking chemistry and alternative form of mAbs are brought into the 
development of ADCs.
• Selection of drugs: For designing efficacious ADC system, the selected drug 
molecule must possess good aqueous phase solubility, potent toxicity, specified site for 
linker conjugation and maintenance of potency after conjugation110,128,129 . In selection of 
potent cytotoxic drugs, lowering the minimum effective dose of cytotoxic drugs should 
be considered to reduce off target toxicity and improve the therapeutic index of ADCs. In 
case of malignant tissue selectivity, the therapeutic index can be improved by focusing on
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increasing the maximum tolerated dose. The drugs must retain the efficacy and have 
aqueous phase stability after modification by linker chemistry. The drugs should be 
synthetically available and the manufacturing process should be cost effective 129. 
Moreover, a better understanding of the toxicity profile of ADCs as a combination drug 
system should be addressed in the development of next generation ADCs.
• Bystander effect: The target antigen expression in solid tumor tissue is 
heterogeneous in nature. The designed ADC selective for a specific antigen might not 
affect a large cell population with low or no antigen expression. This might cause partial 
therapeutic response in cancer treatment. The design consideration or characterization of 
ADCs that allow the system to affect the neighboring malignant cells with low or no 
antigen expression is called bystander effect. For example, the FDA approved ADC 
brentuximab vedotin contains neutral monomethyl auristatin E (MMAE) drug molecule. 
Upon protease mediated cleavage of ADC, MMAE is released, crosses the bio 
membranes and kills the neighboring epithelial cancer cells130-134. Other example of 
ADCs that have been reported to possess bystander effect include trastuzumab 
duocarmazine ( kills HER2- negative cells though targeted against HER2+ breast cancer 
population in vitro )135 , coltuximab ravtansine (targets CD19, phase II clinical trial, 
2017)136 , anetumab ravtansine (targets mesothelin, phase I clinical trial , 2017) 137
• Selection of linkers and conjugation chemistry: The mechanisms of drug release is 
an important consideration for developing ADCs. This is mostly achieved by the 
appropriate selection of linkers. The physiological stimuli such as pH, glutathione 
concentration, and proteolytic degradation are responsible degradation of cleavable 
linkers while the non-cleavable linkers rely on mAb degradation in the lysosomal
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compartment to release the drug after internalization. ADCs comprising the both type 
of linkers were approved by FDA or are currently in clinical trials. For example, The 
ADC brentuximab vedotin (marketed as Adcetres) which was approved in 2011 by FDA 
for anaplastic large cell lymphoma, utilizes the degradation of cleavable linker valine- 
citrulline (vc) by lysosomal proteases such as cathepsin B 138. Another FDA approved (in 
2013) ADC Ado-trastuzumab emtansine (marketed as Kadcyla, popularly known as T- 
DM1) for HER2-positive metastatic breast cancer treatment comprised a non-cleavable 
linker lysine-SMCC that utilized the proteolytic degradation of mAb to release the drug 
molecule 139. Each strategy has their own merits and demerits and optimization is needed 
considering the comprising drug, antibody and targeted site. The conventional 
thiosuccinimide linkage involving the reaction of thiols and alkyl maleimides are being 
replaced by novel site specific conjugation chemistries including engineered cysteines , 
unnatural amino acid engineering, enzyme assisted ligation , glycan remodeling and 
glycoconjugation, amino terminal engineered serine , ligation to Fab nucleotide -binding 
sites, cysteine rebridging, among many others 112.
• Selection of alternative forms of antibody: Alternative configurations of full length 
mAbs are also being investigated in state of the art ADC systems. This include 
nanobodies, tumor tissue specific novel probodies, single chain variable fragments 
(scFvs), antigen binding fragments (Fabs), ADCs with biparatopic activity (binds two 
different epitopes on the same antigen) and other formats.
As discussed, the use of diverse clinically approved chemo therapeutic drugs such 
as methotrexate, taxoids, anthracyclins and alkaloids is still a challenging task to 
incorporate in the ADC platform due to hydrophobic nature, insufficient drug delivery to
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the tumor tissue and off target toxicity in the normal tissue resulting in poor therapeutic 
index 113,129. In this work, these limitations have been addressed by integrating the 
concepts of nanotechnology, actively targeted drug delivery and combination therapy in a 
single novel therapeutic platform. The conventional ADC system was remodeled into an 
actively targeting nanosized therapeutic platform ADN designed for combination 
treatment in HER2-positive breast cancer. Rod shaped nanoparticles were synthesized 
using pure chemotherapeutic drug. The drug nanoparticles were covalently conjugated 
with mAb to target an actively expressed biomarker on the cancer cell surface. The 
engineered ADN showed enhanced in vitro selectivity and a synergistic therapeutic 
efficacy on the HER2-positive breast cancer cells compared to the single drug treatments. 
The therapeutic efficacy of the ADN was also mechanistically determined at the protein 
expression level. In a following study, the deep genetic mechanism and transcriptional 
regulation determining the treatment response with engineered ADN were investigated. 
The objective of the study was to identify the novel genetic pathways that might cause 
enhanced treatment response or potential therapeutic resistance in breast cancer cell lines 
upon treatment with ADN. Taken together, the work presented the development and 
therapeutic efficacy of ADN system for targeted cancer treatment with synergistic 
efficacy. The work also investigated the mechanisms of ADN therapeutic efficacy at 
cellular, molecular and gene expression levels. Figure 1.5 shows the schematic diagram 
of the primary works presented in the dissertation.
In addition, the dissertation also presents a study on the design and therapeutic 
efficacy of a multifunctional polymer coated superparamagnetic NIR responsive
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nanosized therapeutic platform harnessing both the integrity of diagnostics and 
therapeutics in a single platform for cancer treatment.
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Finally, the work presents a study on therapeutic efficacy of a natural 
cyanobacterial extract glycoglycerolipid molecule MGDG, that was investigated for
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Figure 1.5. An overview of the primary works presented in the dissertation
potential anti-cancer application. The sequential overview of the dissertation is shown 
in the following block diagram (Figure 1.6).
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Paper II
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Overview of intrinsic and 
extrinsic programmed cell 
death pathways 
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Paper III
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application in cancer
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• Isolation of a natural anti­
proliferation molecule from 
ocean cyanobacteria
• >65% cell growth inhibition 
in HER2-positive breast 
cancer cells in vitro
• Caspase mediated 
programmed cell death in 
HER2-positive breast cancer 
cells
• No significant toxicity in 
human normal cell lines in
'  vitro
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Figure 1.6. Overview of the dissertation
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PAPER
I. ANTIBODY-DRUG NANOPARTICLES INDUCES SYNERGISTIC 
TREATMENT EFFICACIES IN BREAST CANCER CELLS
ABSTRACT
Chemotherapeutic drugs suffer from non-specific binding, undesired toxicity, and 
poor blood circulation which contribute to poor therapeutic efficacy. In this study, 
antibody-drug nanoparticles (ADNs) are engineered by synthesizing pure anti-cancer 
drug nanorods (NRs) in the core of nanoparticles with a therapeutic monoclonal antibody, 
Trastuzumab on the surface of the NRs for specific targeting and synergistic treatments 
of breast cancer cells. The ADNs were designed by first synthesizing ~95 nm diameter x 
~500 nm long paclitaxel (PTX) NRs using the nanoprecipitation method. The surface of 
PTXNRs was functionalized at 2' OH nucleophilic site using carbonyldiimidazole and 
conjugated to TTZ through the lysine residue interaction forming PTXNR-TTZ 
conjugates (ADNs). The size, shape, and surface charge of ADNs were characterized 
using scanning electron microscopy (SEM), SEM, and zeta potential, respectively. Using 
fluorophore labeling and response surface analysis, the percentage conjugation efficiency 
was found >95% with a PTX to TTZ mass ratio of 4 (molar ratio « 682). In vitro 
therapeutic efficiency of PTXNR-TTZ was evaluated in human epidermal growth factor 
receptor 2 (HER2) positive BT-474 and HER2 negative MDA-MB-231 breast cancer 
cells using MTT assay. PTXNR-TTZ inhibited >80% of BT-474 cells at a higher
efficiency than individual PTX and TTZ treatments alone after 72 h. A combination 
index analysis indicated a synergistic combination of PTXNR-TTZ compared with the 
doses of single drug treatment. The molecular mechanisms of PTXNR-TTZ were 
investigated using cell cycle and Western blot analyses. The cell cycle analysis showed 
PTXNR-TTZ arrested >80% of BT-474 breast cancer cells in the G2/M phase, while 
>70% of untreated cells were found in the G0/G1 phase indicating that G2/M arrest 
induced apoptosis. A similar percentage of G2/M arrested cells were found to induce 
caspase-dependent apoptosis in PTXNR-TTZ treated BT-474 cells as revealed using 
Western blot analysis. PTXNR-TTZ treated BT-474 cells showed ~1.3, 1.4, and 1.6-fold 
higher expressions of cleaved caspase-9, cytochrome C, and cleaved caspase-3, 
respectively than untreated cells, indicating up-regulation of caspase-dependent 
activation of apoptotic pathways. The PTXNR-TTZ ADN represents a novel nanoparticle 
design that holds promise for targeted and efficient anti-cancer therapy by selective 
targeting and cancer cell death via apoptosis and mitotic cell cycle arrest.
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1. INTRODUCTION
Engineering nanoscale drug delivery systems have been studied extensively 
because of several advantages including high drug payloads,1-5 improved drug release,6,7 
enhanced bioavailability,8,9 and increased multivalence effects through receptor-ligand 
interactions.10-13 The use of a ligand allows direct delivery of the cytotoxic agent to target 
cells, however, the clinical success of targeted antibody-drug conjugates is limited due to 
poor bioavailability and low therapeutic efficacy.14-16 Improvements in drug design in
combination with active targeting are shown to enhance cellular uptake, targeting, and 
higher therapeutic efficacy which have led to the design of antibody-drug nanoparticles 
(ADNs). ADNs are comprised of an anticancer drug core nanoparticle conjugated with a 
therapeutic monoclonal antibody on the nanoparticle surface for targeted delivery and 
enhanced therapeutic efficacy. Trastuzumab (TTZ) is used to treat early-stage human 
epidermal growth factor receptor 2 (HER2) positive breast cancer as the first line of 
treatment. However, the complete response of the treatment is not achieved in 20-60% 
cases of the HER2 positive and HER2 enriched breast cancer patients.17 The TTZ 
treatment is associated with the risk of therapeutic resistance and tumor recurrence after a 
certain period of the treatment. The lower risk of tumor recurrence and the better 
outcome can be expected when TTZ is administered with another chemotherapeutic drug 
in combination.18,19 Till 2013, four Phase III clinical trials involving more than 8,000 
patients showed that the risk of recurrence was decreased by 50% when TTZ was 
administered with or after chemotherapy in combination.20-24 The American Society of 
Clinical Oncology (ASCO) guideline updated in 2018, recommended anti-HER2 therapy 
in combination with taxane as the first line of treatment for metastatic HER2 positive 
breast cancer.25
Combination therapy using paclitaxel (PTX) and TTZ for adjuvant HER2 positive 
breast cancer showed promising long-term clinical outcomes in recent years. In 2015, 
after a median follow up period of 4 yr, adjuvant PTX and TTZ combination treatment 
trials reported that the 3 yr disease-free survival rate is 98.7% in HER2 positive breast 
cancer patients.26 In 2019, after 7 yr follow up period, the disease-free survival rate was 
93% with an overall survival rate (OS) of 95%.27 While the combination therapy of PTX
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and TTZ are promising, the following challenges still have to overcome in terms of 
synergy between the drugs, toxicity and therapeutic efficacy.28 The current clinically used 
intratumoral concentration of PTX (1-9 ^M) is shown to be insufficient for breast cancer 
treatment.29 Moreover, PTX is poorly soluble in aqueous phase causing a great limitation 
and trade-off in terms of toxicity in intravenous administration. The high concentration of 
TTZ used in clinical trials have always been associated with the risk of severe cardiac 
arrest.26-28
To overcome the limitations of toxicity and off-site targeting, nanoparticles have 
been engineered with advanced chemical composition,14-16,30 surface functionalization,31- 
35 and geometric modification.35-38 Nanoparticles made of human serum albumin 
(Abraxane™) have been used for the delivery of PTX to breast cancer cells.39 Another 
example of a nanoparticle-based drug delivery system is liposome-based doxorubicin 
(Doxil) for the treatment of ovarian cancer40,41 and breast cancer.42 However, the 
efficiency of these nanoparticles is controversial due to the lack of active targeting and 
controlled drug delivery. Currently, a large number of nanoparticles such as liposomes,43 
polymers,44 micelles,45 solid lipid nanoparticles,46 and other organic and inorganic 
nanoparticles have been explored to improve the therapeutic efficiency by active 
targeting of cancer cells through the design of nanoparticle size, shape and surface 
charge.
Nanoparticle size in the range of 50-500 nm size nanoparticles is desirable for 
enhanced blood circulation, tissue penetration, and cellular interaction.36,47,48 Size less 
than 10 nm is cleared by renal excretion, while larger particles are cleared by 
phagocytosis.11,12,49,50 Non-spherical nanoparticles have been reported to be less clearance
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by macrophages than spherical nanoparticles as dictated by the contact angle of 
nanoparticles with the macrophage membrane.51 Nanoparticle also leads to a dramatic 
increase in surface area for surface functionalization with targeting ligands such as 
monoclonal antibodies, affibodies, peptides, and aptamers. For example, binding of rod­
shaped nanoparticles can be high if the particle aligns with its major axis parallel to the 
cell membrane increasing the multivalence effects of receptor-ligand interactions.10-13
In this study, we synthesized PTX nanorods (PTXNRs) of the size (96.8 ± 33) x 
(503.4 ± 210) nm using the nanoprecipitation method. TTZ was used as a HER2 targeting 
antibody for specific PTX delivery to HER2 positive breast cancer cells. The surface of 
PTXNRs was conjugated via carbonyldiimidazole (CDI), a highly reactive crosslinker to 
form an active N-acyl imidazole group capable of coupling with amine-containing TTZ 
and formed a stable amide linkage. Flow cytometry analysis of a fluorophore-labeled 
PTXNR-TTZ and response surface analysis confirmed the TTZ conjugation efficiency of 
>95%. A combination approach of PTXNR-TTZ ADNs was explored in exploiting the 
therapeutic efficacy of the ADNs towards HER2 positive breast cancer cells. It is 
hypothesized that a combination system using PTXNR-TTZ ADNs enhances therapeutic 
payloads and treatment efficiency by selective targeting of HER2 positive breast cancer 
cells.
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2. MATERIALS AND METHODS
2.1. SYNTHESIS OF PTXNRs
PTXNRs were prepared using the nanoprecipitation method (SI Figure 1).10,52,53 
Briefly, PTX powder (>99.5%, Alfa Aesar) was dissolved in 5 ml of ethanol at a
concentration of 3 mg/ml. The solution was homogenized at 1000 rpm, sonicated, and 
injected to 20 mL deionized (DI) water at a flow rate of 2 ml/min to form PTXNRs. 
PTXNRs were washed three times using DI water by centrifuging at 18,000 rcf for 2 h, 
suspended, and lyophilized (Labconco) overnight to obtain the dried particles.
2.2. CHARACTERIZATION OF PTXNR
The size and shape of PTXNRs were analyzed using a scanning electron 
microscope (Hitachi S4700 FESEM). The images were obtained at 10.0 KV accelerating 
voltage with 4.5 mm working distance and 40,000X magnification. The size distribution 
of NRs was analyzed using Fiji image processing software( Image J; Win 64 Java 1.8.0). 
The surface charge of PTXNRs was measured in DI water and phosphate-buffered saline 
(PBS) using zeta potential (Nano series Zetasizer, Malvern).
2.3. ACTIVATION OF 2' OH NUCLEOPHILIC SITE OF PTXNR
TTZ (Genentech) was conjugated with the 2OH nucleophilic site group of PTX 
using the CDI activation reaction (SI Figure 2). Briefly, 1 mg of dry PTXNRs was 
suspended in 1 ml of PBS. 5 mg CDI was added directly to the NR suspension with a 
continuous stirring speed of 600 rpm. The reaction was carried out at 4oC for 20 min to 
form the amine-reactive PTX-carbamate (PTXNR-CDI). The PTXNRs-CDI were 
centrifuged at 16,000*g for 30 min and washed five times using DI water to remove the 




2.4. *H-NMR ANALYSIS OF ACTIVATED PTXNR
To confirm the linkage of the activated carbamate group at the 2OH site of 
PTXNR, the 'H-NMR experiment was carried out. In carrying out the experiment, 2 mg 
of each unmodified PTXNR and surface functionalized PTXNR particles were dissolved 
in 600 |il of chloroform-d solvent (Alfa Aesar). The solvent was used as the internal 
reference to determine chemical shifts (5) in ppm. !H-NMR spectra were then recorded 
using Bruker advanced III 400 MHz Liquid-State NMR instrument at R.T.
2.5. CONJUGATION OF TTZ WITH ACTIVATED PTXNR THROUGH THE 
LYSINE RESIDUE INTERACTION
The CDI activated PTXNRs were subsequently reacted with the s-amino group of 
lysine residues of TTZ (pKa 10.53) for subsequent conjugation.54 100 |ig of TTZ powder 
was dissolved in 100 |il carbonate buffer at pH 9.3-9.5 and added to the CDI activated 
100 |il of 1 mg PTXNR-CDI particle suspension. The reaction was allowed to proceed 
for 48 h at room temperature (~22°C). The resulting TTZ conjugated PTXNR (PTXNR- 
TTZ) particles were centrifuged at 16,000*g for 25 min and washed using carbonate 
buffer at pH 9.3-9.5 (3* 1 ml). The supernatant was collected after each washing for 
quantifying the unbound TTZ. The concentrate was collected by centrifuging the 
membrane filter at 1,000*g for 2 min. The concentrated PTXNR-TTZ particles were 
finally re-suspended in 300 |il of PBS (pH 7.5). The amount of PTXNR in PTXNR-TTZ 
was quantified by measuring absorbance at 230 nm (BioTek Synergy 2; BioTek, 
Winooski, VT, USA) using a PTX calibration curve (SI Figure 3). The amount of 
unbound antibody was quantified using a BCA protein Assay (Pierce Biotechnology, 
Rockford, IL, USA) and a TTZ calibration curve (SI Figure 4). The size and shape of
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PTXNR-TTZ particles were investigated using SEM (10.0 kV; accelerating voltage with 
5.6 mm working distance and 20,000X magnification). The surface charge of the 
PTXNR-TTZ was measured in DI water and PBS using a Nano series Zetasizer 
(Malvern).
2.6. FLUORESCENCE DATA ANALYSIS TO CONFIRM THE CONJUGATION 
OF TTZ WITH PTXNR
To confirm the successful conjugation of TTZ with PTXNR, TTZ was tagged 
with Alexa 594 red fluorescent dye molecule (Invitrogen) according to the 
manufacturer’s protocol before conjugating with PTXNR. The fluorescence data of both 
unconjugated bare PTXNR and conjugated Alexa 594 tagged PTXNR-TTZ particles 
were obtained using a flow cytometer (BD Accuri C6 plus). The fluorescence signal of 
the particles was acquired using a 585/40 bandpass filter with 488 nm laser excitation.
2.7. OPTIMIZATION OF TTZ CONJUGATION USING RESPONSE SURFACE 
ANALYSIS
The optimum conditions for maximum TTZ conjugation efficiency were 
investigated by the response surface analysis method using JMP statistical modeling 
software. The design of the experiment involved two factors, initial PTXNR, and initial 
TTZ concentration. Three levels were assigned to each of the two factors. For initial 
PTXNR concentration the levels were 5, 10, 15 mg/ml and for initial TTZ concentrations 
the levels were 0.5, 1.0, 1.5 mg/ml. Each experimental design unit was replicated three 
times resulting in a total 27 experimental units. For each experimental unit, a random 
number was assigned using JMP. The experiments were performed according to a
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complete randomized design in three days with nine randomly assigned experiments in a 
single day. Conjugation efficiency of TTZ was chosen to be the yield or response of the 
experimental design. TTZ conjugation efficiency was calculated using Equation (1):
% conjugation efficiency = (initial amount of TTZ )— (unbound am ount of TTZ ) (initial amount of TTZ) x 100 (1)
2.8. IN V IT R O  THERAPEUTIC EFFICACY
BT-474 and MDA-MB-231 cells were cultured in hybricare medium and RPMI- 
1640, respectively supplemented with 10% fetal bovine serum (FBS) and 1% penicillin- 
streptomycin at 37oC and 5% CO2 . Approximately, 10,000 cells per well were plated in 
96-well plates and treated with different doses of PTXNR-TTZ, PTXNRs, TTZ alone, 
and PTX solution alone. After 72 h of incubation, cell viability was assessed using MTT 
(3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, MW 414) assay. MTT 
reagent was added to each well to convert into an insoluble formazan from water-soluble 
MTT. After 4 h, sodium dodecyl sulfate (SDS) solution prepared in 0.01 N HCl was 
added to each well to solubilize the formazan. The percentage of live cells relative to 
untreated control wells was quantified by measuring the absorbance at 570 nm (BioTek 
Synergy 2). Cell viability was calculated as a means of six wells containing BT-474 and 
MDA-MB-231 cells by subtracting the mean background level of wells containing 
medium only. Nonspecific formation of formazan due to the presence of medium was 
determined from triplicate wells. The number of viable cells was calculated as follows 
(Equation (2)):
-̂ 570 o f  sample -̂ 570 o f  medium  .  „ „
%  ceZZ vtafriZity = ------- ------ ------- ----- ------------x 100 (2)
•™570 o f  live cells ^ 570 o f  medium
34
2.9. QUANTITATIVE ANALYSIS OF SYNERGISTIC EFFECTS OF PTXNR-TTZ
We investigated the quantitative effects of PTXNR-TTZ using combination index 
analysis (CI) by the Chou-Talalay method 55,56. The CI of PTXNR alone, TTZ alone, and 
conjugated PTXNR-TTZ were calculated using Equation (3) and plotted as CI versus the
fraction of cells being affected.
_  ( Dosage o f  PTXNR in PTXNR -  TTZ) 
^  (Dosage o f  PTXNR)
(Dosage o f  TTZ in PTXNR -  TTZ)
+ (Dosage o f  TTZ) ( 3)
2.10. CELL CYCLE ANALYSIS
The effect of the PTXNR-TTZ on the cell cycle of BT-474 cells was investigated 
after 24, 48, and 72 h of treatments. BT-474 cells without any treatments, PTXNR alone 
treatment, and TTZ alone treatment were used as controls. The cell cycle analysis 
protocol was developed by modifying the previously reported method 57,58. For each 
sample of the analysis, 2 x  106 cells were seeded in a T25 cell culture flask. After 12 h, 
PTXNR-TTZ, PTXNR alone, and TTZ alone were added and incubated for 24, 48, and 
72 h. The untreated sample was incubated with 1 ml of PBS solution. Before harvesting 
the cells, 100 |il of 5'-Bromo-2'-deoxyuridine (BrdU) (Alfa Aesar) stock solution per 5 
ml of media was added to an active concentration of 40 |iM and incubated for 1 h at 
37oC. The culture media was removed completely, and the cells were collected in 15 ml 
centrifuge tubes. The cells were centrifuged, and the cell pellets were fixed by adding 1 
ml of 100% ice-cold ethanol. The cells were stored at 4oC at least for 30 min. Ethanol 
was removed after centrifugation at 500*g for 5 min and was resuspended in 1 ml of
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0.5% Triton X-100 prepared in 2N HCl. After 30 min of incubation at room temperature, 
cells were pelleted down to mix with 1 ml of 0.1 M Na2B4O7.10 H2O (pH 8.5) solution 
and was incubated for at least 30 min at room temperature. The cells were pelleted down 
again and washed with PBS containing 1mg/ml Bovine Serum Albumin (BSA) and 0.1 % 
Tween-20 (PBST) solution. After washing, cells were resuspended in 50 |il prediluted 
mouse anti-BrdU monoclonal antibody (Novus Biologicals, Cat. NBP248373) stock 
solution. After 30 min of incubation in dark, 0.5 ml PBST stock solution was added and 
washed. A 50 |il prediluted FITC conjugated rabbit anti-mouse secondary antibody 
(Sothern Biotech, Cat. 617002) stock solution was added to cell pellets and were 
incubated for 30 min at room temperature in dark. After washing again with PBST 
solution, cells were resuspended in 100 |il of 1 mg/ml RNAse A (Alfa Aesar) stock 
solution and incubated for at least 20 min. Finally, 300-500 |il of 35 |ig/ml propidium 
iodide (PI) (Alfa Aesar) was added to cell pellets and incubated in the dark at 37oC for 45 
min. Before analyzing the cells in a flow cytometer (BD accuri C6 Plus), cells were 
passed through a 40-micron cell strainer (Thermo Scientific) to remove the cell 
aggregates. For flow cytometry analysis, cells were gated to sort out the singlet cells and 
only the singlets were gated for subsequent analysis. For acquiring the fluorescent data, 
530/30 and 585/40 bandpass filters were used to acquire the BrdU positive and PI- 
positive cells, respectively with a 488 nm of laser excitation.
2.11. WESTERN BLOT ANALYSIS
BT-474 and MDA-MB-231 cells were treated with PTXNR-TTZ, PTXNR alone, 
and TTZ alone for 48 h at 10,000 nM each for Western blot analysis. The cells were
harvested and lysed at 4o C using 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.1% 
Triton X-100, 0.5% sodium deoxycholate and 0.1% sodium dodecyl sulfate (SDS). The 
lysate protein was quantified using the BCA assay and the BSA calibration curve (SI 
Figure 5). For each experiment, 40 |ig of each sample was taken and added to an equal 
volume of 2X Laemmli sample buffer. The cell lysate in the sample buffer was heated at 
86oC for 5 min before running the SDS-PAGE electrophoresis process. Novex Tris- 
Glycine SDS gels (8-16% and 16%) (Invitrogen) were used for gel electrophoresis. The 
electrophoresis was performed for 45 min to 1h at 200 V. The separated proteins were 
transferred from gel to nitrocellulose membrane using a Power Blotter (ThermoFisher 
Scientific) according to the manufacturer’s protocol. After the transfer process, the 
membrane was blocked for 5 h with moderate shaking using 3% BSA protein in TBST 
buffer (20 mM Tris (pH 7.5), 150 mM NaCl, and 0.1% Tween 20). The membrane was 
incubated with a primary monoclonal antibody overnight at 4oC. GAPDH (ThermoFisher, 
Cat. MA5-15738, 1: 5000) monoclonal antibody was used as a loading control. Actin 
(ThermoFisher Cat. MA5-11869, 1: 2000), Caspase -9 (ThermoFisher, Cat PA5-16358, 
1:500), Caspase-3 (ThermoFisher, Cat. 43-7800, 1:500), cleaved caspase-3 
(ThermoFisher Cat. PA5- 23921, 1:1000), XIAP (ThermoFisher, Cat. PA1-84846,
1:1000) and Cytochrome-C (ThermoFisher, Cat. MA5-11674, 1:400) primary 
monoclonal antibodies were used to observe the corresponding proteins of interest. After 
primary antibody incubation, the membrane was washed 3-5 times for 5 min each with 
TBST buffer. The membrane was incubated in Horseradish peroxidase (HRP) enzyme- 
conjugated secondary anti-mouse (ThermoFisher Cat.A27025, 1:10000 or anti-rabbit 
monoclonal antibody (Cell Signaling Technology, Cat.7074P2, 1:10000) depending on
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the primary antibody host species for 1 h followed by washing with TBST washing 
buffer. The electro-chemiluminescent substrate (Super Signal West Dura, ThermoFisher, 
and Cat. 34075) was added on the membrane and incubated for 5 min. The electro­
chemiluminescent signal was captured using a Bio-Rad gel imager. The signals were 
analyzed by image processing using Fiji (Image J) software.
2.12. STATISTICAL ANALYSIS
To observe the statistically significant differences in protein expressions 
compared to controls, we performed the one-tailed (either overregulation or 
downregulation) t-test with a 95% confidence level. All other hypothesis testing was 
performed using a two-tailed t-test. The TTZ conjugation efficiency analysis was 
performed using a complete randomized (CR) model. The final conjugation efficiency 
data was predicted using a response surface analysis using JMP statistical software. 
P<0.05 was considered statistically significant.
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3. RESULTS
3.1. SYNTHESIS OF PTXNRs
The SEM images of PTXNRs as shown in Figure 1(a) confirms the elongated rod 
shape PTX drug NRs. The average diameter and length of PTXNRs were (96.87 ± 33.08) 
and (503.42 ± 210) nm, respectively (Figure 1 (b)). The size distribution plots (Figure 1 
(c), Figure 1 (d)) confirm the moderately narrow dispersity of the particle diameter and 
length. The polydispersity index (pDI) of the particles was measured as 0.20 ± 0.02.
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PTXNRs showed high colloidal stability in DI water having a zeta potential value of (­
32.60 ± 4.82) mV (Figure 1(e), SI Table 1). In 0.15 M PBS solution, the zeta potential 
value was measured (-13.40 ± 2.81) mV, indicating the stability of nanoparticles even in 
high salt concentrations (SI Table 1).
Figure 1. Characterization of PTXNRs. (a) Scanning electron microscopy (SEM) image 
of PTXNRs; (b) Particle size percentile plot of the PTXNR-TTZ particle length and 
diameter; (c) Size distribution of PTXNR particle length; (d) Size distribution of PTXNR 
particle diameter as calculated analyzing SEM images. The number ‘n’ denotes the 
particle population count for the analysis; and (e) Zeta potential (^) of PTXNR is - 
32.6±4.8 mV in water. Three colors indicate three different experiments
3.2. CONFIRMATION OF LINKER CONJUGATION WITH PTXNRs USING JH 
NMR ANALYSIS
We activated the 2OH site of PTXNR to form an imidazole carbamate 
intermediate for subsequent conjugation step with the 8- amino group in the lysine side 
chain of TTZ (SI Figure 2). In 1H NMR analysis, imidazole carbamate intermediate 
linkage was confirmed by the peak of the imidazole ring proton in ‘a’ position (Ha) at 
8.35 ppm (Figure 2).59,60
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Figure 2. 1H-NMR analysis to characterize PTX-imidazole carbamate formation. 1H- 
NMR spectra of hydrolyzed carbonyldiimidazole (CDI), PTX-imidazole carbamate 
(PTXNR-CDI), and PTXNR. The NMR spectra were acquired at room temperature. For 
characterization of PTXNR and PTXNR-CDI deuterated chloroform (CDCI3, 5 7.24) and 
for hydrolyzed CDI deuterated oxide (D2O, 5 4.65) were used as reference carrier
solvents
In a parallel side reaction, CDI hydrolyzes in the aqueous phase of conjugation 
reaction with TTZ. Hydrolyzation of CDI produces free imidazole ring and might 
interfere in the NMR analysis as a free surface-bound residuals. To further confirm the 
linkage of the imidazole carbamate with the PTXNR, we performed the NMR analysis of 
hydrolyzed CDI residuals. Residual imidazole group was identified by the peak of the 
imidazole proton in “a'” position (Ha') at 7.6 ppm.59 So, the shift of NMR peak at 8.35 
ppm represents only the Ha proton and hence confirms the successful linkage of
imidazole carbamate at 2 OH site of PTXNR particles forming the PTX-imidazole 
carbamate intermediate (PTXNR-CDI) particles.
3.3. CONFIRMATION OF TTZ CONJUGATION WITH PTXNR-CDI
The s-amino group in lysine residue of TTZ acts as an active electrophile at the 
reaction pH and attacks the CDI activated site of PTXNR through nucleophilic 
substitution reaction. Attack by the electrophile amine group releases the imidazole ring 
but leaves the carbonyl group resulting in a one-carbon spacer forming a stable carbamate 
linkage. To confirm the TTZ conjugation, Alexa 594 fluorescent molecule was 
conjugated with TTZ. The bare unconjugated PTXNR showed a mean autofluorescence 
intensity of 42.60 a.u. (arbitrary unit). The Alexa 594 fluorophore bound PTXNR-TTZ, 
the mean fluorescence intensity was measured 13889.46 a.u. (Figure 3(a)) that is 326 
fold higher than the mean fluorescence intensity of bare PTXNR confirming a successful 
conjugation of TTZ with PTXNRs (Figure 3(b)). PTXNR-TTZ showed good 
dispersibility in both water and PBS (SI Figure 6).
3.4. OPTIMIZATION OF TTZ CONJUGATION EFFICIENCY
The SEM image of the PTXNR-TTZ particles confirms the consistency in the size 
and shape of the particles after lyophilization (Figure 4(a)). The zeta potential of the 
PTXNR-TTZ in DI water was measured -17.1±3.83 mV (Figure 4(b), SI Table 1). In 
PBS, the zeta potential was measured -9.5± 0.02 mV (SI Table 1).
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Figure 3. The fluorescence intensity of PTXNR-TTZ confirms the conjugation of TTZ on 
the surface of PTXNRs. (a) The F.I. of bare PTXNRs (grey) and Alexa 594 fluorophore 
bound TTZ conjugated PTXNR (PTXNR-TTZ) (green) shows a significant increase in 
emission spectra; (b) The quantitative mean F.I. of PTXNR-TTZ increases by ~14,000 
fold (2.54 logarithmic fold ) compared to bare PTXNRs indicating TTZ is effectively 
conjugated on the surface of PTXNRs using a CDI linker
The conjugated particles had a pDI of 0.21±0.11 showing significant 
homogeneity in size and shape. Optimization of TTZ conjugation efficiency was 
performed using response surface analysis (Figure 4(c)). The surface plot shows that the 
vicinity of lower concentrations of both initial PTXNR and TTZ result in 90-95% of 
conjugation efficiency, whereas the higher initial concentrations predict lower 
conjugation efficiency. The analysis suggests that the higher concentration of PTX results 
in precipitation of nanoparticles and less available surface for conjugation as well as 
several vacant reactive sites on the nanoparticle surface, whereas the higher concentration 
of TTZ produces excess unbound TTZ in the reaction medium. The maximum 
conjugation efficiency of TTZ to PTXNR was calculated 95.24 ± 1.40 % (SI Table 2), 
and hence, considered the optimum amount to use for subsequent experiments. The
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optimum condition for the maximum conjugation efficiency was 5mg/ml and 0.5 mg/ml 
initial concentrations of PTXNR and TTZ, respectively. The drug to antibody ratio 
(DAR) of the conjugated particle was 4.0 ± 0.53 on a weight basis (molar ratio=681.67 ± 
90.23) (SI Table 2).
Figure 4. Characterization of PTXNR-TTZ ADNs. (a) SEM image of PTXNR-TTZ 
ADNs; (b) The zeta potential (^) of PTXNR-TTZ was observed -17.1±3.83 mV in DI 
water; (c) Contour plot of response surface analysis showing % conjugation efficiency of 
TTZ on the surface of PTXNRs. In response surface analysis, two factors PTXNR 
concentration and TTZ concentration were optimized for the highest conjugation 
efficiency. Each concentration factor had three levels. For PTXNR, the concentration 
levels were 5, 10, and 15 mg/ml and for TTZ the levels were 0.5, 1.0, and 1.5 mg/ml. 
Each level was replicated at least three times resulting in a total 27 experimental units. 
The maximum ~95% conjugation efficiency was obtained with PTXNR concentration 5 
mg/ml and TTZ concentration 0.5 mg/ml. The experiment was designed according to a 
Complete Randomized (CR) model using JMP statistical software
3.5. IN V IT R O  ANTICANCER EFFICACY
To determine the anti-cancer efficacy in vitro, the dose-response cytotoxicity was 
measured using PTXNR-TTZ, PTX NR alone, TTZ alone, and PTX solution alone in BT- 
474 and MDA-MB-231 cells (Figure 5). PTXNR-TTZ was found to exert more
therapeutic efficiency in BT-474 cells than the individual effect of PTXNR, TTZ, and 
PTX solution treatments (Figure 5(a)) confirming the HER2 specificity of the ADNs. 
PTXNR-TTZ inhibited >83% and 51% of BT-474 (Figure 5(a)) and MDA-MB-231 
(Figure 5(b)) cancer cells, respectively suggesting specific targeting and more therapeutic 
efficiency in HER2 positive BT-474 cells than MDA-MB-231 cells.
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(a)
Figure 5. In vitro anti-cancer efficiency of PTXNR-TTZ ADNs. The cytotoxic effects of 
PTXNR-TTZ (closed circle), PTXNR (triangle), PTX Solution (diamond), and TTZ 
(square) on the growth of (a) BT-474, and (b) MDA-MB-231 cells. Each experiment was 




Figure 5. In vitro anti-cancer efficiency of PTXNR-TTZ ADNs.The cytotoxic effects of 
PTXNR-TTZ (closed circle), PTXNR (triangle), PTX Solution (diamond), and TTZ 
(square) on the growth of (a) BT-474, and (b) MDA-MB-231 cells. Each experiment was 
replicated at least n=6 times, and the average data is presented with mean ± standard
deviation (cont.)
The half-maximal inhibitory concentration (IC50), as defined as the concentration 
needed to kill 50% of cells, was found 106, 609 and 9000 nM for PTXNR-TTZ, PTX NR 
alone and TTZ alone, respectively in BT-474 cells indicating a synergistic therapeutic 
efficiency using ADNs compared to the individual treatments. MDA-MB-231 cells were 
resistant to PTXNR-TTZ exhibiting an IC50 >3,000 nM indicating intrinsic trastuzumab 
resistance in vitro. PTXNR alone and TTZ solution alone inhibited roughly 40% and 30% 
of the MDA-MB-231 cell growth, respectively. The cytotoxic effects of PTX solution 
were similar in both cell lines showing a dose-dependent cytotoxicity from 30-50%. 
PTXNR effectively killed more BT474 cells from 20-60% in a dose-dependent manner
than that in MDA-MB-231 cells from 10-30%. All these results suggest that PTXNR- 
TTZ exerts specific cytotoxicity in HER2 positive breast cancer cells.
3.6. THE EFFECTS OF PTXNR-TTZ IS SYNERGISTIC IN HER2 POSITIVE 
BREAST CANCER CELLS
The combination effects of PTXNR and TTZ were evaluated in BT-474 and 
MDA-MB-231 cells using the combination index (CI) analysis (Figure 6). The effects of 
the drugs were analyzed to determine whether a synergistic effect occurred in that cell 
line. On the plot, any point showing CI < 1 indicates a synergistic effect, and the values 
showing CI>1 is considered antagonistic. It is found that PTXNR-TTZ shows a 
synergistic effect in BT474 cells by decreasing CI values <1 with increasing fraction 
affected cells (Figure 6(a)). Very different CI vs. fraction affected line was observed in 
MDA-MB-231 cells showing increased CI values with increasing fraction affected cells 
up to 0.8 beyond which antagonistic effects were observed indicating a combination of 
PTX NR and TTZ is irrelevant in this cell line (Figure 6(b)).
3.7. PTXNR-TTZ ARRESTS HER2 POSITIVE BREAST CANCER CELLS IN THE 
G2/M PHASE
We quantified the population of BT-474 cells arrested in G0/G1, S, and G2/M cell 
cycle phases after treatment with PTXNR-TTZ, PTXNR alone, and TTZ alone (Figure 7 
and SI Figures 7-9). PTXNR-TTZ arrested 39.90, 62.56, and 83.55% of BT-474 cells in 
the G2/M phase after 24, 48, and 72 h treatments, respectively. Conversely, it decreased 






Figure 6. Combination Index (C.I.) analysis of PTXNR-TTZ ADNs. The C.I. plot as a 
function of each fraction of cells affected by PTXNR-TTZ particles in (a) BT-474, and 
(b) MDA-MB-231 cells. A C.I. value =1; additive effect, < 1; synergistic effect, > 1; 
antagonistic effect. The downward and upward curves in BT-474 and MDA-MB-231 
cells indicate synergistic and antagonistic effects, respectively
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PTXNR alone caused 39.76, 60.31, 76.18% arrest in the G2/M phase after 24, 48, 
and 72 h, respectively. TTZ alone treatment arrested 56.25, 53.39, 57.83% of BT-474 
cells in the G1 phase after 24, 48, and 72 h, respectively. The cell cycle data confirms 
that PTXNR modulates the mitotic cell cycle arrest, or cell growth inhibition, and 
eventually apoptosis in BT-474 breast cancer cells.
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Figure 7. Cell cycle analysis. BT-474 cells were treated with PTXNR-TTZ, PTXNR 
alone, and TTZ alone. Cell cycle analysis was performed by flow cytometry after (a) 24 
h, (b) 48 h, and (c) 72 h of treatment. Each experiment was replicated at least n=2 times 




Figure 7. Cell cycle analysis.BT-474 cells were treated with PTXNR-TTZ, PTXNR 
alone, and TTZ alone. Cell cycle analysis was performed by flow cytometry after (a) 24 
h, (b) 48 h, and (c) 72 h of treatment. Each experiment was replicated at least n=2 times 
and the average cell count data are presented as mean ± standard deviation (Cont.)
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3.8. PTXNR-TTZ DOWNREGULATES ANTI-APOPTOTIC PROTEIN AND 
INDUCES APOPTOSIS IN A CASPASE-DEPENDENT INTRINSIC 
PATHWAY
We found that >80% of BT-474 cells were inhibited and arrested in the G2/M 
phase by PTXNR-TTZ ADN treatments. We investigated if the prolonged cell cycle 
arrest in the G2/M phase induced programmed cell death or apoptosis in cancer cells and 
the mechanisms of apoptotic induction by PTXNR-TTZ ADNs. PTXNR-TTZ induced 
apoptosis in HER2 positive BT-474 cells in an intrinsic cytochrome-C mediated pathway 
(Figure 8(a) and Figure 8(c)). In BT-474 cells, after 48 h of treatment using PTXNR- 
TTZ and PTX NR, we observed a significant release of cytochrome-C than that of 
untreated cells. We further observed a significantly higher expression of initiator 
apoptotic protein fully cleaved caspase-9. The lower expression of procaspase-3 was 
correlated with the upregulation of cleaved or active form of caspase-3. The observation 
is in agreement with the time-dependent expression study of caspase-3 on taxane treated 
HER2 positive SK-BR-3 cell line.61 In BT-474 cells, the anti-apoptotic protein XIAP was 
significantly downregulated by PTXNR-TTZ treatment than the individual drug 
treatment. XIAP is a natural inhibitor of caspase-3 and caspase-9. 47,62-64 High XIAP 
activity may cause the inactivation of early apoptotic protein caspase-9 and inactivation 
of active caspase-3 at the later phase of apoptosis. The significant downregulation of 
XIAP by PTXNR-TTZ treatment facilitates the late apoptosis by overexpressing the 
effector caspase-3 apoptotic protein that attributes to the synergistic cytotoxic effect in 
BT-474 cells. The high concentration of PTXNR and PTXNR-TTZ significantly 
downregulated the actin production in BT-474 cells compared to MDA-MB-231 cells. In 
MDA-MB-231 cells, although cytochrome-C release was observed for both PTXNR-TTZ
and PTXNR treatments, there was no significant change in the expression of active 
caspase-9 suggesting that the apoptosome was not activated in the cytosolic area (Figure 
8(b) and Figure 8(d)). The procaspase-3 expression in PTXNR-TTZ treated cells was not 
statistically different from that of untreated cells. Eventually, the cleaved form of the 
caspase-3 signal was not observed at all with the individual drug treatment and PTXNR- 
TTZ treatment. XIAP activity was observed in individually treated cells as well as in 
PTXNR-TTZ treated cells. XIAP activity in the drug-treated cells was found to be as 
high as that in untreated MDA-MB-231 cancer cells. XIAP is a potent anti-apoptotic 
protein and abnormal expression of XIAP can block the cell death pathways 47
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Figure 8. Western blot analysis. The cell signaling protein expressions of (a) BT-474 
and (b) MDA-MB-231 cells using PBS, PTX alone, TTZ alone, and PTXNR-TTX 
treatments. The relative intensity of XIAP, actin, cleaved caspase-9, caspase 3, cleaved 
caspase 3 and cytochrome C is analyzed after 48 h of treatment in (c) BT-474 and (d) 
MDA-MB-231 cells. For each protein expression the experiment was replicated at least 
n=2-4 times and the average data is presented as mean ± standard deviation. The relative 
protein expressions are normalized to the untreated control cells and to the housekeeping 
GAPDH protein expression (hypothesized expression mean, g=1). The p-value for 
overexpression or downregulation of cytochrome-C, cleaved caspase-3 and XIAP in (d) 
BT-474 is 0.039, 0.003, and 0.000049, respectively. The p-value for the over expression 
of cytochrome-C in MDA-MB-231 is 0.047
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Figure 8. Western blot analysis. The cell signaling protein expressions of (a) BT-474 
and (b) MDA-MB-231 cells using PBS, PTX alone, TTZ alone, and PTXNR-TTX 
treatments. The relative intensity of XIAP, actin, cleaved caspase-9, caspase 3, cleaved 
caspase 3 and cytochrome C is analyzed after 48 h of treatment in (c) BT-474 and (d) 
MDA-MB-231 cells. For each protein expression the experiment was replicated at least 
n=2-4 times and the average data is presented as mean ± standard deviation. The relative 
protein expressions are normalized to the untreated control cells and to the housekeeping 
GAPDH protein expression (hypothesized expression mean, |i=1). The p-value for 
overexpression or downregulation of cytochrome-C, cleaved caspase-3 and XIAP in (d) 
BT-474 is 0.039, 0.003, and 0.000049, respectively. The p-value for the over expression 
of cytochrome-C in MDA-MB-231 is 0.047
4. DISCUSSION
Many chemotherapeutic drugs including PTX is a water-insoluble drug that 
results in low circulation time, poor bioavailability in the tumor tissue, and higher 
administrative dosage.65-67 Nano-sized drug carriers, liposomes, polymeric nanoparticles, 
and micelles have been designed over the past decades to improve water dispersibility, 
stability and blood circulation half-life of chemotherapeutic drugs.68-71 However, most 
nanoparticles suffer from poor specificity targeting only 1.6% of the administered dose of
the linked small molecule drug to be delivered in the targeted tumor vicinity.72,73 In this 
study, we designed ADNs by conjugating TTZ monoclonal antibody on the surface of 
PTXNRs through a single carbonyl group spacing with >95% conjugation efficiency. 
PTXNR-TTZ was synthesized in two steps. First, PTX NRs were synthesized by phase 
separation of PTX drug solution from ethanol into water. This method is simple and 
scalable. Secondly, PTXNRs were reacted with CDI linker in water to form intermediate 
PTXNR-carbamate followed by coupling with the amine groups of TTZ using 
carbodiimide chemistry that forms PTXNR-TTZ ADN.74,75 The reaction is chemically 
defined, efficient, and scalable with an overall yield of >80% and a high PTX: TTZ w/w 
ratio « 4 (molar ratio « 682). The cytotoxic payload in ADNs is 170-fold more than 
conventional antibody-drug conjugates (molar ratio « 4) which improves the ability to 
deliver more active drugs at the target site and greater in vitro potency. The PTXNR-TTZ 
ADN showed greatly enhanced water dispersibility (>1 mg/ml) compared to PTX 
aqueous solution, indicating little aggregation in water.52
PTXNR-TTZ ADNs are designed to target HER2 receptors overexpressed in 
breast cancer cells so that the ADN binds to target cells, are internalized via endocytosis 
and exerts apoptosis mediated therapeutic effects.10,48,50,76-90 The NRs, when coated with 
TTZ, exhibit high binding toward HER2-overexpressing breast cancer cells.53,91 The 
adhesion strength of NRs has been shown high both experimentally and by theoretical 
modeling.87,92-95 After targeting and internalization, PTXNR-TTZ ADNs activated 
intrinsic apoptosis pathways and inhibited >83% of HER2 positive BT-474 cells which 
was 43% more than the cytotoxicity in HER2 negative MDA-MB-231 cells. No 
difference in cytotoxicity was observed for PTXNR-TTZ, unconjugated PTXNR, PTX
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solution alone, and TTZ alone treatments in MDA-MB-231 cells, indicating non-specific 
cell death. The IC50 of PTXNR-TTZ in BT-474 cells is lower than single drug treatments 
which is consistent with the previously published literature. The IC50s of PTX vary 
between 2-200 nM in breast cancer cells due to differential basal level expressions of P- 
tubulin subunits of microtubules,96-98 sensitivity of PTX toward binding with P-tubulin,96 
the expression of tau proteins involved in microtubule polymerization,99 and HER2 
expression levels.100 PTXNR-TTZ inhibits tubulin polymerization and microtubule 
formation, blocks the cell cycle in G2/M, and induces apoptosis.
The CI analysis showed that PXNR-TTZ augments apoptosis in BT-474 cells 
synergistically indicating an induction in apoptosis through multiple pathways including 
intrinsic caspase-dependent pathway and cell cycle arrest. PTX and TTZ arrest cells in 
G2/M and G0/G1 phase, respectively by disrupting the microtubule dynamics and 
binding with HER2 extracellular domain.101-105 In this study, individual treatment using 
PTXNR alone and TTZ alone arrested 76% and 57% of BT-474 cells in G2/M and 
G0/G1, respectively after 72 h of treatment. In contrast, PTXNR-TTZ arrested 83.5% of 
BT-474 cells in G2/M after 72 h of treatment indicating dominant effects of PTX in 
sensitizing and synchronizing cells in the G2/M phase which correlates with the 
percentage of apoptotic dead cells after PTXNR-TTZ treatment.106-108 The cleaved 
caspase-3 and cytochrome C were significantly increased, while anti-apoptotic XIAP was 
decreased in BT-474 cells after 72 h of PTXNR and PTNR-TTZ treatments compared 
with untreated control. Cytochrome-C binds to apoptosis protease-activating factor-1 
(APAF1), inducing its oligomerization to form apoptosome that recruits and activates an 
apoptosis initiator protein, caspase-9, cleaves caspase-9 into its active small subunits and
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initiates the late apoptotic caspase cascade reactions.47,64,109,110 The cleaved caspase-9 
eventually activates the late apoptotic protein caspase-3.111"113 The overexpression of 
cleaved or active form of caspase-3 ultimately confirms the late phase of apoptosis in BT- 
474 cells using PTXNR-TTZ treatment.111,114-116 In the late phase, apoptosis is facilitated 
by two-fold downregulation of anti-apoptotic XIAP protein after PTXNR-TTZ treatment 
compared to that in the untreated control. In contrast, MDA-MB-231 cells did not show 
any sign of mid- or late phase apoptosis though having overexpression of the 
cytochrome-C protein. No changes in XIAP expression was observed in MDA-MB-231 
cells treated with PTXNR-TTZ. XIAP, a key member of the inhibitor of apoptosis protein 
(IAP) family,117 has been shown to be a direct inhibitor of caspase-3 and to interfere with 
the cytochrome-C pathway by inhibiting caspase-9 in lung cancer cells,118-120 and 
leukemia cells.121-124 In this study, the downregulation of XIAP and activation of caspase 
cascades in BT-474 cells by PTXNR-TTZ has proven to be an effective approach for the 
treatment of HER2 positive breast cancer cells.
5. CONCLUSION
The first synthesis of PTXNR-TTZ ADNs and its therapeutic efficiency in vitro 
are presented which induces higher apoptosis responses than single drug treatments in 
HER2 positive breast cancer cells. The use of PTXNR of ~95 nm in diameter and 500 nm 
in length remove the compromising need for toxic organic carrier solvent for intravenous 
administration of PTX alone. The particles are stable in the aqueous phase that makes it 
suitable for intravenous administration without any need for any organic solvent. The
surface of PTXNR was functionalized by CDI activation reaction in the aqueous phase 
and successfully conjugated TTZ without altering the size and shape of the nanoparticles. 
PTXNR-TTZ synergistically inhibited HER2 positive breast cancer cells. The IC50 of 
PTXNR-TTZ is 106 nM in BT-474 cancer cells which facilitates lower dose, and hence, 
fewer side effects than individual treatments. PTXNR-TTZ arrested >83% of the 
proliferating cells in the G2/M phase of the cell cycle after 72h of the treatment, which 
was well corroborated with cell cycle analysis. The higher number of cells (>80%) 
arrested in the G2/M phase after PTXNR-TTZ treatment than individual treatments using 
PTXNR and TTZ (arrests in the G0/G1 phase) confirms the synergistic crosstalk between 
PTX and TTZ. The Western blot analysis demonstrates that PTXNR-TTZ activates the 
effector caspase proteins in HER2 positive breast cancer cells, and downregulates the 
anti-apoptotic XIAP facilitating caspase-dependent apoptosis followed by the cell cycle 
arrest in G2/M phase. Taken together, it is envisaged that the results from this study will 
facilitate the rational design of combination therapy through a novel design of ADNs.
55
ACKNOWLEDGMENTS
This work was supported by the Center for Biomedical Research (CBR) at 




(1) Vega-Vasquez, P.; Mosier, N. S.; Irudayaraj, J. Nanoscale Drug Delivery 
Systems: From Medicine to Agriculture. Frontiers in Bioengineering and 
Biotechnology 2020, 8.
(2) Patra, J. K.; Das, G.; Fraceto, L. F.; Campos, E. V. R.; Rodriguez-Torres, M. D. 
P.; Acosta-Torres, L. S.; Diaz-Torres, L. A.; Grillo, R.; Swamy, M. K.; Sharma, 
S.; Habtemariam, S.; Shin, H.-S. Nano based drug delivery systems: recent 
developments and future prospects. J Nanobiotechnology 2018, 16, 71-71.
(3) Scicluna, M. C.; Vella-Zarb, L. Evolution of Nanocarrier Drug-Delivery Systems 
and Recent Advancements in Covalent Organic Framework-Drug Systems. ACS 
Applied Nano Materials 2020, 3, 3097-3115.
(4) Hossen, S.; Hossain, M. K.; Basher, M. K.; Mia, M. N. H.; Rahman, M. T.; 
Uddin, M. J. Smart nanocarrier-based drug delivery systems for cancer therapy 
and toxicity studies: A review. Journal of Advanced Research 2019, 15, 1-18.
(5) Liechty, W. B.; Kryscio, D. R.; Slaughter, B. V.; Peppas, N. A. Polymers for 
Drug Delivery Systems. Annual Review of Chemical and Biomolecular 
Engineering 2010, 1, 149-173.
(6) Caldorera-Moore, M.; Guimard, N.; Shi, L.; Roy, K. Designer nanoparticles: 
incorporating size, shape and triggered release into nanoscale drug carriers. 
Expert Opin Drug Deliv 2010, 7, 479-495.
(7) Malam, Y.; Loizidou, M.; Seifalian, A. M. Liposomes and nanoparticles: 
nanosized vehicles for drug delivery in cancer. Trends in pharmacological 
sciences 2009, 30, 592-599.
(8) Lombardo, D.; Kiselev, M. A.; Caccamo, M. T. Smart Nanoparticles for Drug 
Delivery Application: Development of Versatile Nanocarrier Platforms in 
Biotechnology and Nanomedicine. Journal of Nanomaterials 2019, 2019, 
3702518.
(9) Qin, S.-Y.; Zhang, A.-Q.; Cheng, S.-X.; Rong, L.; Zhang, X.-Z. Drug self­
delivery systems for cancer therapy. Biomaterials 2017, 112, 234-247. 10*
(10) Barua, S.; Yoo, J.-W.; Kolhar, P.; Wakankar, A.; Gokarn, Y. R.; Mitragotri, S.
Particle shape enhances specificity of antibody-displaying nanoparticles.
Proceedings of the National Academy of Sciences 2013, 110, 3270-3275.
57
(11) Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O. C. Cancer
nanotechnology: The impact of passive and active targeting in the era of modern 
cancer biology. Advanced Drug Delivery Reviews 2014, 66, 2-25.
(12) Larson, N.; Ghandehari, H. Polymeric Conjugates for Drug Delivery. Chemistry 
of Materials 2012, 24, 840-853.
(13) Srinivasarao, M.; Galliford, C. V.; Low, P. S. Principles in the design of ligand- 
targeted cancer therapeutics and imaging agents. Nature Reviews Drug Discovery 
2015, 14, 203-219.
(14) Chari, R. V. J. Targeted delivery of chemotherapeutics: tumor-activated prodrug 
therapy. Advanced Drug Delivery Reviews 1998, 31, 89-104.
(15) Lin, K.; Tibbitts, J. Pharmacokinetic Considerations for Antibody Drug 
Conjugates. Pharmaceutical Research 2012, 29, 2354-2366.
(16) Mack, F.; Ritchie, M.; Sapra, P. The Next Generation of Antibody Drug 
Conjugates. Seminars in Oncology 2014, 41, 637-652.
(17) Braso-Maristany, F.; Griguolo, G.; Pascual, T.; Pare, L.; Nuciforo, P.; Llombart- 
Cussac, A.; Bermejo, B.; Oliveira, M.; Morales, S.; Martinez, N.; Vidal, M.; 
Adamo, B.; Martinez, O.; Pernas, S.; Lopez, R.; Munoz, M.; Chic, N.; Galvan, P.; 
Garau, I.; Manso, L.; Alarcon, J.; Martinez, E.; Gregorio, S.; Gomis, R. R.; 
Villagrasa, P.; Cortes, J.; Ciruelos, E.; Prat, A. Phenotypic changes of HER2- 
positive breast cancer during and after dual HER2 blockade. Nature 
communications 2020, 11, 385.
(18) Marty, M.; Cognetti, F.; Maraninchi, D.; Snyder, R.; Mauriac, L.; Tubiana-Hulin, 
M.; Chan, S.; Grimes, D.; Anton, A.; Lluch, A. Randomized phase II trial of the 
efficacy and safety of trastuzumab combined with docetaxel in patients with 
human epidermal growth factor receptor 2-positive metastatic breast cancer 
administered as first-line treatment: the M77001 study group. Journal of clinical 
oncology 2005, 23, 4265-4274.
(19) Von Minckwitz, G.; Procter, M.; De Azambuja, E.; Zardavas, D.; Benyunes, M.; 
Viale, G.; Suter, T.; Arahmani, A.; Rouchet, N.; Clark, E. Adjuvant pertuzumab 
and trastuzumab in early HER2-positive breast cancer. New England Journal of 
Medicine 2017, 377, 122-131. 20*
(20) Goldhirsch, A.; Gelber, R. D.; Piccart-Gebhart, M. J.; De Azambuja, E.; Procter,
M.; Suter, T. M.; Jackisch, C.; Cameron, D.; Weber, H. A.; Heinzmann, D. 2
years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer
(HERA): an open-label, randomised controlled trial. The Lancet 2013, 382, 1021­
1028.
58
(21) Piccart-Gebhart, M. J.; Procter, M.; Leyland-Jones, B.; Goldhirsch, A.; Untch,
M. ; Smith, I.; Gianni, L.; Baselga, J.; Bell, R.; Jackisch, C. Trastuzumab after 
adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of 
Medicine 2005, 353, 1659-1672.
(22) Romond, E. H.; Perez, E. A.; Bryant, J.; Suman, V. J.; Geyer Jr, C. E.; Davidson,
N. E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P. A. Trastuzumab plus 
adjuvant chemotherapy for operable HER2-positive breast cancer. New England 
Journal of Medicine 2005, 353, 1673-1684.
(23) Slamon, D.; Eiermann, W.; Robert, N.; Pienkowski, T.; Martin, M.; Press, M.; 
Mackey, J.; Glaspy, J.; Chan, A.; Pawlicki, M. Adjuvant trastuzumab in HER2- 
positive breast cancer. New England Journal of Medicine 2011, 365, 1273-1283.
(24) Perez, E.; Romond, E.; Suman, V. Trastuzumab plus adjuvant chemotherapy for 
HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) 
from NSABP B-31 and NCCTG N9831. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 2014, 32, 3744-3752.
(25) Giordano, S. H.; Temin, S.; Chandarlapaty, S.; Crews, J. R.; Esteva, F. J.; 
Kirshner, J. J.; Krop, I. E.; Levinson, J.; Lin, N. U.; Modi, S.; Patt, D. A.; 
Perlmutter, J.; Ramakrishna, N.; Winer, E. P.; Davidson, N. E. Systemic Therapy 
for Patients With Advanced Human Epidermal Growth Factor Receptor 2­
Positive Breast Cancer: ASCO Clinical Practice Guideline Update. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 
2018, 36, 2736-2740.
(26) Tolaney, S. M.; Barry, W. T.; Dang, C. T.; Yardley, D. A.; Moy, B.; Marcom, P. 
K.; Albain, K. S.; Rugo, H. S.; Ellis, M.; Shapira, I.; Wolff, A. C.; Carey, L. A.; 
Overmoyer, B. A.; Partridge, A. H.; Guo, H.; Hudis, C. A.; Krop, I. E.; Burstein,
H. J.; Winer, E. P. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, 
HER2-Positive Breast Cancer. New England Journal of Medicine 2015, 372, 134­
141. 27*
(27) Tolaney, S. M.; Guo, H.; Pernas, S.; Barry, W. T.; Dillon, D. A.; Ritterhouse, L.;
Schneider, B. P.; Shen, F.; Fuhrman, K.; Baltay, M.; Dang, C. T.; Yardley, D. A.;
Moy, B.; Marcom, P. K.; Albain, K. S.; Rugo, H. S.; Ellis, M. J.; Shapira, I.;
Wolff, A. C.; Carey, L. A.; Overmoyer, B.; Partridge, A. H.; Hudis, C. A.; Krop,
I. E.; Burstein, H. J.; Winer, E. P. Seven-Year Follow-Up Analysis of Adjuvant
Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth
Factor Receptor 2-Positive Breast Cancer. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2019, 37, 1868-1875.
59
(28) Bullock, K.; Blackwell, K. Clinical efficacy of taxane-trastuzumab combination 
regimens for HER-2-positive metastatic breast cancer. The Oncologist 2008, 13, 
515-525.
(29) Weaver, B. A. How Taxol/paclitaxel kills cancer cells. Molecular biology of the 
cell 2014, 25, 2677-2681.
(30) Muller, R. H.; Keck, C. M. Challenges and solutions for the delivery of biotech 
drugs -  a review of drug nanocrystal technology and lipid nanoparticles. Journal 
of Biotechnology 2004, 113, 151-170.
(31) Schrama, D.; Reisfeld, R. A.; Becker, J. C. Antibody targeted drugs as cancer 
therapeutics. Nature Reviews Drug Discovery 2006, 5, 147-159.
(32) Beck, A.; Goetsch, L.; Dumontet, C.; Corvaia, N. Strategies and challenges for 
the next generation of antibody-drug conjugates. Nature reviews Drug discovery 
2017, 16, 315.
(33) Panowski, S.; Bhakta, S.; Raab, H.; Polakis, P.; Junutula, J. R. Site-specific 
antibody drug conjugates for cancer therapy. mAbs 2014, 6, 34-45.
(34) Tsuchikama, K.; An, Z. Antibody-drug conjugates: recent advances in 
conjugation and linker chemistries. Protein & Cell 2018, 9, 33-46.
(35) Flygare, J. A.; Pillow, T. H.; Aristoff, P. Antibody-Drug Conjugates for the 
Treatment of Cancer. Chemical Biology & Drug Design 2013, 81, 113-121.
(36) Simone, E. A.; Dziubla, T. D.; Muzykantov, V. R. Polymeric carriers: role of 
geometry in drug delivery. Expert Opin Drug Deliv 2008, 5, 1283-1300.
(37) Mitragotri, S.; Burke, P. A.; Langer, R. Overcoming the challenges in 
administering biopharmaceuticals: formulation and delivery strategies. Nature 
Reviews Drug Discovery 2014, 13, 655-672.
(38) Vicent, M. J.; Duncan, R. Polymer conjugates: nanosized medicines for treating 
cancer. Trends in Biotechnology 2006, 24, 39-47. 39*
(39) Gradishar, W. J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.;
Hawkins, M.; O'Shaughnessy, J. Phase III Trial of Nanoparticle Albumin-Bound
Paclitaxel Compared With Polyethylated Castor Oil-Based Paclitaxel in Women
With Breast Cancer. Journal of Clinical Oncology 2005, 23, 7794-7803.
60
(40) McGuire, W. P.; Hoskins, W. J.; Brady, M. F.; Kucera, P. R.; Partridge, E. E.; 
Look, K. Y.; Clarke-Pearson, D. L.; Davidson, M. Cyclophosphamide and 
Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and 
Stage IV Ovarian Cancer. New England Journal of Medicine 1996, 334, 1-6.
(41) Campos, S. M.; Penson, R. T.; Mays, A. R.; Berkowitz, R. S.; Fuller, A. F.; 
Goodman, A.; Matulonis, U. A.; Muzikansky, A.; Seiden, M. V. The Clinical 
Utility of Liposomal Doxorubicin in Recurrent Ovarian Cancer. Gynecologic 
Oncology 2001, 81, 206-212.
(42) Ranson, M. R.; Carmichael, J.; O'Byrne, K.; Stewart, S.; Smith, D.; Howell, A. 
Treatment of advanced breast cancer with sterically stabilized liposomal 
doxorubicin: results of a multicenter phase II trial. Journal of Clinical Oncology 
1997, 15, 3185-3191.
(43) Abu Lila, A.; Ishida, T.; Kiwada, H. Targeting Anticancer Drugs to Tumor 
Vasculature Using Cationic Liposomes. Pharmaceutical Research 2010, 27, 1171­
1183.
(44) Muro, S.; Garnacho, C.; Champion, J. A.; Leferovich, J.; Gajewski, C.; 
Schuchman, E. H.; Mitragotri, S.; Muzykantov, V. R. Control of endothelial 
targeting and intracellular delivery of therapeutic enzymes by modulating the size 
and shape of ICAM-1-targeted carriers. Mol Ther 2008, 16, 1450-1458.
(45) Wang, Y.; Yang, T.; Wang, X.; Wang, J.; Zhang, X.; Zhang, Q. Targeted 
Polymeric Micelle System for Delivery of Combretastatin A4 to Tumor 
Vasculature &lt;i&gt;In Vitro&lt;/i&gt. Pharmaceutical Research 2010, 27, 1861­
1868.
(46) Zih-rou, H.; Shu-chiou, H.; Yueh-lung, Y.; Jia-you, F. Development and 
evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid 
lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta 
Pharmacologica Sinica 2008, 29, 1094-1102.
(47) Fulda, S.; Vucic, D. Targeting IAP proteins for therapeutic intervention in cancer. 
Nature Reviews Drug Discovery 2012, 11, 109-124.
(48) Gratton, S. E. A.; Ropp, P. A.; Pohlhaus, P. D.; Luft, J. C.; Madden, V. J.; Napier, 
M. E.; DeSimone, J. M. The effect of particle design on cellular internalization 
pathways. Proceedings of the National Academy of Sciences 2008, 105, 11613­
11618. 49*
(49) Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C. Factors Affecting the
Clearance and Biodistribution of Polymeric Nanoparticles. Molecular
Pharmaceutics 2008, 5, 505-515.
61
(50) Arnida; Janat-Amsbury, M. M.; Ray, A.; Peterson, C. M.; Ghandehari, H. 
Geometry and surface characteristics of gold nanoparticles influence their 
biodistribution and uptake by macrophages. European journal of pharmaceutics 
and biopharmaceutics : official journal of Arbeitsgemeinschaft fur 
Pharmazeutische Verfahrenstechnik e.V 2011, 77, 417-423.
(51) Champion, J. A.; Mitragotri, S. Role of target geometry in phagocytosis. 
Proceedings of the National Academy of Sciences of the United States of America 
2006, 103, 4930-4934.
(52) Laemthong, T.; Kim, H. H.; Dunlap, K.; Brocker, C.; Barua, D.; Forciniti, D.; 
Huang, Y.-W.; Barua, S. Bioresponsive polymer coated drug nanorods for breast 
cancer treatment. Nanotechnology 2016, 28, 045601.
(53) Barua, S.; Mitragotri, S. Synergistic targeting of cell membrane, cytoplasm, and 
nucleus of cancer cells using rod-shaped nanoparticles. ACS nano 2013, 7, 9558­
9570.
(54) Dennler, P.; Fischer, E.; Schibli, R. Antibody conjugates: from heterogeneous 
populations to defined reagents. Antibodies 2015, 4, 197-224.
(55) Chou, T. C. Drug combination studies and their synergy quantification using the 
Chou-Talalay method. Cancer Res 2010, 70, 440-446.
(56) Chou, T.-C.; Talalay, P. Quantitative analysis of dose-effect relationships: the 
combined effects of multiple drugs or enzyme inhibitors. Advances in enzyme 
regulation 1984, 22, 27-55.
(57) Cecchini, M. J.; Amiri, M.; Dick, F. A. Analysis of cell cycle position in 
mammalian cells. JoVE (Journal of Visualized Experiments) 2012, e3491.
(58) Sarsour, E. H.; Agarwal, M.; Pandita, T. K.; Oberley, L. W.; Goswami, P. C. 
Manganese superoxide dismutase protects the proliferative capacity of confluent 
normal human fibroblasts. Journal of Biological Chemistry 2005, 280, 18033­
18041.
(59) Olsson, J. V.; Hult, D.; Cai, Y.; Gartia-Gallego, S.; Malkoch, M. Reactive 
imidazole intermediates: simplified synthetic approach to functional aliphatic 
cyclic carbonates. Polymer Chemistry 2014, 5, 6651-6655. 60*
(60) Hornig, S.; Liebert, T.; Heinze, T. Structure design of multifunctional furoate and
pyroglutamate esters of dextran by polymer-analogous reactions. Macromolecular
bioscience 2007, 7, 297-306.
62
(61) Jelmek, M.; Balu&kova, K.; Schmiedlova, M.; Nemcova-Furstova, V.; Sramek,
J.; Stanakova, J.; Zanardi, I.; Ojima, I.; Kovar, J. The role of individual caspases 
in cell death induction by taxanes in breast cancer cells. Cancer cell international 
2015, 15, 8.
(62) Allan, L. A.; Clarke, P. R. Apoptosis and autophagy: Regulation of caspase-9 by 
phosphorylation. The FEBS journal 2009, 276, 6063-6073.
(63) Galban, S.; Duckett, C. S. XIAP as a ubiquitin ligase in cellular signaling. Cell 
death and differentiation 2010, 17, 54.
(64) Wurstle, M. L.; Laussmann, M. A.; Rehm, M. The central role of initiator 
caspase-9 in apoptosis signal transduction and the regulation of its activation and 
activity on the apoptosome. Experimental cell research 2012, 318, 1213-1220.
(65) Kipp, J. The role of solid nanoparticle technology in the parenteral delivery of 
poorly water-soluble drugs. International journal of pharmaceutics 2004, 284, 
109-122.
(66) Lukyanov, A. N.; Torchilin, V. P. Micelles from lipid derivatives of water-soluble 
polymers as delivery systems for poorly soluble drugs. Advanced drug delivery 
reviews 2004, 56, 1273-1289.
(67) Zhang, Z.; Mei, L.; Feng, S.-S. Paclitaxel drug delivery systems. Expert Opin 
Drug Deliv 2013, 10, 325-340.
(68) Senapati, S.; Mahanta, A. K.; Kumar, S.; Maiti, P. Controlled drug delivery 
vehicles for cancer treatment and their performance. Signal Transduction and 
Targeted Therapy 2018, 3, 7.
(69) Tong, R.; Cheng, J. Anticancer Polymeric Nanomedicines. Polymer Reviews 
2007, 47, 345-381.
(70) Mishra, B.; Patel, B. B.; Tiwari, S. Colloidal nanocarriers: a review on 
formulation technology, types and applications toward targeted drug delivery. 
Nanomedicine: Nanotechnology, Biology and Medicine 2010, 6, 9-24.
(71) Naksuriya, O.; Okonogi, S.; Schiffelers, R. M.; Hennink, W. E. Curcumin 
nanoformulations: A review of pharmaceutical properties and preclinical studies 
and clinical data related to cancer treatment. Biomaterials 2014, 35, 3365-3383. 72*
(72) Teicher, B. A.; Chari, R. V. J. Antibody Conjugate Therapeutics: Challenges and
Potential. Clinical Cancer Research 2011, 17, 6389.
63
(73) Nejadmoghaddam, M.-R.; Minai-Tehrani, A.; Ghahremanzadeh, R.; Mahmoudi, 
M.; Dinarvand, R.; Zarnani, A.-H. Antibody-Drug Conjugates: Possibilities and 
Challenges. Avicenna J Med Biotechnol 2019, 11, 3-23.
(74) Ghosh, A. K.; Brindisi, M. Organic Carbamates in Drug Design and Medicinal 
Chemistry. Journal of Medicinal Chemistry 2015, 58, 2895-2940.
(75) Quiles, S.; Raisch, K. P.; Sanford, L. L.; Bonner, J. A.; Safavy, A. Synthesis and 
Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody 
Conjugates for Tumor-Targeted Chemotherapy. Journal of Medicinal Chemistry
2010, 53, 586-594.
(76) Fahmy, T. M.; Samstein, R. M.; Harness, C. C.; Saltzman, W. M. Surface 
modification of biodegradable polyesters with fatty acid conjugates for improved 
drug targeting. Biomaterials 2005, 26, 5727-5736.
(77) Steenblock, E. R.; Fadel, T.; Labowsky, M.; Pober, J. S.; Fahmy, T. M. An 
artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the 
magnitude and direction of the T cell response. Journal of Biological Chemistry
2011, 286, 34883-34892.
(78) Steenblock, E. R.; Fahmy, T. M. A Comprehensive Platform for Ex Vivo T-cell 
Expansion Based on Biodegradable Polymeric Artificial Antigen-presenting 
Cells. Molecular Therapy 2008, 16, 765-772.
(79) Ben-Akiva, E.; Meyer, R. A.; Wilson, D. R.; Green, J. J. Surface engineering for 
lymphocyte programming. Advanced Drug Delivery Reviews 2017, 114, 102­
115.
(80) Munisvaradass, R.; Kumar, S.; Govindasamy, C.; Alnumair, K. S.; Mok, P. L. 
Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit 
Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast 
Cancer Cells. International Journal of Molecular Sciences 2017, 18, 1797.
(81) Sunshine, J. C.; Perica, K.; Schneck, J. P.; Green, J. J. Particle shape dependence 
of CD8+ T cell activation by artificial antigen presenting cells. Biomaterials 2014, 
35, 269-277.
(82) Meyer, R. A.; Sunshine, J. C.; Perica, K.; Kosmides, A. K.; Aje, K.; Schneck, J.
P.; Green, J. J. Biodegradable Nanoellipsoidal Artificial Antigen Presenting Cells 
for Antigen Specific T-Cell Activation. Small 2015, 11, 1519-1525. 83*
(83) Schutz, C.; Fleck, M.; Mackensen, A.; Zoso, A.; Halbritter, D.; Schneck, J. P.;
Oelke, M. Killer artificial antigen-presenting cells: A novel strategy to delete
specific T cells. Blood 2008, 111, 3546-3552.
64
(84) Perica, K.; Tu, A.; Richter, A.; Bieler, J. G.; Edidin, M.; Schneck, J. P. Magnetic 
field-induced t cell receptor clustering by nanoparticles enhances t cell activation 
and stimulates antitumor activity. ACS Nano 2014, 8, 2252-2260.
(85) Champion, J.; Mitragotri, S. Shape Induced Inhibition of Phagocytosis of Polymer 
Particles. Pharmaceutical Research 2009, 26, 244-249.
(86) Champion, J. A.; Mitragotri, S. Role of target geometry in phagocytosis. 
Proceedings of the National Academy of Sciences of the United States of America 
2006, 103, 4930-4934.
(87) Decuzzi, P.; Ferrari, M. The adhesive strength of non-spherical particles mediated 
by specific interactions. Biomaterials 2006, 27, 5307-5314.
(88) Decuzzi, P.; Ferrari, M. The receptor-mediated endocytosis of nonspherical 
particles. Biophysical journal 2008, 94, 3790-3797.
(89) Yan, G.; Paul, D.; Shenshen, C.; Richard, T.; Manorama, T.; Tamara, M.; Dennis, 
E. D. Shape effects of filaments versus spherical particles in flow and drug 
delivery. Nature Nanotechnology 2007, 2, 249-255.
(90) Huang, X.; Teng, X.; Chen, D.; Tang, F.; He, J. The effect of the shape of 
mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials 
2010, 31, 438-448.
(91) Barua, S.; Yoo, J.-W.; Kolhar, P.; Wakankar, A.; Gokarn, Y. R.; Mitragotri, S. 
Particle shape enhances specificity of antibody-displaying nanoparticles. Proc. 
Natl. Acad. Sci. U.S.A. 2013.
(92) Gentile, F.; Chiappini, C.; Fine, D.; Bhavane, R. C.; Peluccio, M. S.; Cheng, M. 
M.-C.; Liu, X.; Ferrari, M.; Decuzzi, P. The effect of shape on the margination 
dynamics of non-neutrally buoyant particles in two-dimensional shear flows. 
Journal of Biomechanics 2008, 41, 2312-2318.
(93) Decuzzi, P.; Godin, B.; Tanaka, T.; Lee, S. Y.; Chiappini, C.; Liu, X.; Ferrari, M. 
Size and shape effects in the biodistribution of intravascularly injected particles. 
Journal of Controlled Release 2010, 141, 320-327. 94*
(94) Adriani, G.; de Tullio, M. D.; Ferrari, M.; Hussain, F.; Pascazio, G.; Liu, X.;
Decuzzi, P. The preferential targeting of the diseased microvasculature by disk­
like particles. Biomaterials 2012, 33, 5504-5513.
65
(95) Godin, B.; Chiappini, C.; Srinivasan, S.; Alexander, J. F.; Yokoi, K.; Ferrari, M.; 
Decuzzi, P.; Liu, X. Drug Delivery: Discoidal Porous Silicon Particles: 
Fabrication and Biodistribution in Breast Cancer Bearing Mice (Adv. Funct. 
Mater. 20/2012). Advanced Functional Materials 2012, 22, 4186-4186.
(96) Tommasi, S.; Mangia, A.; Lacalamita, R.; Bellizzi, A.; Fedele, V.; Chiriatti, A.; 
Thomssen, C.; Kendzierski, N.; Latorre, A.; Lorusso, V.; Schittulli, F.; Zito, F.; 
Kavallaris, M.; Paradiso, A. Cytoskeleton and paclitaxel sensitivity in breast 
cancer: The role of P-tubulins. International Journal of Cancer 2007, 120, 2078­
2085.
(97) Marc, S. G.; Ahmed, T. A.; Asok, B.; Cassandra, D. M. C.; Philip, W.; Mariusz,
K.; Carol E., C.; Richard, F. L.; Jack A., T.; Sambasivarao, D.: IC<sub>50</sub> 
Values for Paclitaxel and Analogs in Cytotoxicity Assays with Breast Cancer Cell 
Lines, 2015.
(98) McCloskey, D. E.; Kaufmann, S. H.; Prestigiacomo, L. J.; Davidson, N. E. 
Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer 
cells. Clinical Cancer Research 1996, 2, 847-854.
(99) Rouzier, R.; Rajan, R.; Wagner, P.; Hess, K. R.; Gold, D. L.; Stec, J.; Ayers, M.; 
Ross, J. S.; Zhang, P.; Buchholz, T. A.; Kuerer, H.; Green, M.; Arun, B.; 
Hortobagyi, G. N.; Symmans, W. F.; Pusztai, L. Microtubule-associated protein 
tau: a marker of paclitaxel sensitivity in breast cancer. Proceedings of the 
National Academy of Sciences of the United States of America 2005, 102, 8315­
8320.
(100) Haghnavaz, N.; Asghari, F.; Elieh Ali Komi, D.; Shanehbandi, D.; Baradaran, B.; 
Kazemi, T. HER2 positivity may confer resistance to therapy with paclitaxel in 
breast cancer cell lines. Artificial cells, nanomedicine, and biotechnology 2018, 
46, 518-523.
(101) Fisi, V.; Katai, E.; Bogner, P.; Miseta, A.; Nagy, T. Timed, sequential 
administration of paclitaxel improves its cytotoxic effectiveness in a cell culture 
model. Cell Cycle 2016, 15, 1227-1233.
(102) Sui, M.; Dziadyk, J. M.; Zhu, X.; Fan, W. Cell Cycle-Dependent Antagonistic 
Interactions between Paclitaxel and y-Radiation in Combination Therapy. Clinical 
Cancer Research 2004, 10, 4848-4857. 103*
(103) Weissenstein, U.; Kunz, M.; Urech, K.; Regueiro, U.; Baumgartner, S. Interaction
of a standardized mistletoe (Viscum album) preparation with antitumor effects of
Trastuzumab in vitro. BMC Complement Altern Med 2016, 16, 271-271.
66
(104) Rodriguez, C. E.; Reidel, S. I.; De Kier Joffe, E. D. B.; Jasnis, M. A.; Fiszman, G.
L. Autophagy protects from trastuzumab-induced cytotoxicity in HER2 
overexpressing breast tumor spheroids. PLoS ONE 2015, 10, e0137920.
(105) Wang, C.-X.; Koay, D. C.; Edwards, A.; Lu, Z.; Mor, G.; Ocal, I. T.; DiGiovanna,
M. P. In vitro and in vivo Effects of Combination of Trastuzumab (Herceptin) and 
Tamoxifen in Breast Cancer. Breast Cancer Research and Treatment 2005, 92, 
251-263.
(106) Foley, E. A.; Kapoor, T. M. Microtubule attachment and spindle assembly 
checkpoint signalling at the kinetochore. Nature reviews Molecular cell biology 
2013, 14, 25.
(107) Kops, G. J.; Weaver, B. A.; Cleveland, D. W. On the road to cancer: aneuploidy 
and the mitotic checkpoint. Nature Reviews Cancer 2005, 5, 773.
(108) Lara-Gonzalez, P.; Westhorpe, F. G.; Taylor, S. S. The spindle assembly 
checkpoint. Current biology 2012, 22, R966-R980.
(109) Portt, L.; Norman, G.; Clapp, C.; Greenwood, M.; Greenwood, M. T. Anti­
apoptosis and cell survival: a review. Biochimica et Biophysica Acta (BBA)- 
Molecular Cell Research 2011, 1813, 238-259.
(110) Twiddy, D.; Cain, K. Caspase-9 cleavage, do you need it? Biochem J 2007, 405, 
e1-e2.
(111) Gupta, S.; Kass, G. E. N.; Szegezdi, E.; Joseph, B. The mitochondrial death 
pathway: a promising therapeutic target in diseases. Journal of Cellular and 
Molecular Medicine 2009, 13, 1004-1033.
(112) Brunelle, J. K.; Letai, A. Control of mitochondrial apoptosis by the Bcl-2 family. 
Journal of Cell Science 2009, 122, 437-441.
(113) Galluzzi, L.; Morselli, E.; Kepp, O.; Vitale, I.; Rigoni, A.; Vacchelli, E.; 
Michaud, M.; Zischka, H.; Castedo, M.; Kroemer, G. Mitochondrial gateways to 
cancer. Molecular Aspects of Medicine 2010, 31, 1-20.
(114) Allan, L. A.; Clarke, P. R. Phosphorylation of Caspase-9 by CDK1/Cyclin B1 
Protects Mitotic Cells against Apoptosis. Molecular Cell 2007, 26, 301-310. 15*
(115) Andersen, J. L.; Johnson, C. E.; Freel, C. D.; Parrish, A. B.; Day, J. L.;
Buchakjian, M. R.; Nutt, L. K.; Thompson, J. W.; Moseley, M. A.; Kornbluth, S.
Restraint of apoptosis during mitosis through interdomain phosphorylation of
caspase-2. The EMBO Journal 2009, 28, 3216-3227.
67
(116) Ola, M. S.; Nawaz, M.; Ahsan, H. Role of Bcl-2 family proteins and caspases in 
the regulation of apoptosis. Molecular and Cellular Biochemistry 2011, 351, 41­
58.
(117) Deveraux, Q. L.; Reed, J. C. IAP family proteins - Suppressors of apoptosis.
Genes and Development 1999, 13, 239-252.
(118) Pardo, O. E.; Lesay, A.; Arcaro, A.; Lopes, R.; Ng, B. L.; Warne, P. H.; McNeish, 
I. A.; Tetley, T. D.; Lemoine, N. R.; Mehmet, H.; Seckl, M. J.; Downward, J. 
Fibroblast growth factor 2-mediated translational control of IAPs blocks 
mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer 
cells. Mol Cell Biol 2003, 23, 7600-7610.
(119) Ferreira, C. G.; van der Valk, P.; Span, S. W.; Jonker, J. M.; Postmus, P. E.;
Kruyt, F. A. E.; Giaccone, G. Assessment of IAP (inhibitor of apoptosis) proteins 
as predictors of response to chemotherapy in advanced non-small-cell lung cancer 
patients. Annals of Oncology 2001, 12, 799-805.
(120) Dong, F.; Guo, W.; Zhang, L.; Wu, S.; Teraishi, F.; Davis, J. J.; Fang, B. 
Downregulation of XIAP and induction of apoptosis by the synthetic cyclin- 
dependent kinase inhibitor GW8510 in non-small cell lung cancer cells. Cancer 
Biology & Therapy 2006, 5, 165-170.
(121) Asselin, E.; Mills, G. B.; Tsang, B. K. XIAP Regulates Akt Activity and Caspase- 
3-dependent Cleavage during Cisplatin-induced Apoptosis in Human Ovarian 
Epithelial Cancer Cells. Cancer research 2001, 61, 1862-1868.
(122) Deveraux, Q. L.; Roy, N.; Stennicke, H. R.; Van Arsdale, T.; Zhou, Q.; 
Srinivasula, S. M.; Alnemri, E. S.; Salvesen, G. S.; Reed, J. C. IAPs block 
apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of 
distinct caspases. EMBO J 1998, 17, 2215-2223.
(123) Almenara, J.; Rosato, R.; Grant, S. Synergistic induction of mitochondrial damage 
and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase 
inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 2002, 16, 1331­
1343. 124
(124) Dai, Y.; Chen, S.; Wang, L.; Pei, X.-Y.; Kramer, L. B.; Dent, P.; Grant, S. 
Bortezomib interacts synergistically with belinostat in human acute myeloid 
leukaemia and acute lymphoblastic leukaemia cells in association with 
perturbations in NF-kB and Bim. British Journal of Haematology 2011, 153, 222­
235.
68
II. THE ROLE OF INTRINSIC SIGNALING PATHWAYS IN CELL
PROLIFERRATION
ABSTRACT
Programmed cell death, or apoptosis, and controlled cell division, or mitosis are 
two highly regulated processes in the cell cycle. A balance between apoptosis and mitosis 
is critical for multiple distinct states including embryonic development, immune cell 
activation, stem cell differentiation, tissue formation (wound healing), and tumor 
prevention, among others. A cell undergoing apoptosis shows a series of characteristic 
morphological changes similar to normal mitosis and an aberrant form of mitosis. During 
each of these processes, nuclear chromatin condenses, the nuclear lamina and 
cytoplasmic membranes disintegrate, and cells decrease in volume. The morphological 
resemblance among cells undergoing these processes suggests that the underlying 
intracellular signaling pathways influence the mitotic cell fate. In this review paper, the 
relationship of intracellular signaling pathways, cell cycle dynamics, and apoptotic cell 
signaling pathways are discussed. The MAPK/Ras/Raf/ERK, PI3K/Akt, JAK/STAT,
Wnt, and TGF-P are major cell signaling pathways that transmit signals from multiple 
cell surface receptors to transcription factors in the nucleus. The pathways are stimulated 
by cytokines, growth factors, and external stimuli, i.e., reactive oxygen species which 
induce signal transduction pathways and regulate complex processes such as cell cycle 
progression, cell proliferation, cellular growth, differentiation, and apoptosis. Aberrant 
mutations in particular genes and proteins of these pathways contribute to cancers usually
by inhibiting pro-apoptotic proteins and stimulating anti-apoptotic proteins. The cell 
cycle is regulated by intracellular signaling pathways such as the MAPK/Ras/Raf/ERK 
and PI3K pathways to synthesize cyclin D and other mitosis regulating proteins (Myc and 
Jun). Cyclin D1 binds to CDK4/6 to form an effective complex, activate several 
substrates, and initiate the cell cycle. The prominent molecules that regulate signaling 
pathways in normal and cancer cells are described.
1. INTRODUCTION
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Cell death and cell proliferation are coordinated in the cell cycle to maintain 
tissue function and tissue homeostasis.1-4 The mammalian cell cycle is a regulated 
process that monitors the replication of genetic information and the division of cells. This 
regulation involves growth -  regulatory signals and protein signals that ensure the genetic 
sequence of the cell receives no damage.5 The cell cycle consists of four phases including 
a GO or quiescence phase, G1 or Gap 1, S or DNA synthesis phase, a G2 or Gap 2 phase 
with mitosis or M phase at the end (Figure 1 (a)). These cell cycle phases are tightly 
controlled by a series of cell cycle proteins cyclin/cyclin-dependent kinases (CDKs) and 
cyclin inhibitors.6 There are four cyclin groups (cyclin D, E, A, and B) that once bound 
activate specific cyclin-dependent kinase (CDK) pathways. The CDK pathways act as 
checkpoints that regulate the structure and property of the cellular chromosomes to either 
allow or deny entry into the next phase. Once the cyclin/CDKs of cyclin D1 to CDK 
4/CDK 6 are bound and activated, the complex phosphorylates the retinoblastoma (Rb)
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proteins and releases the activated E2F. At E2F this protein family determines whether 
the cells will reenter the cell cycle or eliminate the cell completely.7
Figure 1. The cell cycle. (a) The cell cycle comprises four phases: G1, S, G2, and M. 
Extracellular signals received during the G1 phase lead to the production of D-type 
cyclins that interact with their dependent kinases. If the concentration of these cyclins is 
sufficient, the cell will pass the R phase, and E-, A-, and B-type cyclins will trigger DNA 
synthesis, a second gap phase to perform DNA repair, and mitosis. The cell is only 
responsive to extracellular signals in G1. (b) Cyclin levels during the cell cycle. The 
concentration of different types of cyclins varies with cell cycle progression. When a cell 
enters a new phase, a new type of cyclin associates with CDKs, ensuring the cycle only 
moves in the forward direction. The figure is reproduced with permission from Robert A.
Weinberg (The Biology of Cancer, second edition) (2013)
Entry into the cell cycle is regulated by the mitogenic signaling pathways. The 
signaling pathways activate the downstream growth-promoting transcription factors 
including Myc, activator protein (API), P-catenin. Such transcription factors induce 
several cell cycle proteins such as cyclin D. D-type cyclins are typically present in the 
cell in extremely low concentrations. Unlike other cyclins, D-type cyclins are responsive 
to extracellular signals including mitogens. The E, A, and B-type cyclins are regulated in
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a preprogrammed cyclic fashion to maintain the cell cycle in a unidirectional way 
(Figure 1 (b)). In response to the appropriate signals, the concentration of D-type cyclins 
increases in the cell. D-type cyclins bind to and activate CDK4 and CDK6.8 Formation of 
active cyclin D-CDK4/6 complex is inhibited by the inhibitor of CDK-4 (INK4) family 
CDKIs (Figure 2 (a)). CDKIs act in response to growth factors, DNA damage, and other 
stressors. Two families of CDKIs exist p21 family members and INK4 proteins. p21, 
p27, and p57 belong to the p21 family and act by binding to cyclin-CDK complexes to 
block their active and binding sites.8 Proteins of the INK4 family include p16, p15, p18, 
and p19 which bind to the catalytic subunit of CDK4/6 to bind D-type cyclins from 
activating them. The CDK inhibitors are activated in response to senescence inducing or 
growth-inhibitory signals including DNA damage, transforming growth factor-P (TGF- 
P), forkhead box protein 01/ O3 (FOXO1/ FOXO3) signaling pathways.
Figure 2. The pRb-E2F pathway. (a) pRb in a hypo- and hyperphosphorylated state. 
CDKIs act on CDKs and CDK-cyclin complexes to prevent pRb from becoming 
phosphorylated. (b) In the absence of CDKIs, CDK-cyclin complexes are free to 
phosphorylate pRb. This induces a conformational change that allows pRb to release E2F
proteins
The retinoblastoma protein (pRb) normally exists in a hypophosphorylated 
state. Hypophosphorylated pRb binds E2F proteins. Upon the formation of active cyclin 
D-CDK4/6 complex and subsequent hyperphosphorylation of pRb, E2Fs are released 
which stimulate the transcription of several genes involved in cell cycle progression and 
cell division (Figure 2 (b)). D-type cyclin-CDK4/6 complexes begin the process of 
phosphorylating pRb. Among the many genes stimulated by E2Fs encode E-type cyclins. 
E-type cyclins form cyclin-CDK complexes with CDK2 and phosphorylate pRb. This 
positive feedback loop allows pRb to become hyperphosphorylated and allows the cell to 
progress from the G1 phase to the S phase.8,9
E2Fs activated the transcription of S phase promoting genes including CCNE1 
and CCNE2, translating into cyclin E proteins. Cyclin E proteins pairs with CDK2 
proteins. The cyclin E-CDK2 complexes remain in an inactivated state by the interactions 
with p27KIP1 and p21CIP1 cyclin-CDK complex inhibitor proteins. These inhibitor proteins 
are regulated by the p53 dependent DNA damage checkpoint protein molecules and 
growth-inhibitory signals. The sequestration of p27KIP1 and p21CIP1 inhibitory proteins by 
cyclin D-CDK4/6 complex and phosphorylation of p27KIP1 by cyclin E-CDK2 complex 
activates the cyclin E-CDK2 complex. Upon activation of the cyclin E-CDK2 complex 
and further phosphorylation of pRb and other target proteins, the cells enter the S phase 
(Figure 3 (a)).
Entering the S phase, D type cyclins is exported to the cytoplasm from the 
nucleus where its level is no longer influenced by the extracellular growth factors. DNA 
replication occurs during the S phase while A-type cyclins replace E-type cyclins. The S 
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Figure 3. Representation of G1-S, G2-M cell cycle phase transition. The figure shows the 
regulation of (a) G1-S and (b) G2-M transition in the cell cycle. The cell cycle machinery 
is controlled by multiple proteins including cyclins, CDKs, CDKIs, and several
transcription factors
This ensures that the cell has adequate time to complete DNA replication and 
repair any DNA damage that occurred during replication. During the late G2 phase, 
several G2 phase regulator proteins including B type cyclin proteins are translated 
replacing the A-type cyclins. The translation requires the association of multi-vulval class 
B protein (MUVB) complex with the forkhead box M1 (FOXM1) transcription factor. 
Together they bind with the cell cycle genes homology promoter region (CHR) and 
induce the transcription of G2 phase regulatory genes including cyclin B genes. Cyclin B 
pairs with CDK1 for cell cycle progression. The Cyclin B-CDK1 complex is activated in 
the following mechanism: CDK1 requires phosphorylation at threonine (Thr161) by the 
cyclin H-CDK7 protein complex and dephosphorylation at threonine 14 (Thr14) and 
tyrosine 15(Tyr15) kinase sites by cell division cycle 25 (CDC25) phosphatase enzyme. 
CDK7 is known as CDK activating kinase (CAK). The activation of the cyclin A/B- 
CDK2 complex promotes the cell cycle progression to the mitosis or M phase. This 
progression can be halted by checkpoint kinase-1 (CHK1) dependent G2 phase 
checkpoint upon DNA damage (Figure 3 (b)).
The events of mitosis include prophase, prometaphase, metaphase, anaphase, and 
telophase, resulting in two identical cells. After the M phase, the cell returns to G1 where 
it is once again receptive to internal and external signals and must divide whether to enter 
G0 or repeat the cell cycle. In this review, we will emphasize the major growth and anti­
growth signals that stimulate the cells to take the exit from or retrieve to their quiescence 
phase. Aberrations in these signaling pathways can lead to two closely related hallmarks 
of cancer: evading growth suppressors and self-sufficiency in growth signals.10 Pathways
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of interest reviewed in this study are the MAPK, PI3K, Jak-STAT, Wnt, and TGFP 
signaling pathways.
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2. CELL SIGNALING PATHWAYS
2.1. MAPK/Ras/Raf/ERK SIGNALING PATHWAY
The MAPK pathway is a kinase cascade, also known as the extracellular signal- 
regulated kinase pathway (ERK). The first step in this pathway is Ras activation (or 
activation of other Ras family proteins). Ras activation begins when specific growth 
factors bind to transmembrane receptors, primarily receptor tyrosine kinases.11 These 
receptors most commonly phosphorylate growth factor receptor-bound protein 2 (Grb2) 
or Shc. If Shc is phosphorylated, it will phosphorylate Grb2. Grb2 contains two 
functional domains: SH2 and SH3.9 Upon phosphorylation, the SH2 domain binds to Shc 
or the receptor, and the SH3 domain is available for Sos binding.9 This brings Sos into 
close proximity to Ras.12
Ras (and related Ras family proteins) are membrane-bound GTPases that function 
as G proteins. G proteins act as molecular switches that cycle between being GDP and 
GTP bound depending on extracellular signals such as growth factors and survival 
signals.13 Sos can activate Ras by inducing it to convert GDP to GTP (Figure 4).
Ras binding and activation lead to Raf kinases including ARAF, BRAF, and 
CRAF, thus beginning the kinase cascade (Figure 5). Rafs are MAPKKKs which activate
MAPKKs MEK1 and MEK2. MEK1/2 activates MAPKs ERK1 and ERK2.
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Figure 4. The Ras activation pathway. Growth factors bind to their respective receptors 
allowing them to bind Shc or Grb2. Grb2 binds Sos bringing it in proximity to Ras. This 
induces Ras to switch from an “off’ to an “on” conformation, converting GDP to GTP
These MAPKs translocate to the nucleus and phosphorylate several proliferation 
promoting transcription factors including Myc.14 Myc is a major regulator of cell cycle 
progression and pRb.9 Myc is a transcription factor that elevates the expression of D-type 
cyclins, CDK4/6, and several E2F proteins. Myc also signals the expression of Cull, a 
protein which phosphorylates the CDKI p27 for subsequent ubiquitination and 
degradation.13 Myc is also capable of repressing p15 and p21 expression by associating 
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Figure 5. The MAPK signaling pathway. Ras activation initiates a kinase cascade. 
Eventually, MAPK proteins ERK1 and ERK2 enter the nucleus to phosphorylate and 
activate several pro-mitotic transcription factors including Myc
2.2. MAPK PATHWAY ASSOCIATED TARGETS FOR CANCER THERAPY
Extensive studies have been conducted targeting the Ras-Raf-MEK-ERK pathway 
alterations in cancer. The pathway is altered in almost 40% of all types of human 
cancers.11,15 RAS point mutations are found in up to 30% of all human cancers and 90% 
of pancreatic adenocarcinomas.11 These mutations often render Ras insensitive to 
inactivation leading them to remain activated in the absence of pro-mitotic factors.11 
BRAF mutation accounts for almost 10% of all human cancers.16 In metastatic 
melanoma, BRAF mutation is altered in almost 50-60% of the cases and is considered to 
be the most prevalent acquired hallmark in melanoma.15 Mutations resulting in 
hyperactive Raf proteins are also common among thyroid17-19 and colon cancer,20,21, 
among other types.11 The prevalence of these mutations in cancer has led to considerable 
research into treatments and mechanisms of resistance targeting this pathway.15
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One of the major strategies of targeting and blocking the MAPK signaling 
pathway includes the use of MEK inhibitors.11 MEK inhibitors are small molecules that 
inhibit MEK1/2 either by inhibiting Raf phosphorylation activity or by allosterically 
blocking the conformational shift of MEK1/2 typically induced by phosphorylation.22 
Cobimetinib (brand name Cotellic) is an FDA approved MEK inhibitor which may be 
used in combination with Vemurafenib to treat melanoma. Vemurafenib (a Raf inhibitor) 
was previously approved for patients with a BRAF V600E mutation.22 Dabrafenib and 
Encorafenib are also approved for advanced melanoma patients with BRAF V600E 
mutation. In combination, Cobimetinib has been shown to improve progression-free 
survival and response to the drug compared to Vemurafenib alone.23 Two other MEK 
inhibitors, Trametinib (Mekinist) and Binimetinib (Mektovi) have been approved by the 
FDA to treat melanomas with mutations in the BRAF genes in combination with Raf 
inhibitors. The epidermal growth factor receptor (EGFR) inhibitors Gefitinib and 
Lapatinib are two approved drugs to inhibit the MAPK pathway in cancer treatment.
Though MEK inhibitors showed tremendous potency and high selectivity to 
inhibit this pathway, their success was limited by the acquired resistance upon treatment 
with single-arm MEK inhibitor.24-26 Upon perturbation by the MEK inhibitor, a negative 
feedback loop mechanism inactivates the Raf protein in the pathway causing the drug to 
be ineffective on the MEK eventually. This negative feedback loop mechanism results in 
the restoration of the ERK signaling pathway. Hence, targeting the inhibition of both Raf 
and MEK is now a standard therapy in metastatic melanoma treatment. Inhibition of 
restoration of ERK pathway upon therapeutic intervention by Raf or MEK inhibitors is a 
major challenge in dealing with drug resistance.27-29 The mechanisms of restoration often
impinge on the dimerization of Raf kinases,30 though dimerization is a part of 
physiological Raf activation.31 Raf kinases are frequently dimerized in tumors with 
mutated RAS. The dimerized Raf is drug-resistant can paradoxically reactivate the ERK 
pathways causing therapeutic resistance. Inhibitors targeting the inhibition Raf 
dimerization may overcome such resistance. Furthermore, the therapeutic resistance in 
this pathway is also attributed to the role of Jun N-terminal kinase (JNK) and p38 MAPK 
pathway mediated drug resistance.31-35
2.3. PI3K/Akt SIGNALING PATHWAY
The PI3K/Akt pathway influences cell proliferation (Figure 6). Extracellular 
cytokines bind to transmembrane receptors which activate PI3K via two mechanisms. 
Some receptors bind the regulatory subunit of PI3K (p85), recruiting the catalytic subunit 
(p110) of PI3K.36 Ras can also activate the p110 subunit of PI3K in addition to its 
function in the MAPK signaling pathway.14,36 Once activated, PI3K causes 
phosphatidylinositol-dependent kinase-1 (PDK1) to localize at the membrane.36 PDK1 
phosphorylates and activates Akt. Akt is known to phosphorylate a number of substrates, 
many of which have implications in controlling the cell cycle regulation.9 Notably, it 
phosphorylates glycogen synthase kinase 3 beta (GSK-3P), tagging it for degradation.9 
GSK-3P, a major player in the Wnt signaling pathway described below, is responsible for 
phosphorylating P-catenin (an upstream regulator of Myc and cyclin D) for ubiquitination 
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Figure 6. The PI3K signaling pathway. Ligand-receptor binding activates and associates 
p85 with p110 to form PI3K. PI3K activates PDK1 which phosphorylates Akt. 
Phosphorylated Akt can inhibit anti-mitotic proteins including GSK-3P or phosphorylate 
them for subsequent ubiquitination and degradation. Akt also has anti-apoptotic effects
Upon phosphorylation, p21 moves from the nucleus to the cytoplasm where it 
actually exhibits anti-apoptotic functions. The third substrate for Akt involved in 
proliferation is FOXO4. FOXO4 induces CDKI p27 expression; however, upon 
phosphorylation, FOXO4 is transported to the cytoplasm like p21.9
It is also interesting to note that Akt phosphorylates substrates directly related to 
the apoptotic machinery. Akt inhibits the pro-apoptotic proteins Bad and caspase 9 and
activates mouse-double minute 2 homolog (MDM2). Thus, Akt drives cell survival and 
proliferation by transmitting anti-apoptotic and pro-mitotic signals within the cell. 
Because of its role in regulating cell death and proliferation, it is perhaps unsurprising 
that aberrations in the PI3K pathway have been found in several cancers. Notably, a 
mutant p85 has been identified in Hodgkin’s lymphoma cells and has been linked to 
breast cancer, lung cancer, melanomas, and leukemia.36
2.4. PI3K/Akt PATHWAY ASSOCIATED TARGETS FOR CANCER THERAPY
The PI3K/Akt pathway is an attractive therapy for chemotherapy due to its role in 
so many cancer types. PI3K inhibitors act via various mechanisms to inhibit members of 
the PI3K/Akt pathway, primarily PI3K or Akt.36 Wortmannin was the first PI3K inhibitor 
to be approved by the FDA.36 Wortmannin is not selective and binds to PI3K as well as 
several related proteins.38 Wortmannin irreversibly inhibits PI3K by covalently binding to 
a lysine residue in the protein’s catalytic subunit.38 Wortmannin has good efficacy but is 
somewhat unstable; following its development other PI3K inhibitors have been 
developed.
Two more recently approved drugs include Aleplisib and Idelalisib. Alpelisib 
(Piqray) was approved by the FDA to treat HER2 negative breast cancer with mutant 
PI3K. Idelalisib (Zydelig) has been approved for solo or combination treatment of 
chronic lymphocytic leukemia and two types of Non-Hodgkin lymphomas. PIK3CA is a 
mediator of HER2 targeted treatment resistance. PIK3CA mutation accounts for almost 
20% of HER2 positive breast cancer patients and imposes the insufficiency of HER2 
blockade strategy to suppress the downstream PI3K signaling pathway. PI3K activation
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pathway is most often accompanied by loss of tumor suppressor gene PTEN in breast 
cancer.
2.5. Jak-STAT SIGNALING PATHWAY
The Jak-STAT signaling pathway offers another method for cytokines and growth 
factors to directly influence cell proliferation (Figure 7).39
Figure 7. The Jak-STAT signaling pathway. Associated growth factors bind receptors to 
activate Jak family proteins. These proteins phosphorylate each other followed by their 
receptor. This leads to the binding and phosphorylation of STAT proteins. STAT proteins 
dimerize and translocate to the nucleus to activate pro-mitotic genes that encode for D-
type cyclins, CDK4/6, and Myc
Upon the binding of their extracellular ligands, receptors in the Jak-STAT 
pathway dimerize and associated Janus kinases (Jaks) phosphorylate tyrosines on the 
opposing receptors. Activated Jaks can then phosphorylate STATs (signal transducers
and activators of transcription). Upon phosphorylation, STAT proteins dimerize and 
translocate from the cytoplasm to the nucleus. STATs activate several target genes 
involved in cell proliferation including those encoding for Myc and two D-type cyclins. 
This pathway offers a simple opportunity for signal transduction between extracellular 
signals and the cell cycle; however, this pathway also interacts with some of the more 
complex pathways described above. For example, Jaks are capable of phosphorylating 
tyrosines on receptors in the MAPK or PI3K pathway as well as their own pathway. This 
phosphorylation leads to the same activation of Ras (in MAPK signaling) and p85 (in 
PI3K), enabling those pathways to send proliferative signals to the nucleus as well.39,40
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2.6. Jak-STAT PATHWAY ASSOCIATED TARGETS FOR CANCER THERAPY
In healthy cells, STAT proteins are only active upon phosphorylation by Jaks. In 
some cancers, constitutively active STAT proteins have been found, signaling for 
proliferation in the absence of cytokines and growth factors. Notably, STAT3 (a protein 
in the STAT family) has been found to be constitutively active in 40% of breast cancers 
and T-cell large granular lymphocytic leukemia cases, as well as many cases of prostate, 
glioblastoma, thyroid, and non-small cell lung cancer.40 The Jak-STAT pathway also 
regulates components of the immune response; several mutations resulting in hyperactive 
Jak or STAT proteins are known to influence immune diseases.40,41 Because of this, Jak 
and STAT inhibitors have been studied for many cancers and immune diseases.42 Several 
Jak inhibitors have been approved to treat immune disorders such as psoriasis, 
myelofibrosis, and rheumatoid arthritis.41,43 While many of these agents are also being 
investigated to treat different cancer types, none have yet passed clinical trials.41,43
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2.7. Wnt SIGNALING PATHWAY
The Wnt signaling pathway can also influence cellular proliferation (Figure 8).37
Figure 8. The Wnt signaling pathway. Wnt binds to the transmembrane receptor 
Frizzled to activate Disheveled. Disheveled inhibits GSK-3P preventing P-catenin 
degradation. Instead, B-catenin translocates to the nucleus, associates with Tcf/Lef, and 
induces the transcription of D-type cyclins and Myc
Wnts are secreted glycoproteins that interact with several signaling pathways that 
are not fully understood.37,44 The most well-known is the canonical pathway which 
influences cell cycle progression.9,37,44 P-catenin is normally present in the cell in very
low concentrations with a half-life of 20 minutes.9 Cytoplasmic P-catenin forms a 
complex with axin, adenomatous polyposis coli protein (APC), and GSK-3P.9 This 
multiprotein complex enables GSK-3P to phosphorylate P-catenin, tagging it for 
ubiquitination and subsequent degradation, thus maintaining its short half-life and low 
intracellular concentration.9 However, the canonical Wnt signaling pathway prevents this 
degradation from occurring. Wnts associate with low-density lipoprotein receptor-related 
protein (LRP) 5 and 6, Wnt ligand co-receptors, and bind to transmembrane receptors of 
the Frizzled gene family.44 This binding, in turn, inhibits GSK-3P.44 With GSK-3P unable 
to phosphorylate P-catenin, it accumulates in the cytoplasm before translocating to the 
nucleus.44 There it binds to and activates the T-cell factor/lymphoid enhancer factor 
(Tcf/Lef) transcription factors.9 This complex is responsible for the transcription of many 
genes, including Myc and cyclin D1, both of which are involved in cell cycle
44progression.44
2.8. Wnt SIGNALING PATHWAY ASSOCIATED TARGETS FOR CANCER 
THERAPY
Colorectal cancers (CRC) are the most commonly affected cancers by the 
dysregulation in the Wnt signaling pathway. A sequencing study on 1134 CRC samples 
identified that almost 96% % of the human CRC was associated with Wnt oncogenic 
activity.45 Loss of function mutation in APC is the most common in colorectal cancers,46- 
50 followed by alterations causing inhibition of the proteasomal degradation or 
downregulation of P-catenin.51-54 Due to the acquired resistance upon conventional 
therapeutic intervention, a few Wnt/P-catenin inhibitors have been identified as useful 
agents in treating any type of cancer with Wnt pathway dysregulation. Krishnamurthy
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and Kurzrock summarized 35 therapeutic drugs that inhibit the Wnt signaling 
pathway.55 Of those, three off label drugs were FDA approved: Niclosamide, a drug 
traditionally used to treat tapeworm infestations, thought to downregulate disheveled; 
Sulindac, a nonsteroidal anti-inflammatory drug, also thought to target disheveled; and 
Pyrvinium, an anthelmintic, thought to target the Wnt inhibitor CK1a.55 The wide domain 
of Wnt signaling dysregulation across the cancer types has led to the identification of 
cancer-specific therapeutic targets in the Wnt signaling pathway. The list of Wnt/ P- 
catenin inhibitors in the past and present clinical trials and potential therapeutic target in 
this pathway beyond the P-catenin destruction pathways are well summarized in a recent 
review by Jung et. al.56 In addition to the malignant progression caused by the aberrant 
Wnt signaling pathway emerging evidence suggests that Wnt pathway also alters the 
cancer-immune system surveillance and offers resistance to the immunotherapeutic 
drugs.57-59
2.9. TGF- p SIGNALING PATHWAY
The above-mentioned signaling pathways all rely on growth signals to stimulate 
proliferation. When those pathways acquire mutations resulting in constitutively active 
components, they fire and signal for cell cycle progression, whether or not growth signals 
are present. This is known as “self-sufficiency in growth signal,” a hallmark of cancer.10 
However, cells do not rely solely on the presence of growth signals to stimulate 
proliferation. Anti-growth signals also regulate proliferation by commanding a cell not to 
progress through the cell cycle.
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Transforming growth factor-beta (TGF-P) is the best studied growth-inhibitory 
signal (Figure 9).5
Figure 9. The TGF P signaling pathway. TGF P inhibits cell cycle progression by 
binding Type I (blue) and Type II (green) receptors. Binding induces Smad2/3 
phosphorylation. Smad 2/3 then dimerizes with Smad 4 and translocates to the nucleus to 
associate with Miz-1. The Smad dimer-Miz-1 complex acts as a transcription factor for
the CDKIs p21 and p15
When the TGF-P ligand binds receptors on the cell’s surface, type I and II 
receptors associate leading to the phosphorylation of Smad2 and Smad3. Phosphorylated
Smad 2/3 is capable of dimerizing with Smad4.9 These Smad dimers translocate to the 
nucleus where they associate with Miz-1.9 Upon binding with Miz-1, Smad complexes 
act as transcription factors for CDKIs p15 and p21.9
In healthy cells, Smad complexes and Myc compete to bind with Miz-1 to control 
the expression or repression of these CDKIs.9 To prevent proliferation, Smad3 is capable 
of binding to the promoter site of the MYC gene, blocking its expression and favoring 
binding between Miz-1 and Smads.9 Many cancer cells develop strategies to avoid TGF- 
P’s growth inhibitory effects, known as “insensitivity to antigrowth signals”.10
Overexpression of Myc will favor Miz-1 binding to Myc rather than Smad 
dimers, preventing the expression of p21 and p15.9 It is common among cancer cells for 
mutations in the MYC promoter site to prevent TGF-P induced repression.5 In other cells, 
pRb is lost and the MAPK pathway is no longer the main pathway signaling to advance 
in the cell cycle.9 Since TGF-P primarily inhibits Myc and the MAPK signaling pathway, 
this renders TGF-P ineffective as other signaling pathways continue to trigger 
activation.13 In colon cancers, mutations in the TGFP pathway are common. These take 
the form of mutations in the gene which encodes Smad2 or through the presence of Ski 
and Sno, proteins that bind to and inhibit Smad dimers.9 Other colon cancers acquire 
mutations which inactivate the transmembrane receptors in the TGF-P pathway.9
2.10. TGF-p SIGNALING PATHWAY ASSOCIATED TARGETS FOR CANCER 
THERAPY
In premalignant state, TGF P maintains the tissue homeostasis by cytostasis, 
differentiation, induction of apoptosis, suppression of tumorigenic inflammation and 
stroma derived mitogens. The malignant cells can adulterate the suppressive pathway of
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TGF P promoting tumor growth and invasion, deceiving the immune surveillance, and 
finally causing metastasis. There are two ways to do that. The first one is the upstream 
inactivation of the core component in the pathway, for example, mutations in the 
receptors. Secondly, the downstream alterations in the tumor-suppressive arm in the 
pathway such as defective cytostatic response in tumorigenesis. The consequence of the 
first type of malignancy in the cancer cells removes the chance for tumor suppression 
upon suppressive growth signals. The second type of malignancy is more aggressive as it 
allows the cancer cells to aberrantly use the TGF P regulatory functions, produce 
autocrine mitogens, release prometastatic cytokines and hence, create a pro-tumorigenic 
microenvironment along with deactivation of growth suppression capability.
Additionally, TGF-P may contribute to invasion and metastasis.60 Cancer cells TGF-P has 
been shown to induce Smad 2/3 dependent epithelial-mesenchymal transition (EMT).60 
EMT is a critical acquired ability in metastatic cancers. The therapeutic targets in this 
pathway include antisense oligonucleotides for TGF-P production inhibition, anti-TGF-P 
antibodies, and anti-receptor antibodies to inhibit the ligand-receptor interactions, small 
molecules targeting TGF-P receptor kinases and TGF-P trapping receptor codomain 
proteins.61-64
3. CELL CYCLE PROTEINS: CYCLINS, CDKs AND CDK INHIBITORS
In the following sections, the main molecules participating in the signaling 




Cyclin Ds are important for the cell entry into the G1 phase of the cell cycle and 
the transition to the S phase. There are three members of the cyclin D family: D1, D2, 
and D3. Cyclin D1 plays an important role in cell cycle progression. Cyclin D1 conducts 
specific functions to regulate gene expression in the context of chromatin, cellular 
migration promotion, and chromosomal instability promotion.65 Once the cyclin D family 
activates the kinases, CDK4 and CDK6, the cells can transition into the S phase. The 
cyclin E family plays an important checkpoint that allows the cells to transition from the 
G1 phase to the S phase. There are two members of the cyclin E family: E1 and E2. The 
cyclin E family limits the number of cells that enter the S phase and the G0 phase. Cyclin 
E also plays an important role in replication of DNA, the genomic stability, and the 
centrosome cycle. Once the cyclin E family activates the kinase CDK2, the cells can 
transition into the S phase. The cyclin A family regulates the cell proliferation through 
the S phase. The cyclin A family activates the kinase CDK2, during the S phase and will 
activate the kinase CDK2 at the checkpoint, to determine if  the cell will transition to the 
G2 phase or remain in the S phase. Lastly, the cyclin B family regulates the last 
checkpoint that allows the cell to transition from the G2 phase to the M phase to complete 
division. The cyclin B family activates the kinase CDK1 to further allow entry of the cell 
into the M phase.
3.2. CYCLIN DEPENDENT KINASES
CDK4 and CDK6, activated by the cyclin D family, promote the cell transitioning 
by two major mechanisms; they sequester the CDK inhibitors p21 and p27, and they
phosphorylate the RB family to code for the p107 and p130 proteins.5 The proteins p21 
and p27 are responsible for the cell’s progression through the G1 to the S phase by 
inhibiting the activity of CDK4/6. The proteins p107 and p130 are responsible for 
monitoring the activity of the E2F family by limiting the genetic material needed for the 
cell’s transition through the cell cycle. Another way to describe the p107 and p130 
proteins are as “pocket proteins”.66
CDK2 can be activated by either cyclin E or cyclin A family. CDK2 is a 
serine/threonine protein kinase that is the key regulator in the cell phases of G1/S and 
S/G2.67 In the transition from the G1/S phases, CDK4/6 phosphorylates the Rb proteins 
from the activation caused by cyclin D. CDK2, activated by cyclin E, further completes 
the phosphorylation of Rb to activate the E2F family. CDK2 is also required for mini 
chromosome maintenance proteins that are essential for the initiation of replication.67 
Overall CDK2 is responsible for the drive of the progression through the cell cycle.
CDK1 can be activated by either the cyclin A or cyclin B family. CDK1 is 
responsible for the successful completion of the M phase in the cell cycle. CDK1 
activated by cyclin A, regulates the cell’s entry into mitosis and proceeds until cyclin A 
eliminates the ubiquitin -  proteasome system that starts in the early stages of 
prometaphase.68 When CDK1 is activated by cyclin B, the cell is signaled to proceed 
onward through mitosis to complete the DNA replication to divide.
3.3. CYCLIN DEPENDENT KINASE INHIBITORS (CDKIs)
CDKIs are proteins that inhibit the activated CDKs of the cell cycle. Seven CDKI 
proteins can cause the cell’s progression to be delayed including p15, p16, p18, p19, p21,
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p27, and p57. p15 targets CDK4 by the CDKN2B gene to prevent the activation of the 
cyclin D family in the G0/G1 phase.69 Thus, the p15 protein inhibits the cells progression 
in the early phase of the cell cycle. p16 delays the proliferation of the cell through the G1 
and S phase by targeting CDK4/6 and is encoded by the gene CDKN2A. When 
CDKN2A is deleted, it can cause the p16 to be non-functional and result in an 
acceleration of the cell cycle.70 p18 is encoded by the CDKN2C gene to target the 
activation of CDK4/6 in the early phase of cell progression. p19 also targets CDK4/6 in 
the early phase of cell progression by the CDKN2D gene. As mentioned in the cyclin - 
dependent kinase section, p21 and p27 can be sequestered by CDK4/6. p21 and p27 are 
encoded by the genes CDKN1A and CDKN1B to target CDK2 and CDK4. By inhibiting 
the activity of CDK4/6, p21 and p27 are responsible for the cell’s progression through the 
cell cycle. Lastly, p57 is encoded by the gene CDKN1C to target CDK2 in the cells 
transition from the G1 phase to the S phase. Each CDKI protein acts as a tumor 
suppressor to delay the activity of the tumor formation.
3.4. THE ROLE OF p53 IN CELL CYCLE REGULATION
p53 is a nuclear transcription factor that targets genes involved in the induction of 
cell cycle arrest and/or apoptosis.71 DNA damage usually involves the activation of p53 
in response to damages to the DNA and stresses. Once p53 is activated, there are two 
pathways the cell can go. The first is cell cycle arrest and the second is apoptosis. The 
p53 pathway can signal to p21 that will mediate the binding to CDK2 and CDK1 to lead 
the arrest at specific stages in the cell cycle due to various stimuli.72 On the other hand, 
p53 can activate either Bax or Puma for cell apoptosis. Bax is an apoptosis regulator that
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is part of the Bcl-2 family of proteins that are the main regulators of cell death. BAX is 
the central mediator and contains BH1, BH2, and BH3 domains with a hydrophobic 
membrane.72 Puma is a potent killer among the Bcl-2 homology 3 that transduces 
apoptosis signals primarily to the mitochondria.73 PUMA indirectly responds with BAX 
to promote apoptosis of the cell.
3.5. THE ROLE OF Bax AND Puma IN p53 -  MEDIATED THERAPY
Bax is one of two nuclear encoded proteins that mediate cell death. Bax was the 
first death inducing member of the Bcl-2 family due to studies that involved protein 
purification with Bcl-2. Bax is a globular protein that contains nine helices; Alpha 1 to 
Alpha 8 are the inhibitors of apoptosis.74 Bax can be activated by cleavage of caspases, 
inhibition of protein kinases, activation of phosphates, and an increase in intracellular 
pH.75 Specifically, to p53, under stress signals cytochrome c is released, inducing 
apoptosis. Puma is essential for apoptosis and is activated due to DNA damage on p53. 
Puma p53-mediated apoptosis includes the neuronal cell death induced by 6 - 
hydroxydopamine,76 and cancer cell death induced by proteasome inhibitors.77 Oncogenic 
stress can also activate Puma to function as a safeguard against neoplastic 
transformation.73 Puma- induced apoptosis requires interactions with the Bcl-2 family 
proteins such as Bax and once triggered, mitochondrial dysfunction and caspase 
activation is induced. In cancer, Puma can be compromised due to p53 mutations caused 
by irradiation and chemotherapy drugs, overexpression of the Bcl-2 family proteins, and 
poor levels of Puma detection.73 Even with the compromises, it is important to note that
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Puma in p53-mediated therapies is still emerging and deciphering the different 
signaling pathways will contribute to targeting Puma p53-mediated therapies.
3.6. CYCLIN, CDK AND CDKI TARGETS FOR CANCER THERAPY
The CDK4/6-Rb pathway is frequently deregulated in cancer that influences the 
tumor cells to enter the restriction (R) point at the late G1 phase and complete the cell 
cycle.5 The deregulations of major cell cycle proteins in this pathway in terms of 
deletions, amplifications and point mutations are summarized by Otto et.al.5 In this 
pathway, the tumor suppressor CDK4/6 inhibitor p16INK4A protein is often silenced by 
promoter methylation or the p16INK4A encoding gene CDKN2A is frequently deleted 
across all human cancer types.78 The frequent deletion of RB1, the pRb encoding gene 
also causes the proliferation of tumor cells irrespective of their cyclin D-CDK4/6 
catalytic activity.78
The cyclin D1 gene (CCND1) is the second most frequently amplified gene in all 
cancer types.5,78 The overexpression of cyclin D1 increases the catalytic activity of their 
binding partner CDK4/6 and hence increases the proliferation rate of tumor cells. In a 
transgenic mice model overexpression of cyclin D1 induced hyperplasia and carcinoma 
in mammary glands.79 Carcinogen induced skin tumorigenesis was induced by the 
overexpression of cyclin D1 protein, cyclin D2 gene, and CDK4 protein 
overexpression.16,80,81 Cyclin D1 protein is overexpressed in 50-70% of the breast cancer 
cases and is most frequent in Luminal B type and human epidermal growth factor 
receptor-2 (HER2) positive breast cancer.82,83 Cyclin D1 promotes tumorigenesis in 
HER2 positive breast cancer.84 The amplification in the CCND1 gene copy number is
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present in only 9-30% of the cases suggesting underlying mechanisms of protein 
overexpression other than the copy number amplification.83 An integrative study of 
CCND1 amplification in 2305 breast tumors found that CCND1 amplified tumors 
induced the co-expression of proliferative gene MKI67 across all of the PAM50 
classified breast cancer subtypes including HER2 positive breast cancer.83 The same 
study also suggests that CCND1 amplification is independent of CDK4/6 gene 
upregulation and could be a poor predictive biomarker for the prediction of response to 
CDK-4/6 inhibitors. CDK4 is constitutively amplified in glioblastomas.85 CDK4 is most 
commonly mutated by an R24C point mutation in melanomas and becomes insensitive to 
the INK4 members of CDKIs promoting unhalted growth.86 CDK4 promotes 
tumorigenesis in HER2 positive breast cancer cells.87,88 An oncogenic KrasG12V driven 
lung cancer showed selective sensitivity to CDK4 inhibition indifferent to CDK2 or 
CDK6.89 Altogether the data suggest that the CDK4/6-Rb pathway is a crucial target for 
cell cycle targeted therapeutic trials. The CDK 4/6 inhibitors Palbociclib, Ribociclib, and 
Abemaciclib have been approved for the treatment of Herceptin receptor-positive 
(HER2+) and Herceptin receptor-negative (HER2-) breast cancer treatment. Several other 
CDK 4/6 targeted therapeutic trials are ongoing for breast cancer,90-92 and other solid 
tumors.5,93
Cyclin E1 encoding gene CCNE1 is commonly amplified in ovarian94 and breast 
cancer.95 CCNE1 copy number amplification or Cyclin E overexpression and 
corresponding CDK2 activity is associated with worse clinical benefit, poor progression- 
free survival with statistical significance. In a study on 395 breast cancer patients, Cyclin 
E expression was the most powerfully negatively correlated with patients overall and
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disease-free survival.96 CDK2 mutation is rare but the Cyclin E protein overexpression 
causes the hyper catalytic activity of Cyclin E-CDK2 complex.5 CDK2 activity is 
normally kept inactivated by the association of CDK inhibitors p21CIP1 and p27KIP1 
protein molecules. Degradation of these molecules has been shown to increase the 
activity of CDK2 and cyclin E-CDK2 complex and promote tumor formation.97-99
Cyclin A2/B-CDK1 catalytic activity is required for entry into the mitotic phase. 
CDK1 is rarely deregulated in cancer. But there is some evidence that CDK1 activity is 
required for tumorigenesis. For example, CDK1 inhibition induced apoptosis in Myc has 
driven mouse lymphomas, liver tumors,100 and human triple-negative breast cancer 
cells.101 In a KRas mutant colorectal cancer xenograft model, CDK inhibition blocked the 
tumor growth.102 Despite of these evidence the inhibition of CDK1 is a tricky target as 
normal cells also require CDK1 for regular cell cycle progression.5 103
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4. APOPTOTIC SIGNALING PATHWAYS
Apoptosis, programmed cell death, is used to regulate tissue development and 
homeostasis.104 In healthy cells, this critical process is regulated by internal and external 
signals. The intrinsic pathway can be triggered by a myriad of events including severe 
DNA damage, anoxia, or other internal signaling imbalances. The extrinsic pathway is 
primarily triggered by death receptor ligands.
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4.1. INTRINSIC PATHWAY
p53 is the primary regulator for triggering apoptosis in response to internal stress. 
p53 is always present in the cell at extremely low levels.105 This is maintained by MDM2 
which ubiquitinates p53 for degradation.105 Stresses including but not limited to DNA 
damage, oncogene activation, anoxia, radiation, heat shock, oxidative stress, osmotic 
stress, and nutrient deprivation can increase the expression of p53 through various 
mechanisms.
For example, while small levels of DNA damage will trigger DNA repair 
pathways, extreme DNA damage will trigger apoptosis. The Mre11-Rad50-Nbs1(MRN) 
complex binds to double-stranded breaks in DNA.106 MRN then recruits and activates 
ataxia telangiectasia protein (ATM). Similarly, ATR interacting protein (ATRIP) binds to 
single-stranded DNA exposed due to damage and recruits ATM-related protein (ATR).106 
ATM and ATR phosphorylate and activate p53.107 Additionally, the ARF protein battles 
with MDM2 to regulate p53 levels in the cell. However, the insertion of an additional 
exon between the CDKIs INK4A and INK4B leads to the translation of an alternate 
reading frame (ARF).108 The resulting protein, ARF, binds to MDM2 and prevents it 
from ubiquitinating p53.108 Oxygen levels also influence p53 levels in the cell. Though 
not fully understood, the mechanism by which hypoxic conditions stabilize p53 in the cell 
involved hypoxia-inducible factor 1 alpha (HIF-1a) and von Hippel-Lindau tumor 
suppressor (VHL).109 Under normal conditions, VHL interacts with and degrades HIF-1a. 
Under hypoxic or anoxic conditions, this interaction is disrupted. This allows HIF-1a to 
bind to p53, preventing ubiquitination by MDM2.109
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Figure 10. Examples of p53 activation via DNA damage, hypoxia, and ARF activation 
mechanisms,(1) MRN and ATRIP interact with exposed double-stranded and single­
stranded DNA, respectively. Upon binding, MRN activates ATM and ATRIP activates 
ATR. ATM and ATR phosphorylate and activate p53. (2) Hypoxia disrupts the 
interaction between VHL and HTF-1a to prevent VHL from inhibiting HTF-1a. HIF-1a 
then phosphorylates and activates p53. (3) ARF interacts with MDM2 to prevent the
ubiquitination and degradation of p53
Additionally, p53 is also capable of inhibiting MDM2, driving a positive feedback 
loop further stabilizing it in the cell. Through these and other pathways, p53 escapes 
degradation by MDM2 and triggers apoptosis (Figure 10). In this capacity, p53 primarily 
acts in the nucleus as a transcription factor for many apoptotic proteins (Figure 11).109
99
Figure 11. The Intrinsic apoptotic pathway. Upon activation, p53 acts as a transcription 
factor for several pro-apoptotic genes including those transcribing Noxa, Puma, and Bid. 
These proteins inhibit Bcl-2 from maintaining the mitochondrial membrane. Bid also acts 
with cytoplasmic p53 to activate Bax and related proteins to poke holes in the 
mitochondrial membrane. This releases cytochrome c to the cytoplasm where it interacts 
with Apaf-1 and caspase 9 to form the apoptosome. The apoptosome cleaves and 
activates caspase 3 to further stimulate bid and act on several death substrates to carry out
apoptotic events
This begins with several members of the Bcl-2 family. Bcl-2 and related anti-
apoptotic proteins keep the membrane of the mitochondria closed.110 P53 acts as a
transcription factor for Puma and Noxa.109 These two BH3 only proteins inhibit Bcl-
2. Other transcriptional targets include Bax, Bid, and Bim. Bid acts like Puma and Noxa 
to inhibit Bcl-2 and other anti-apoptotic family members.110 Bid and Bim also directly 
bind to and activate Bak and Bax which poke holes in the mitochondrial membrane.110 
p53 is capable of transporting to the cytoplasm to directly activate Bax, Puma, and 
Noxa73,111,112 As the mitochondrial membrane opens, cytochrome c is released.110
Cytochrome c is a member of the electron transport chain (ETC) and is normally 
involved in ATP production; however, when it is present in the cytosol it associates with 
Apaf-1. Together, they form the apoptosome, also known as the “wheel of death,” which 
activates caspase 9. This is the first caspase activated in a caspase cascade. Caspases 
comprise a family of cysteine proteins which initiate apoptosis by activating downstream 
caspases or by directly carrying out apoptotic functions.113
Caspase 9, an initiator caspase, cleaves pro-caspase 3 to activate caspase 3, an 
execution phase caspase.113 Caspase 3 activates downstream caspases by cleaving their 
respective pro-caspases, eventually triggering caspases which carry out functions to 
induce an apoptotic phenotype such as destruction of intracellular structures and 
organelles.9,10,113
4.2. MOLECULAR TARGETS OF THE DEFECTIVE INTRINSIC PATHWAY
Oxaliplatin (diaminocyclohexane) and other platinum-containing drugs also 
damage nuclear DNA.114 Oxaliplatin binds to DNA to block replication and transcription, 
form lesions, and cause single-stranded breaks. These particular lesions are poorly 
recognized by DNA repair proteins in the cell so damage accumulates. An accumulation
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of damaged DNA in the cell causes stress signals within the cell which activate the 
intrinsic apoptotic pathway.114
Oxaliplatin (brand name Eloxatin) has been approved by the FDA to treat 
colorectal and stage three colon cancer. Like most current small molecule cancer 
therapies, Oxaliplatin alone is not specific to cancer cells and has many undesirable side 
effects.114,115 Shad et. al. investigated a strategy to encapsulate Oxaliplatin in folate 
conjugated hyaluronic acid-coated alginate nanogels.115 In this system, folate is used for 
specific targeting to folate receptors which are overexpressed in many types of colorectal 
cancers and hyaluronic acid and alginate are natural, biocompatible polymers.115 In this 
study, HT29 colorectal cancer cells were treated with encapsulated Oxaliplatin. Cells 
treated with encapsulated Oxaliplatin showed a higher ratio of apoptosis to necrosis, 
higher gene expression of Bax, and lower expression of Bcl-2 compared to untreated cells 
or cells treated with unencapsulated Oxaliplatin.115 This suggests that novel drug delivery 
systems may improve treatment with Oxaliplatin and other platinum-based 
chemotherapeutics; however, further testing in animal models and clinical trials is 
required to determine if the encapsulation strategy employed here will improve efficacy 
and specificity and decrease negative side effects.
The function of p53 is lost in more than half of all human cancer cases.71 Since 
cancer is typically the result of an accumulation of genetic mutations that occur over the 
years or decades, loss of the enzyme responsible for suicide in cells with damaged DNA 
greatly enables this process. A majority of p53 mutations occur in its reading frame and 
cause conformational changes.71 Many mutations disable the catalytic site of p53 but 
allow it to still bind other p53 proteins and form the homotetramer required for its
activity. In this way, mutant p53 is an inhibitor to wild type p53 since the 
homotetramer requires four wild-type p53 proteins in order to function.105 The use of 
small molecules and peptides to activate a p53-dependent process in cells with mutant 
forms of p53 are being investigated for clinical use.116,117 However, p53 reactivation has 
proved difficult clinically.
While the loss of function of p53 is the most common mutation across human 
cancers, it is also common that p53 is still functional but its regulators such as MDM2 are 
overexpressed.9,116"118 Nutlins, small molecule inhibitors that bind to MDM2, are 
currently being investigated as potential chemotherapeutics.118 The first MDM2 inhibitor 
to undergo clinical trials was RG7112 which demonstrated high selectivity and efficacy 
in preclinical studies.118 However, Clinical trials revealed that the necessary dose to 
activated p53 had severe side effects including death.118 Now, second-generation MDM2 
inhibitors such as Idasanutlin, which are thought to have more desirable toxicity profiles, 
are undergoing clinical trials.118 These trials primarily investigate the use of MDM2 
inhibitors in combination therapies or alongside radiation therapy.
4.3. EXTRINSIC PATHWAY
Apoptosis can also be triggered externally via the extrinsic or receptor-activated 
apoptotic pathway (Figure 12). The cell membrane contains several transmembrane 
proteins including death receptors which share a common “death domain”. Members of 
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Figure 12. The extrinsic apoptotic pathway. Death receptor ligands such as FasL bind 
death receptors at the cell surface. Fas activates FADD, which in turn activates DISC. 
Disc cleaves and activates initiator caspases 8 and 10 which act on executioner caspases 
3, 6, and 7. These caspases act on death substrates to achieve an apoptotic phenotype. 
Additionally, caspase 3 can activate Bid to activate the internal pathway
The most common death receptor ligand is the Fas ligand (FasL) which binds to 
the death receptor Fas (Apo-1 or CD95).119 Ligand binding induces activation of the Fas- 
associated death domain (FADD) protein within the cytosol.119 FADD triggers the death- 
inducing signaling complex (DISC) which in turn cleaves and triggers initiator caspases 8 
and 10. At this point, the extrinsic pathway converges on the intrinsic pathway by 
activating the execution phase caspases 3, 6, and 7. Caspase 3 is also capable of cleaving 
and activating Bid to act on Bcl-2, amplifying pro-apoptotic signals and recruiting 
additional members of the intrinsic pathway.
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4.4. MOLECULAR TARGETS OF THE DEFECTIVE EXTRINSIC PATHWAY
Several existing and potential cancer treatments attempt to kill cancer cells by 
taking advantage of apoptotic machinery in the cells. For example, all trans retinoic acid 
(ATRA) is a naturally occurring derivative of vitamin A that can be used to target 
apoptotic pathways in cancerous cells.120 ATRA binds to the retinoic acid transmembrane 
receptors retinoic acid receptor (RAR) and retinoid x receptor (RXR), causing them to 
form a heterodimer.121 This binding activates apoptosis through the external apoptotic 
pathway.121 NB4 cells treated with ATRA showed decreased viability due to the 
activation of the apoptotic pathway.113 ATRA has been shown to treat acute 
promyelocytic leukemia (APL).122 Ades et al analyzed data from elderly patients at 
European centers who were treated for APL with ATRA in combination with 
chemotherapy122. Combination of ATRA with other chemotherapeutics improved the 
survival of elderly patients compared to traditional chemotherapy.122
ATRA is now also being investigated to treat other types of cancer. ATRA has a 
low solubility in water which makes delivery a challenge.121 Ravichandran et al. 
encapsulated ATRA in liposome carriers to improve distribution.9 The lipo-ATRA 
system reduced tumors in mice.121 Another possible therapeutic agent is oxymatrine. 
Oxymatrine is derived from marine, an active in the Chinese herb Sophora flavecens.123 
Several laboratory studies have shown that oxymatrine inhibits cellular proliferation by 
inducing apoptosis.123-125 Although the exact mechanism is not fully understood, 
Oxymatrine was shown to increase caspases associated with apoptosis in T24 cells 
(human bladder cancer) 123 and in A549 cells (human lung cancer).125 It has also been 
shown to increase expression of p53 and Bax, and decrease expression of Bcl-2 in
DU145 cells (human prostate cancer), PC3 cells (human prostate cancer), and PNT1B 
cells (human prostate).124 These effects on p53, Bax, and Bcl-2 were also seen in mice 
xenograft models.124 Additionally, tumor weight stopped increasing in these mice, though 
the tumors did not shrink.124
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5. DISCUSSION
Healthy cells depend on internal and external signals to decide whether to live or 
die, proliferate, or become quiescent entering the G0 phase. These signals are interpreted 
through signaling pathways within the cell to stimulate the production of proteins to carry 
out these actions. The cells get a license for the division at the late G1 phase or R point, 
and the later phases follow more or less the same mechanisms as normal cells unless 
there are major genetic and molecular alterations in cell cycle-associated genes or 
therapeutic intervention. So, the G0/G1 transition and early G1 phase are of much interest 
in cancer research. There is growing evidence that the R point deregulation is the 
determinant of abnormal cell growth and accompanies the tumorigenesis process in 
almost all the cancer types.126-129
For cell cycle targeted therapy, CDK4/6-Rb is one of the most critical pathways to 
target as it provides the cells license to enter the R point. In addition to the active 
targeting of molecules involved in the G1-S transition of the CDK4/6-Rb pathway, the 
cell cycle targeted therapy has already been shifted towards the inhibition of key players 
of the S and G2 checkpoints. Several chemo and radiotherapy target the alterations of the 
DNA as a mechanism of action against cancer progression. Cancer cells can manipulate
the cell cycle checkpoints to halt the progression allowing them time for DNA repair 
in response to the damage caused. The rationale for targeting the checkpoints is that 
inhibition of these regulatory proteins in cancer cells prevents cell cycle arrest in S and 
G2 phase allowing the cells to enter the mitosis phase with a defective genetic component 
and become susceptible to apoptosis or permanent arrest during mitosis, a mechanism 
known as a mitotic catastrophe.130,131 Such indirect therapeutic strategy includes 
inhibition of ATM and ATR (inhibition of DNA damage response),106,132-135 Aurora A 
and B kinases (inhibition of spindle machinery during mitosis),136-141 PLK1 (inhibition of 
chromosome segregation, the permission of mitotic entry upon DNA damage),142-145 
BRCA1/2 (inhibition of homologous recombination), 146,147 MPS1,148-151 CHK1 
(induction of aberrant replication, chromosome fragmentation, mitotic death),152-155 and 
WEE1 (induction of premature mitosis) molecules.156-160 One of the major concerns in 
targeting the cell cycle targeted therapy is selectivity. To address the challenge, the cell 
cycle targeted therapeutic regimen can benefit to a great extent by incorporating the 
personalized treatment approach. The genomic signature tools can identify the subsets of 
patients who will get a maximum therapeutic response to the intervened cell cycle 
targeted treatment.
The role of major molecular circuitries responsible for cell proliferation, cell 
cycle, and apoptosis are interlinked and also share common molecular machinery.2,161,162 
There are evidence that apoptosis can be triggered by the genes that are involved in cell 
cycle progression. For example, Myc regulates several genes that control both cell cycle 
progression and apoptosis and metabolism in tumorigenesis.163-171 Similarly, p53 is 
involved in molecular signaling circuitries for cell cycle arrest and cell death,172,173 DNA
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damage response,174-176 and increasing evidence as a regulator of cell homeostasis 
and metabolism in cancer cells.177 Cancer cells manipulate such interlinked cell signaling 
pathways for the acquisition of major hallmarks in cancer such as self-sufficiency in 
growth signals and suppressing or insensitivity to the death signals and tissue invasion 
and metastasis.10,178 Thus, a comprehensive understanding of the linkage between the cell 
proliferation and apoptosis pathways will unveil the underlying causes of imbalanced 
tissue homeostasis and is critical to discover new therapeutic strategies to defeat cancer. 
Such elucidations help to behold cancer in a more logical way.
6. CONCLUSION
In this review, intracellular signaling pathways such as MAPK/Ras/Raf/ERK, 
PI3K/Akt, Jak-STAT, and Wnt regulating the cell proliferation and apoptosis are 
discussed. Growth factors activate the MAPK/Ras/Raf/ERK, PI3K, and Wnt pathways to 
synthesize cyclin Ds and other mitosis regulating proteins (Myc and Jun). Cyclin D1 
binds to CDK4/6, forms CDK complexes, activates several substrates, and initiates the 
cell cycle. In contrast, TGFP prevents the cells from initiating the cell cycle by 
expressing CDKIs and p53. p53 stops the cell cycle when DNA is not replicated correctly 
during the S phase, producing p21 proteins and promoting the transcription of apoptotic 
proteins. Alterations in the signaling pathways lead to diseases including cancer, 
cardiovascular diseases, immunological disorders, neurodegenerative diseases, and many 
other infectious diseases. As cancer therapy is becoming more and more personalized 
through precision medicine, understanding the intercorrelated cell signaling pathways and
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III. TRANSCRIPTIONAL REGULATION ACTIVITY OF A TARGETED 
ANTIBODY DRUG NANOROD IN BREAST CANCER CELLS
ABSTRACT
Transcriptional activity in cancer cells is a key factor for determining the 
therapeutic outcome in patients. Therapeutic drugs with diverse mechanisms regulate 
certain gene expression activity in cancer cells causing enhanced tumor cell death. 
However, the aberrant gene regulation activity during the tumor evolution process or 
even following the therapeutic drug treatment significantly causes drug resistance and 
disease recurrence. Hence, such genomic instability in tumor cell population has to be 
comprehensively unfolded for better treatment response. In this study, we investigated 
the transcriptional regulation activity of a Trastuzumab conjugated Paclitaxel drug 
nanorod system (PTXNR-TTZ) in breast cancer cell lines. We investigated the gene 
regulation activity of DNA metabolism, cell cycle checkpoint and inflammatory 
pathways that might determine the therapeutic response or drug resistance in PTXNR- 
TTZ treatment. Hyperactivity in DNA repair pathways can offset the effect of therapeutic 
drugs and cause treatment resistance. In HER2-positive breast cancer cells, we found that 
PTXNR-TTZ did not alter the DNA repair pathways although a significant 
downregulation in this pathway was observed in individual treatment with Trastuzumab. 
PTXNR-TTZ also induced significantly high expression of NR4A3 gene. The 
upregulation of nuclear NR4A3 gene has role in inducing enhanced apoptosis mechanism 
by activating the pro-apoptotic and inhibiting the anti-apoptotic gene regulation activity.
The pathway enrichment analysis showed a significant upregulation of the Rho 
GTPase signaling network following PTXNR-TTZ treatment. The effector genes in this 
pathway are associated with spindle assembly checkpoint (SAC) regulation in mitosis 
phase and hyperactivation of this pathway is responsible for cell cycle progression and 
aberrant exit from mitosis phase of the cell cycle potentially causing poor treatment 
outcome. PTXNR-TTZ also induced oncogenic CDC20 gene expression activity that 
functions in mitosis phase and promotes the cell cycle progression. In HER2-negative 
breast cancer cell line, PTXNR-TTZ significantly upregulated a set of tumorigenic 
chemokine and cytokine encoding genes IL6, CXCL1, CXCL2, CXCL3, CXCL8, IL1A 
and IL1B suggesting an induction of enhanced survival signaling and aggressive 
tumorigenic behavior in cancer cells.
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1. INTRODUCTION
Chemotherapeutic drugs can be categorized into the cell cycle phase specific or 
non-specific drugs based on their therapeutic effect window1-4. For example, the DNA 
damaging drugs have almost no therapeutic effect on the cells that are in the resting phase
2. Rather, the effect is maximum when the cells are actively replicating their genetic 
contents in the synthesis phase5-7. Similarly, the taxanes (e.g., Paclitaxel) depend on the 
active mitosis cell cycle phase for exerting their therapeutic efficacy 8. Such variations in 
treatment outcome are due to the alterations in gene expression in different cell cycle 
phases 2,4 In combination chemotherapy, cell cycle mediated drug resistance is 
minimized by appropriate scheduling of different cell cycle targeted chemotherapeutic
agents 4 In our recent study, we designed an actively targeted nanoparticle based 
combination therapeutic system ADN that induced apoptosis in HER2-positive breast 
cancer cell lines by arresting the cells in the G2/M phase. In this study, we investigated 
the alterations in gene expressions in breast cancer cells induced by ADN. We 
hypothesized that the cell cycle plays a critical role in determining the therapeutic 
efficacy of ADN in HER2-positive breast cancer treatment.
The cell cycle and apoptosis are two complementary mechanisms for tissue 
homeostasis and normal functioning of the tissues to perform a specific task in a 
coordinated way 9"15. Most cells rest at the quiescent phase (G0) and perform tissue 
specific tasks. At the same time, these cells keep receiving the mitogenic signaling via 
several growth factors from the cellular environment and enter the cell cycle phase Gap 
1(G1) when they commit to divide 16. In the synthesis (S) phase, the cells start replicating 
their genetic contents and progress through the Gap 2/Mitosis (G2/M) phase resulting in 
cell division. During the cell cycle, the cells progress through a subsequent series of 
regulatory checkpoints17-20. These regulatory cell cycle checkpoints make sure that the 
genetic materials of the dividing cells are kept intact before the distribution to the 
daughter cells 2. Failure to maintain the intact nature of the genetic materials causes the 
initiation of a programmed cell death or apoptosis mechanism to maintain the normal 
tissue functioning 15. Mutations and aberrant growth signaling pathways cause the cancer 
cells to respond more frequently to these external mitogenic signaling and unregulated 
progression through the cell cycle. Evading the apoptosis mechanism and unregulated 
division with aberrant genetic contents are the major acquired hallmarks of cancer 21,22. 
The cell cycle targeted drugs alter the regulatory machineries of the cells causing forced
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apoptosis or halt the cellular growth. The cancer cells also activate a series of 
molecular machinery e.g., DNA metabolism 23-26, cell cycle checkpoints 27-29, 
inflammatory pathways30-32 upon any genotoxic stress on the cells to maintain the 
aberrant genomic and phenotypic integrity resulting in partial treatment response or 
therapeutic resistance.
We previously synthesized targeted ADN using rod shaped Paclitaxel 
nanoparticles (PTXNR) of 500 nm length and 100 nm diameter. We covalently 
conjugated the nanorods with therapeutic monoclonal antibody (mAb) Trastuzumab 
(PTXNR-TTZ). The current study extends our investigation in understanding the effects 
of PTXNR-TTZ on breast cancer cells at the gene expression level. For the investigation, 
we treated HER2-positive BT-474 and HER2- negative MDA-MB-231 breast cancer 
cells with PTXNR-TTZ. The cells were also treated by different cell cycle targeted drugs 
e.g., Trastuzumab and Rapamycin targeting the early G1 phase, 5-Fluorouracil targeting 
the S phase, and Paclitaxel, Doxorubicin targeting the G2/M phase of the cell cycle. The 
untreated cells mostly arrested in the G0/G1 phase were used as control. We performed 
RNAseq analysis following the treatment with different cell cycle targeted drugs. The 
study aims to investigate the PTXNR-TTZ induced gene regulation activity that might 
determine the treatment response in breast cancer. We investigated the PTXNR-TTZ 
induced transcriptional activity in DNA metabolism, cell cycle checkpoint, apoptosis and 
inflammatory pathways in breast cancer cell lines to determine potential genetic means of 




BT-474 and MDA-MB-231 cells were cultured in hybricare medium and RPMI- 
1640, respectively supplemented with 10% fetal bovine serum (FBS) and 1% penicillin- 
streptomycin at 37oC and 5% CO2 . Approximately, 1M cells were seeded in 25 cm2 cell 
culture flask for each cell line and treated with IC50 doses of 5-Fluorouracil, Doxorubicin, 
Rapamycin, Paclitaxel, Trastuzumab and Trastuzumab conjugated Paclitaxel drug 
nanorods (PTXNR-TTZ) (SI Table 1) . After 72 h of incubation, the total RNA was 
extracted from the samples using TRIzol Plus RNA purification kit (Invitrogen) by 
following the manufacturerer’s protocol. Briefly, 1 ml of TRIzol was used for 1 million 
cells to lyse. The cell lysates were passed through an 18-21 gauge syringe needle for 
homogenization. The cell lysates were kept at room temperature (RT) for 5 min for 
complete dissociation of the nucleoprotein complex. To the lysate mixture 0.2 ml of 
chloroform was added per 1 ml of TRIzol reagent . The mixture was centrifuged at 
12,000*g for 15 minutes at 4oC. The mixture separates into two layers: the bottom red 
phenol-chloroform layer, an interphase and colorless aquous layer containing the total 
RNA. The upper phase ( ~600 |il) was then transferred to a new sterile RNase free tube 
followed by addition of an equal volume of 70% ethanol. The mixtutre was vortexed well 
and the total RNA was bound on the membrane provided by the manufacturer. In 
subsequent steps, the RNA was washed on the membrane and eluted with RNase free 
water by following the manufacturers protocol. The RNA quality was determined by 
measuring the RNA integrity number (RIN) using Agilent Bioanalyzer .
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2.2. RNAseq ANALYSIS
The extracted RNA samples from BT-474 and MDA-MB-231 human breast 
cancer cell lines were used for sequencing using the RNAseq technology. Briefly, the 
mRNA was isolated from the total RNA extract using poly-A enrichment method. The 
mRNA was fragmented and the fragmentation quality was confirmed using Agilent 
Bioanalyzer. cDNA was synthesized from the fragmented mRNA and amplified using the 
polymerase chain reaction (PCR) technique. The mRNA stranded RNAseq library was 
prepared using TruSeq stranded mRNA library preparation kit (Illumina). The 
constructed libraries were then sequenced using the NovaSeq 6000 Sequencing System 
on a single NovaSeq S1 PE-50 flow cell. The samples were sequenced to an average read 
count of 50 million paired end reads per sample. The library construction and sequencing 
work was performed with the support of the University of Missouri DNA Core Facility.
2.3. GENOMICS DATA ANALYSIS OF ALTERATIONS IN BC
The Oncoprint analysis was performed in cBioPortal platform to investigate on 
the DNA copy number alterations, overall survival and genetic co-expressions in HER2- 
positive breast cancer patients. The clinical data were obtained from the Molecular 
Taxonomy of Breast Cancer International Consortium (METABRIC) study. The study 
comprised the genomics data of more than 2,000 primary breast cancer specimens that 
were obtained from the tumor banks in the UK and Canada. Nearly none of the estrogen 
receptor positive (ER+) and lymph node-negative (LN-) patients received any form of 
chemotherapy. In our analysis, we screened 224 HER2-positive breast cancer patients’ 
genomics data from the study according to the PAM50 breast cancer subtype classifier
method. None of the HER2-positive patients had gone through treatment with 
Trastuzumab.
2.4. DATA NORMALIZATION
The RNAseq gene expression data sets were normalized using the BioJupies 
RNAseq data analysis platform. For a specific drug treated sample the raw counts of a 
specific gene expression were divided by the total sum of all gene expression counts and 
multiplied by a factor of 106 and subsequent a log- 10 transform. The resulting 
normalized unit becomes log10-Counts Per Million (logCPM).
2.5. DIFFERENTIAL GENE EXPRESSION
The differential gene expression table was generated for both BT-474 and MDA- 
MB-231 breast cancer cell lines using the BioJupies RNAseq data analysis notebook 
platform. The differential gene expression table was generated by normalizing the gene 
expression levels of drug-treated samples to the gene expression levels in untreated 
control samples for each cell line. The platform used the embedded limma R package for 
generating the differential gene expression table. The heatmaps and hierarchical 
clustering were generated by python Jupyter notebook (6.0.3) using the seaborn statistical 
data visualization library. The pathway-specific signature gene sets were derived from the 
Kegg gene sets database.
2.6. PRINCIPAL COMPONENT ANALYSIS
Principal component analysis (PCA) was performed to identify the similarity and 
variance across the treatments for a specific gene signature or pathway. The PCA was
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generated using the differential G1, S and G2/M cell cycle signature gene expressions 
obtained from the cell cycle treated drug samples for both BT-474 and MDA-MB-231 
cancer cell lines. The analysis was performed using the MATLAB 2018 version. For the 
analysis we obtained the statistical PC1, PC2 components from the differential cell cycle 
gene expression signatures across all the drug treatments covering 58.06%, 38.97% of the 
differentially expressed genes respectively, in BT-474 cells and 62.92%, 20.06%, 
respectively in MDA-MB-231 cells.
2.7. GENE ONTOLOGY (GO) ENRICHMENT ANALYSIS
The GO enrichment analysis was performed to identify the collective functions of 
genes or gene sets for a specific biological process. The database contains a large 
collection of experimentally validated biological functions that correspond to a specific 
set of genes. The database also contains predicted associations between genes and 
biological terms. In this study, the GO analysis was generated using the Enrichr. The GO 
terms were selected for analysis based on the statistical significance (p-value).
2.8. PATHWAY ENRICHMENT ANALYSIS
Pathway enrichment analysis was performed to identify the significant biological 
or genetic interactions. The analysis aims to understand the intracellular response more 
clearly following a therapeutic intervention. The Reactome database containing a myriad 
of such biological or genetic interactions was used for this analysis. The enrichment 
analysis was generated using Enrichr by leveraging the Reactome database. In this study,
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the upregulated or downregulated pathways were selected for analysis based on their 
statistical significance (p-value).
2.9. GENE REGULATORY NETWORK ANALYSIS
Gene regulatory network analysis was performed to identify the set of genes that 
are involved in specific intracellular biological functions. The analysis was performed 
using the NetworkAnalyst platform. The significant differentially upregulated or 




3.1. CELL CYCLE GENE SIGNATURES
The PCA was generated using the cell cycle signature (G1-S transition phase, S 
and early G2 phase, G2/M phase) gene expression values of Rapamycin, 5-Fluorouracil, 
Trastuzumab, Doxorubicin, Paclitaxel, and PTXNR-TTZ treated BT-474 (Figure 1a) and 
MDA-MB-231 (Figure 1b) cells normalized to the untreated control cells . In BT-474 
cells, the PCA plot showed that Paclitaxel and PTXNR-TTZ, 5-Fluorouracil, and 
Trastuzumab formed two distinct clusters suggesting lower variance in cell cycle gene 
expression between the samples in each cluster. Rapamycin and Doxorubicin treated cells 
formed two distinct clusters suggesting high variance in gene expression between the 
treatments. In MDA-MB-231 cell line, Paclitaxel and PTXNR-TTZ formed a cluster but 
with larger variance than in BT-474 cells. This suggests that the alterations in cell cycle 
gene expression by these drugs slightly vary between BT-474 and MDA-MB-231 cell
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lines. Trastuzumab and Rapamycin treated samples were almost invariant in cell 
cycle gene expression and formed a cluster together. With a slight variance to this cluster, 
5-Fluorouracil treated cells formed a distinct cluster. In similar to the BT-474 cells, 
Doxorubicin treated MDA-MB-231 cells formed a distinctly variant cluster.
Figure 1. Cell cycle gene signature of cell cycle arresting drugs. PCA plot of cell cycle 
related gene expression signatures following Rapamycin, 5-Fluorouracil, Doxorubicin, 
Paclitaxel, Trastuzumab and PTXNR-TTZ drug treatments in (a) BT-474 and (b) MDA-
MB-231 cell line
3.2. PTXNR-TTZ DOES NOT ALTER THE DNA METABOLISM PROCESSES IN 
HER2-POSITIVE BREAST CANCER CELL LINE
Therapeutic drugs that downregulate the DNA metabolism related genes might 
augment the effect of platinum based therapeutics that induce hyperactivity in DDR 
pathways causing therapeutic resistance. We investigated the PTXNR-TTZ induced DNA 
metabolism related gene expressions in HER2-positive breast cancer cells. Paclitaxel or
PTXNR-TTZ did not alter the regulation of DNA metabolism related genes compared 
to the untreated cancer cells. In contrast, the gene ontology (GO) terms enrichment 
analysis of the biological process showed that DNA metabolism processes were 
significantly downregulated by the drugs that target either the G1 or the S phase cell 
cycle arrest mechanism. In Figure 2a, the colored bubbles represent all the significantly 
downregulated GO terms for individual treatment with Rapamycin, 5-Fluorouracil and 
Trastuzumab. The GO terms are represented in a similarity based scatter plots with 
arbitrary space, called semantic space (with no intrinsic meaning) where the distance 
depicts the relative similarity between two GO terms. The size of the bubbles represents 
the percentages of genes annotated with the GO term suggesting a more general GO term 
(larger bubble ) and specific GO term (smaller bubble) . The color bar represents the p- 
values of individual GO terms. In HER2-positive breast cancer, Rapamycin and 
Trastuzumab (G1) and 5-Fluorouracil (S) significantly downregulated the DNA 
replication and DNA repair mechanism in response to therapeutic intervention. 
Transcriptional signatures of the major DNA repair pathways upon treatment with these 
drugs were further investigated. Hierarchical clustering was generated for DNA repair 
pathways with the normalized gene expression values for each treatment compared to the 
untreated HER2- positive breast cancer cell gene expression. Most of the HR (Figure 2b) 
and MMR (Figure 2c) pathway related genes were downregulated in response to 
treatment with Rapamycin, Trastuzumab, and 5-Fluorouracil. Notably, Rapamycin 
downregulated the HR and MMR pathways by significantly inhibiting the expressions of 
BRCA2, RAD54B, RAD51, BLM, RAD54L, EMEI, RFC2, RFC3, RFC4, RFC5, MSH2, 
EXO1, LIG1, and PCNA genes. A significant seven-fold upregulation of NHEJ pathway
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associated DNTT gene was overserved upon Doxorubicin treatment while no other 
treatments showed the DNTT gene expression.
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Figure 2. The cell cycle targeted drug induced gene expression analysis in DNA repair 
pathways. (a) The significantly downregulated GO terms are shown for treatment with 
Rapamycin, 5-Fluorouracil, and Trastuzumab in BT-474 cell line. The colored bubbles 
represent a specific GO term that is significantly downregulated in each treatment. The 
distance between the bubbles represents relative similarity between the respective GO 
terms. Hierarchical clustering showing alterations in (b) HR and (c) MMR pathways by 
cell cycle arresting drugs in BT-474 cell line
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Figure 2. The cell cycle targeted drug induced gene expression analysis in DNA repair 
pathways.(a) The significantly downregulated GO terms are shown for treatment with 
Rapamycin, 5-Fluorouracil, and Trastuzumab in BT-474 cell line. The colored bubbles 
represent a specific GO term that is significantly downregulated in each treatment. The 
distance between the bubbles represents relative similarity between the respective GO 
terms. Hierarchical clustering showing alterations in (b) HR and (c) MMR pathways by 
cell cycle arresting drugs in BT-474 cell line (cont.)
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Figure 2. The cell cycle targeted drug induced gene expression analysis in DNA repair 
pathways.(a) The significantly downregulated GO terms are shown for treatment with 
Rapamycin, 5-Fluorouracil, and Trastuzumab in BT-474 cell line. The colored bubbles 
represent a specific GO term that is significantly downregulated in each treatment. The 
distance between the bubbles represents relative similarity between the respective GO 
terms. Hierarchical clustering showing alterations in (b) HR and (c) MMR pathways by 
cell cycle arresting drugs in BT-474 cell line (cont.)
3.3. PTXNR-TTZ MAY INDUCE NR4A3 MEDIATED INTRINSIC APOPTOSIS 
PATHWAY IN HER2-POSITIVE BREAST CANCER CELL LINE
PTXNR-TTZ induces significant upregulation of PRKG1 and NR4A3
genes in HER2-positive BT-474 cell line (Figure 3).
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Figure 3. NR4A3 mediated apoptosis induced by PTXNR-TTZ in HER2-positive breast 
cancer cell line. The gene regulatory network analysis showing the regulation of 
apoptosis following the activation of PRKG1-NR4A3 axis induced by PTXNR-TTZ in
BT-474 cell line
The gene regulatory network showed that upregulation of PRKG1 positively 
regulates the activation of CREB1, which subsequently regulates the orphan receptor 
NR4A3 gene. The significantly upregulation of NR4A3 upon PTXNR-TTZ treatment can 
possibly induce apoptosis in BT-474 cell line. The network showed that the NR4A3 gene
can also be regulated directly by tumor suppressor gene TP53 for apoptosis induction.
The NR4A3 function in the gene regulatory network is consistent with the recent finding 
that showed NR4A3 can induce apoptosis both in p53 dependent and independent manner
33
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3.4. PTXNR-TTZ UPREGULATES DOWNSTREAM EFFECTORS OF Rho- 
GTPase SIGNALING NETWORK
The Reactome pathway enrichment analysis generated by Enrichr showed 
significant upregulation of Rho-GTPase signaling pathway (R-HSA-194315) induced by 
PTXNR-TTZ treatment in BT-474 cell line. In total 37 genes related to this pathway were 
upregulated with the p value 6.2 e-13, FDR 1.9 e-10 and a Z score of 4.03. A heatmap 
was generated showing all the 37 upregulated gene expression by PTXNR-TTZ treatment 
(Figure 4a). The effector proteins of the Rho-GTPase signaling pathway critically 
regulates the mitosis and cell cycle progression. Cell division cycle protein -20 
homologue (encoded by CDC20 gene) is one of the downstream effector proteins in this 
pathway. The protein binds and activates the anaphase promoting complex APC/C. 
Together the APC/CCDC20 protein complex promotes the exit from mitosis cell cycle 
phase. The upregulation in CDC20 can promote an aggressive form of breast cancer. A 
gene regulatory network was generated using all the significantly upregulated genes in 
the Rho-GTPase signaling pathway. The upregulated genes are shown in red nodes in the 
network. The network (Figure 4b) shows that CDC20 can be positively regulated by 
PLK1 gene and subsequently activate the APC/C complex. We found that CDC20 
overexpression is correlated with poor overall survival in HER2-positive breast cancer 
patients. From the METABRIC study, we screened 224 patients with HER2-positive
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breast cancer according to PAM-50 plus claudin low subtype breast cancer classifier 
method. Among 224 patients approximately 4% of the patients (8 patients) had CDC20 
DNA copy number alteration. The rest of the 216 patients were considered to be in the 
unaltered group for the analysis. The overall survival analysis (Figure 4c) showed that the 
median overall survival for the unaltered group was 107.10 months while the median 
survival was only 71.63 months in case of the CDC20 altered group (log-rank test p- 
value 0.296). In the CDC20 altered group, out of 8 patients 6 patients were deceased. 
Only 4% of the patients showed CDC20 DNA copy number alteration. The mRNA 
expression shows that two more effector proteins encoding genes of this pathway KIF2C 
and CDCA8, were also upregulated in most of the HER2-positive breast cancer patients 
in METABRIC study. In the co expression analysis we observed that KIF2C (Figure 4d) 
and CDCA8 (Figure 4e) gene expression highly correlated with the CDC20 gene 
expression. The Spearman correlation factor was 0.86 (p=2.38 e-64) and 0.70 (9.9 e-34) 
for KIF2C and CDCA8, respectively. We also found that the patients with KIF2C and 
CDCA8 DNA copy number alterations completely overlapped with the CDC20 altered 
group in the overall survival analysis. Out of 8 patients with CDC20 alteration, 6 of them 
also had KIF2C alteration and 2 of them had alterations in CDCA8 DNA copy number. 
This suggests that KIF2C and CDCA8 might also be a prognostic marker in HER2- 
positive breast cancer patients along with CDC20. The Oncoprint analysis (Figure 4f) 
showed that the most of the patients with HER2-positive breast cancer had high CDC20 
mRNA expression along with a high expression of KIF2C and CDCA8, suggesting a post 
transcriptional alteration in patients.
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Figure 4. Activation of Rho-GTPase signaling network by PTXNR-TTZ in HER2- 
positive breast cancer cell line. Heatmap showing the upregulation of downstream 
effectors in the Rho-GTPase signaling network. (b) Gene regulatory network showing the 
activation of mitotic progression promoting APC/C complex following overregulation of 
oncogenic CDC20 gene. (c) Overall survival analysis of HER2-positive breast cancer 
patients in METABRIC study with CDC20 DNA copy number alterations. The median 
overall survival of CDC20 altered group (n=8) was 71 months against 110 months in the 
unaltered group (without CDC20 DNA copy number alteration). Correlation analysis 
showing mRNA expression data of patients with CDC20 DNA copy number alteration 
with (d) KIF2C (e) CDCA8 altered patients. The patients with either KIF2C or CDCA8 
alterations completely overlapped with the CDC20 altered patients and also showed a 
high correlation mRNA expression with CDC20 altered patients. The Spearman 
correlation factor for KIF2C and CDCA8 mRNA expression against CDC20 mRNA 
expression were 0.86 and 0.71, respectively. (f) The Oncoprint analysis showing the 
DNA copy number and post transcriptional alterations in CDC20 , KIF2C and CDCA8 
genes. The data are shown for individual 224 HER2-positive breast cancer patients in the 
METABRIC study. The majority of the hER2-positive breast cancer patients showed 
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transcriptional alterations (cont.)
3.5. PTXNR-TTZ SIGNIFICANTLY INDUCES INFLAMMATORY PATHWAYS 
IN BREAST CANCER CELL LINES
The Kegg pathway enrichment analysis showed significant upregulation of the
TNF signaling pathway (HSA-04668) and NF- kappa B inflammatory signaling pathway
(HSA-04064) related genes in the MDA-MB-231 cell line induced by PTZNR-TTZ
treatment. In TNF pathway, 18 genes showed overlap in the analysis with p-value 2.6 e-
10, FDR 7.5 e-08 and Z-score of 6.55. The heatmap (Figure 5a) shows the gene 
expressions of significantly upregulated genes in this pathway. In the NF-kappa B 
pathway, 12 genes in the analysis showed overlap with this pathway with p-value 3.5 e- 
06, FDR 0.0002, and Z score of 5.16 and a heatmap was generated showing all the 
overlapped upregulated genes (Figure 5b). A gene regulatory network was generated 
using all the significantly upregulated genes in these pathways. All the red nodes in the 
network represent the upregulated gene expression in our analysis for this particular 
pathway. The gene regulatory network (Figure 5c) shows that the upregulated genes, in 
turn, activate the NF-Kappa B p65/p50 signaling complex. The network also suggests 
that NF-Kappa B p65/p50 signaling complex activation can subsequently induce IL6 
expression. Induction of IL6 can positively regulate STAT-3 transcription factor and 
cause inflammation in triple negative breast cancer cell lines. Such sequential activation 
of NF-kappa B-IL6-STAT3 inflammatory circuit has been reported to be associated with 
maintenance of cancer stem cell like population causing therapeutic resistance in breast 
cancer both in vitro and in vivo. We further investigated the mRNA expression levels of 
selected inflammatory genes (CCL20, CXCL1, CXCL2, CXCL3, CXCL8, IL6, IL1A and 
IL1B) in response to PTXNR-TTZ treatment that has been previously reported to be 
associated with enhanced inflammation, cancer cell progression or therapeutic resistance. 
We found that all of these genes were highly upregulated in PTXNR-TTZ treated MDA- 
MB-231 cell line (Figure 5d). In BT-474 cells, all of the genes except IL1A and CXCL8 
were not differentially expressed at all. This suggests that PTXNR-TTZ treatment 
significantly induced inflammatory pathways in the MDA-MB-231 cell line which might 





Figure 5. PTXNR-TTZ induces inflammatory gene expressions in triple negative breast 
cancer cells. The heatmap shows the upregulation of (a) TNF (b) NF-kappa-B pathway 
genes in MDA-MB-231 cell line induced by PTXNR-TTZ. (c) The gene regulatory 
network showing the possible activation of the NF-kappa-B p65/p50 signaling complex 
leading to potential activation of tumorigenic NF-kappa-B -IL6- STAT-3 signaling axis. 
(d) Gene expression analysis of a set of selected tumorigenesis promoting inflammatory 
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Figure 5. PTXNR-TTZ induces inflammatory gene expressions in triple negative breast 
cancer cells. The heatmap shows the upregulation of (a) TNF (b) NF-kappa-B pathway 
genes in MDA-MB-231 cell line induced by PTXNR-TTZ. (c) The gene regulatory 
network showing the possible activation of the NF-kappa-B p65/p50 signaling complex 
leading to potential activation of tumorigenic NF-kappa-B -IL6- STAT-3 signaling axis. 
(d) Gene expression analysis of a set of selected tumorigenesis promoting inflammatory 
genes in BT-474 and MDA-MB-231 cell line induced by PTXNR-TTZ (cont.)
150
(d)
Figure 5. PTXNR-TTZ induces inflammatory gene expressions in triple negative breast 
cancer cells. The heatmap shows the upregulation of (a) TNF (b) NF-kappa-B pathway 
genes in MDA-MB-231 cell line induced by PTXNR-TTZ. (c) The gene regulatory 
network showing the possible activation of the NF-kappa-B p65/p50 signaling complex 
leading to potential activation of tumorigenic NF-kappa-B -IL6- STAT-3 signaling axis. 
(d) Gene expression analysis of a set of selected tumorigenesis promoting inflammatory 
genes in BT-474 and MDA-MB-231 cell line induced by PTXNR-TTZ (cont.)
In our analysis, we observed significantly high expression of IL1A and IL1B in 
triple negative MDA-MB-231 breast cancer cell line, whereas only IL1A was highly 
overexpressed in HER2-positive BT-474 cell line upon PTXNR-TTZ treatment. 
Recently, it has been reported that HER2-overexpression induces the expression of IL1-
alpha (encoded by IL1A), promoting tumorigenesis and chemotherapeutic resistance 
in HER2-positive breast cancer 34
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4. DISCUSSION
Hyperactive DNA repair and replication mechanisms are the traits of therapeutic 
drug resistance in cancer cells. Cancer cells activate the several DNA repair pathways in 
a direct or indirect way in response to the stress caused by the chemo drugs. For example, 
platinum based drugs inhibit the cancer cells by DNA damage and subsequent DNA 
damage associated (e.g., p53) apoptosis pathways 35. In response, hyperactivity of DNA 
repair pathways such as HR, NER cause the therapeutic resistance to these DNA 
damaging chemotherapeutic drugs 35. In particular, mutations or inactivation in HR 
pathway is influential and one of the major determinants of platinum based therapeutic 
outcome in high grade serous cancer (HGCC)36. A study conducted on HGCC patients 
who extraordinarily responded to platinum based treatment response showed that overall, 
73% of the exceptional responder patients had disruption in HR DNA repair pathway 37 
From the transcriptional analysis, we found that Paclitaxel molecule or PTXNR-TTZ do 
not alter of affect the DNA metabolism pathways. On the other hand, Rapamycin, 5- 
Fluorouracil and Trastuzumab downregulate the DNA repair pathways in HER2-positive 
breast cancer cell line (Figure 2a). The hierarchical heatmap showed that Rapamycin, 5- 
Fluorouracil, and Trastuzumab specifically altered majority of the gene expression in HR 
and MMR pathways (Figure 2b, Figure 2c). This suggests that these G1/S cell cycle 
arresting agents can be used in combination with platinum based chemotherapy for a
possible synergistic outcome by suppressing the hyperactive treatment resistive DNA 
repair pathways.
We found that PTXNR-TTZ might induce apoptosis in BT-474 cell line via 
PRKG1- NR4A3 mediated intrinsic apoptosis pathway (Figure 3). Olga et al. recently 
reported NR4A3 as a novel transcriptional target of p53 transcription factor and mediate 
apoptosis 33. The protein p53 directly binds to the promoter region of NR4A3 gene and 
induces the transcription. NR4A3 interacted with ant-apoptotic protein Bcl-2 for 
sequestration and induction of apoptosis. Interestingly, the study also showed that the 
orphan receptor NR4A3 gene also showed tumor suppressive function both in p53 
dependent and independent way. In another recent study by Zhao et. al. showed that 
microRNA miR-665 promoted epithelial-mesenchymal transition (EMT) , cancer cell 
invasion, and metastasis by inhibiting the NR4A3 gene in MCF-7 and MDA-MB-231 
breast cancer cell lines in vitro 38.
We found that Rho-GTPase signaling pathway genes were highly overregulated 
by PTXNR-TTZ treatment in HER2-positive BT-474 breast cancer cell line (Figure 4a). 
One of the major downstream effectors of this pathway CDC20 gene expression was 
significantly upregulated in response to PTXNR-TTZ treatment. The gene regulatory 
network shown in Figure 4b suggests that the overexpression of CDC20 further activates 
the APC/C complex. The post translational over-regulation of CDC20 gene can 
potentially cause aberrant mitotic exit and therapeutic resistance. The translated protein 
Cdc20 is an essential regulator of mitosis and exhibits forced induction of cell cycle 
progression by partnering with APC/C in subsequent downstream ubiquitination process 
39. Ubiquitination has a critical role in cell cycle control and tumor initiation and
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transformation 40. APC/C binds and gets activated by Cdc20 (cell division cycle 20 
homologue) and Cdh1 (Cdc20 homologue-1) forming two distinct multi subunit E3 
ubiquitin ligase sub complexes APC/CCdc20 and APC/CCdh1, respectively to promote cell 
cycle progression 41,42. Emerging evidences have suggested two distinct and opposing 
roles of the closely related cell division cycle proteins Cdc20 and Cdh1 in tumorigenesis. 
Cdc20 largely functions as an oncogene whereas Cdh1 has tumor suppressive role in the 
tumorigenesis process 42. The oncogenic role of Cdc20 has been associated with a wide 
range of cancer types including breast cancer, pancreatic cancer, prostate cancer, 
colorectal cancer, lung cancer, glioblastomas and other types 41. The protein Cdc20 
critically regulates the activation of APC/C in the mitosis cell cycle phase. The complex 
APC/CCdc20 promotes the metaphase to anaphase transition by degrading the cell cycle 
regulatory proteins 43. Inhibition of Cdc20 protein has been showed to induce enhanced 
apoptosis in skin tumor mouse model in vivo 44 The ablation of CDC20 gene in mice 
caused aberrant mitotic arrest resulting in embryonic lethality suggesting possible role of 
CDC20 gene in embryonic development 45. Moreover, inhibition of endogenous Cdc20 
resulted in mitotic arrest and subsequent cell death in multiple human cancer cell lines. 
Zeng et al. showed that inhibition of APC/CCdc20 and APC/CCdh1 by an IR-mimetic 
inhibitor caused cell death in various cancer cell lines 46. In the survival analysis of 
METABRIC data, 224 HER2 positive breast cancer patients showed that the patients who 
had CDC20 DNA copy number alteration suffered from much worse overall median 
survival compared to the unaltered group (71.10 vs 107.10 months) (Figure 4c). 
Altogether, the increasing evidences suggest that CDC20 might be a potential therapeutic 
in HER2-positive breast cancer treatment to overcome therapeutic resistance and aberrant
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mitotic exit upon Paclitaxel based drug treatment. In co-expression analysis, KIF2C 
and CDCA8 were highly correlated with the CDC20 mRNA expression in METABRIC 
HER2-positive breast cancer patients (figure 4d, Figure 4e). The patients with KIF2C and 
CDCA8 DNA copy number alterations completely overlapped with the CDC20 altered 
patients. Moreover, both KIF2C and CDCA8, along with CDC20, showed high mRNA 
expression in 224 METABRIC HER2-positive breast cancer patients irrespective of their 
DNA copy number alterations (Figure 4f). KIF2C and CDCA8 were also upregulated 
following PTXNR-TTZ treatment. Kinesin family member KIF’s are involved in 
cytoskeleton remodeling and take part in chromosomal segregation and spindle 
orientation during mitosis47,48. Overexpression of kinesin family member 2C or mitotic 
centromere associated kinesin, KIF2C is associated with detachment of microtubules 
from the centromere by enhanced microtubule depolymerization. KIF2C has been 
reported to be positively regulated by aurora-kinase B 49,50 and negative regulation by p53 
tumor suppressor protein 51. KIF2C has been shown to have a role in correcting improper 
kinetochore-microtubule attachment during mitosis 49,50. KIF2C overexpression has been 
shown to induce mammary carcinogenesis, and suppression of KIF2C inhibited the 
growth of breast cancer cell lines in vitro51. The cell division cycle associated protein-8, 
encoded by CDCA8 gene translates a chromosomal passenger complex (CPC) which is 
an essential regulator of mitosis 52. The CPC complex functions at the centromere regions 
ensuring proper chromosomal segregation. The complex is cell cycle regulated and 
essential for microtubule stabilization and spindle assembly. Overexpression of CDCA8 
has also been showed to promote the malignant proliferation of melanoma cell lines in 
vitro and correlated with poor prognosis 53. Moreover, a recent study leveraging the
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weighted gene co-expression network analysis (WCGA) and protein-protein 
interaction network analysis from the Gene Expression Omnibus (GEO) database showed 
that both KIF2C and CDCA8 are potential bio marker for metastatic breast cancer 54
Inflammation is well correlated with poor therapeutic outcomes and increased risk 
of breast cancer recurrence. The pathway enrichment analysis showed PTXNR-TTZ 
significantly upregulated the TNF and NF-kappa B inflammatory pathway related genes 
in MDA-MB-231 cell line (Figure 5a, Figure 5b). We further investigated the induction 
of these inflammatory pathways using the gene regulatory network generated with the 
significantly upregulated gene expressions in this pathway. The gene regulatory network 
showed that the upregulated genes might induce the activation of the NF-kappa B- 
p65/p50 signaling complex and possible sequential activation of NF-kappa B-IL6-STAT3 
signaling axis (Figure 5c). We observed significant upregulation of IL6 in PTXNR-TTZ 
treated triple negative MDA-MB-231 breast cancer cell line which further suggests the 
possibility of activation of this signaling circuit. Overregulation of IL6 has been shown to 
promote stem cell like phenotype in the breast cancer causing tumor progression and 
therapeutic resistance55-58. NF-kappa B activation was shown to be required for the 
elevated expression of Il6, IL8 and CXCL1 and concurrent inhibition of IL6 and IL8 
inhibited the growth of triple negative breast cancer cell growth in vitro and in vivo59. 
Altogether our transcriptomic analysis suggests that inhibition of IL6 might improve the 
therapeutic outcome in the taxane based chemotherapeutic treatment of triple negative 
breast cancer cells. We further investigated the PTXNR-TTZ induced selected 
inflammatory gene expression signature in MDA-MB-231 cell line and BT-474 cell line. 
The signature gene set is associated with enhanced inflammation and promotion of cell
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proliferation 34 In MDA-MB-231 cell line we found significantly high expression of 
the signature genes suggesting a possible role in therapeutic resistance while most of the 
genes were not expressed at all in BT-474 cell line (Figure 5d). In BT-474 cell line, we 
also found that IL1A gene is overexpressed upon PTXNR-TTZ treatment. Recently, Liu 
et. al. showed the role of IL1-alpha (encoded by IL1A gene) on tumorigenesis and 
therapeutic resistance in HER2-positive breast cancer cell lines 34 The study showed that 
HER2 overexpression induced the activation of IL1-alpha and IL6 for maintaining the 
therapeutically resistant cancer stem cell like phenotype. More importantly, IL1A 
knockdown depleted the cancer stem cell population, dampened the inflammatory 
microenvironment and ultimately inhibited the HER2-induced tumorigenesis in HER2- 
positive breast cancer cells in vivo. The study also showed that pharmacologic blockade 
of IL1-alpha reduced the therapeutically resistant stem cell population and improved the 
chemotherapeutic treatment response with Cisplatin and Paclitaxel in vivo. Hence, we 




The transcriptional regulation of PTXNR-TTZ was investigated in breast cancer 
cells. PTXNR-TTZ treatment significantly overexpressed PRKG1 and NR4A3 genes in 
HER2-positive breast cancer cells. It was concluded that the overexpression of the 
PRKG1-NR4A3 axis might induce an intrinsic apoptosis pathway to inhibit the HER2- 
positive breast cancer growth. The pathway enrichment analysis showed that the CDC20
was significantly overexpressed by PTXNR-TTZ treatment. CDC20 is a promoter of 
mitotic exit and might act as an oncogene by activating the anaphase promoting complex 
APC/C. Two other genes KIF2C and CDCA8 were also upregulated in this pathway 
which have been reported to have role in cell growth progression. Moreover, KIF2C and 
CDCA8 genes have recently been proposed as potential metastatic biomarkers in breast 
cancer. Altogether, it was proposed that targeted inhibition of CDC20, KIF2C and 
CDCA8 will enhance the therapeutic efficacy in HER2-posiitive breast cancer treatment. 
PTXNR-TTZ induced high mRNA expression of selected tumorigenic inflammatory 
genes in MDA-MB-231 cell line which suggests possible causes of drug resistance in 
triple negative breast cancer cells.
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IV. POLYMER COATED GOLD-FERRIC OXIDE SUPERPARAMAGNETIC 
NANOPARTICLES FOR THERANOSTIC APPLICATIONS
ABSTRACT
A multifunctional magnetic nanoparticle (NP) is designed to perform a near­
infrared (NIR)-responsive remote control photothermal ablation for the treatment of 
breast cancer. In contrast to the previously reported studies of gold (Au) magnetic 
(Fe3O4) core-shell nanoparticles (NPs), a Janus-like nanostructure is synthesized with 
Fe3O4 NPs decorated with Au resulting in an approximate size of 60 nm mean diameter. 
The surface of trisoctahedral Au-Fe3O4 NPs were coated with a positively charged 
polymer, poly- i-lysine (PLL) to deliver the NPs inside cells. The PLL coating increased 
the colloidal stability and robustness of Au-Fe3O4 NPs (PLL-Au-Fe3O4) in biological 
media including cell culture medium, phosphate buffered saline (PBS) and PBS with 
10% fetal bovine serum. The PLL-Au-Fe3O4 NPs were characterized by transmission 
electron microscopy (TEM), XRD, FT-IR and dynamic light scattering (DLS). The 
unique properties of both Au surface plasmon resonance and superparamagnetic moment 
result in a multimodal platform for use as a nanothermal ablator and also as a magnetic 
resonance imaging (MRI) contrast agent, respectively. Taking advantage of the 
photothermal therapy, PLL-Au-Fe3O4 NPs were incubated with BT-474 and MDA-MB- 
231 breast cancer cells, investigated for the cytotoxicity and intracellular uptake, and 
remotely triggered by a NIR laser of ~808 nm (1 W/cm2 for 10 min). It is revealed that 
no significant (<10%) cytotoxicity was induced by PLL-Au-Fe3O4 NPs itself in BT-474
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and MDA-MB-231 cells at concentrations up to 100 ^g/ml. Brightfield microscopy, 
fluorescence microscopy and TEM showed significant uptake of PLL-Au-Fe3O4 NPs by 
BT-474 and MDA-MB-231 cells. The cells exhibited 40 and 60% inhibition in BT-474 
and MDA-MB-231 cell growth, respectively following the internalized NPs were 
triggered by a photothermal laser using 100 ^g/ml PLL-Au-Fe3O4 NPs. The control cells 
treated with NPs but without laser showed <10% cell death compared to no laser 
treatment control. Combined together, the results demonstrate a new polymer gold 
superparamagnetic nanostructure that integrates both diagnostics function and 
photothermal ablation of tumors into a single multimodal nanoplatform exhibiting a 
significant cancer cell death.
1. INTRODUCTION
Assembly of the hyperthermia property of superparamagnetic nanoparticles (NPs) 
with imaging function into a single nanostructure offers a promising way to dynamically 
monitor the progress of the disease and enhance therapeutic efficacy. Unlike single­
component materials, which usually contain only one unique property of the active 
ingredient, the ingredients of multicomponent materials offer the possibility of 
multimodal application of these functional components thereby increasing versatility of 
these materials.1,2 The development of multicomponent materials as theranostic 
nanosystems has a potential to establish a new therapeutic mode to combine imaging and 
hyperthermia, which can greatly increase the therapeutic efficacy with real-time 
monitoring in tissues. Normal tissues and tumors differ only slightly in relaxation time,
and hence, cannot propagate proper diagnosis signals during magnetic resonance 
imaging (MRI).3 The development of new MRI contrast agents based on NPs is a 
fascinating field of research that focuses on improving MRI techniques for the early 
detection of disease. Superparamagnetic NPs such as ferric oxide (Fe3O4) have been 
extensively employed as an MRI contrast agent,4-10 altering the magnetic resonance (MR) 
signals by reducing the relaxivity through de-phasing of the transverse magnetization.11,12 
A gold (Au) shell coating may be useful in this regard in order to enhance not only the 
imaging contrasts for MRI but also the photothermal effect via the plasmon-derived 
optical resonances of gold shells in the visible and near-infrared region (NIR).13 The 
combination of Au-coated NPs has tremendous potential in improving optical properties, 
thermal properties, tunable geometry, and imaging contrasts in MRI. As a bifunctional 
NP, Au-Fe3O4 can inherit excellent surface chemistry characteristics, unique optical 
properties (attributed to Au) and superparamagnetic characteristics attributed to Fe3O4 . 
First of all, the NPs offer size controllability, ranging from few to hundreds of 
nanometers with different and unique size-dependent properties. Second, the NPs can be 
easily controlled and manipulated from outside with the help of external magnetic field 
being operated from a distance. Third, the NPs can provide enhanced contrast in medical 
imaging that can be used to diagnose the situation efficiently. These characteristics would 
enhance and broaden the application of these nanoparticles for theranostic applications.
While only a few number of Au and magnetic NPs have been approved for 
clinical and preclinical trials by the U.S. Food and Drug Administration (FDA),14-17 
toxicity of both coated and uncoated magnetic NPs remain a serious concern.18-21 Both 
Au and Fe3O4 NPs exhibit toxicity to cells via numerous mechanisms including the
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disruption of cell membrane, DNA damage, induction of oxidative stress, generation 
of free radicals, impairment of mitochondrial function and alteration in cell signaling 
among others.22-24 The toxicity may not be caused by single NP, but rather due to the 
aggregation of NPs in biological media and serum.25,26 Given the unstable nature of NP 
formulation, it is hypothesized that an optimum dose of a cationic polymer coating onto 
Au-Fe3O4 NPs play a role in determining NP configuration on cellular cytotoxicity as 
well as direct therapy. Coating the surface of Au-Fe3O4 NPs with suitable polymers may 
offer several features: (i) reduced aggregation tendency of the particles; (ii) improved 
dispersibility; (iii) enhanced colloidal stability; (iv) protected undesirable surface 
oxidation; (vi) surface conjugation for targeting; (v) decreased cytotoxicity; and (v) 
increased intracellular uptake by target cells. A charged polymer coating on the NP 
surface enhances the electrosteric stabilization by attractive and repulsive forces. Poly-1- 
lysine (PLL) is a biocompatible polycation that promotes cell adhesion by the presence of 
amine (-NH2) groups.27-29 PLL has been used to increase blood circulation, improve 
solubility as well as enhance MRI imaging contrasts of gadolinium imaging chelates.27,29- 
32 Steric stabilization has proven to be an effective method to improve NP colloidal 
stability in ionic media.33 A uniform coating of Fe3O4 NPs with polysaccharides leads to 
a decrease in saturation magnetization as compared to uncoated particles.34 This drop in 
saturation magnetization is undesirable due to poor signaling in MRI imaging. Therefore, 
there is a need for a stable coating on the surface of Au-Fe3O4 NPs to prepare colloidal 
dispersion in biological medium and attain high MRI imaging contrasts.
In this study, multifunctional Au-Fe3O4 NPs were designed for medical imaging 
and hyperthermal treatments of breast cancer cells. To overcome the limitation of
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colloidal stability and low dispersity of NPs, a PLL polymeric coating was introduced 
to the surface of Au-Fe3O4 as a physical barrier for preventing NP aggregation as well as 
enhancing their intracellular uptake by breast cancer cells. Our results showed that the 
PLL coating on Au-Fe3O4 enhanced it stability in biological fluids such as water, 
phosphate buffered saline (PBS), cell culture medium and PBS containing 10% fetal 
bovine serum (FBS). PLL coated Au-Fe3O4 NPs further enhanced the contrast of MRI 
imaging signals, exhibited intracellular uptake across the breast cancer cell membrane 
and decreased the cancer cell viability following photothermal treatment. The novelty of 
this work is to generate a nanometer-thick PLL layer for the stable dispersion of Au- 
Fe3O4 NPs in biological fluids that results in excellent optical, magnetic and therapeutic 
properties for the cancer treatment.
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2. MATERIALS AND METHODS
2.1. SYNTHESIS OF Au-Fe3O4 NPs
The Au-Fe3O4 NPs were synthesized by a one-pot synthesis technique based on 
the method that has been published by Pariti et al.35 Briefly, the NPs were synthesized by 
injecting 2.5 mM of Fe(CO)5, 0.25 mM of HAuCU, 2.5 mM oleic acid, and 2.5 mM of 
oleylamine into 5 ml of Triton® X-100 at 85 °C. The reaction was conducted for 10 min 
in a three-neck round bottom flask equipped with a magnetic stir bar and air condenser. 
The temperature was increased to 300°C. The product was a black precipitate that was 
isolated from the reaction mixture by magnetic filtration, followed by ultrasonication, 
centrifugation, and washing to remove excess Triton® X-100 and any unreacted
precursors. The powder collected at the bottom of the centrifuge tube was dried in air.
The preparation of Au-Fe3O4 NPs was confirmed by XRD analysis using a D/max-2400 
diffractometer and CuK radiation (k = 0.1541 nm).
2.2. POLYMER COATING ON Au-Fe3O4 NPs
25 mg of Au-Fe3O4 NPs were dispersed in 1 ml of reverse osmosis water. 660 |il 
of 0.1 % ( j)  PLL (Sigma Aldrich, MW: 150000-300000) was added into the NP
dispersion and incubated for 24 h at room temperature (~22 °C) under continuous 
shaking. Unbound PLL was removed by centrifuging at 5000Xg for 30 min that was 
repeated twice and measured using the trypan blue assay, spectrophotometry, and a 
standard curve (SI Figure 1a).36 The concentration of Au-Fe3O4 NPs was determined 
using a standard curve of the NP absorption at 710 nm peak (SI Figure 1b). The mass 
ratio of PLL and NPs were calculated. The presence of PLL coating was confirmed by 
Fourier Transform Infrared (FT-IR) spectroscopy. The FT-IR spectrometer (Perkin- 
Elmer) was equipped with an Electronic Temperature Control (ETC) EverGlo IR Source 
and a Deuterated Triglycine Sulfate (DTGS) detector. FT-IR analysis was carried out for 
uncoated and PLL coated Au-Fe3O4 NPs by mixing with potassium bromide (KBr) and a 
pellet method, after a baseline correction being made with dried KBr, to confirm the 
compatibility. The pellet was prepared to a pressure of about 5 x 106 Pa, in an evacuated 
chamber, to produce a clear transparent disc of diameter 2 cm and thickness of 0.2 cm. 




To measure the dmean of Au-Fe3O4 and PLL-Au-Fe3O4 NPs, transmission 
electron microscope (TEM) images were obtained using a Tecnai F20 at an accelerating 
voltage of 120 kV. A drop of 10 ^l of each NP sample in water was air-dried on carbon- 
coated copper grids (Ted Pella). Images were recorded and analyzed using ImageJ 
(version 1.45S, NIH, USA) to calculate dmean for at least 20 particles. The size 
distribution of Au-Fe3O4 and PLL-Au-Fe3O4 NPs was determined by dynamic light 
scattering (DLS). The zeta potential was measured via laser Doppler anemometry using a 
Zetasizer Nano ZS (Malvern Instruments). Samples were prepared in water, PBS, RPMI 
1640 cell culture medium and PBS with 10% FBS. Measurements were performed in 
triplicates and shown as the mean ± standard deviation (S.D.). The X-ray diffraction 
(XRD) patterns were performed by a Philips X-Pert X-ray powder diffractometer with 
CuKa (1.5418 A) radiation from 5 to 90 degrees. The UV-Vis absorption spectra of Au- 
Fe3O4 and PLL-Au-Fe3O4 NPs were measured using a Bio-Tek microplate reader 
(BioTek Synergy 2) between 400-900 nm. Fourier transform infrared (FT-IR) 
spectroscopy of Au-Fe3O4 and PLL-Au-Fe3O4 NPs was carried out using a Perkin Elmer 
spectrum GX spectrophotometer. Thermal gravimetric analysis (TGA) was performed 
using a Q50 thermal gravimetric analyzer (TA instruments). The samples were heated 
from 25°C to 1000°C at a heating rate of 10°C /min under N2 flow. Results are expressed 
in weight percent as a function of temperature.
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2.4. MRI RELAXOMETRY OF PLL- Au-Fe3O4 NPs
To measure the relaxation variables in MRI, Au-Fe3 O4 NPs coated with PLL (PLL- 
Au-Fe3 O4) were prepared in water at 250 Mg/ml concentration. All measurements were 
conducted at room temperature using a Bruker’s magnetic relaxometer mq20 (0.47 T) for 
the spin-spin magnetic relaxation time (T2) experiments. The specimens were dispersed 
in PBS and PBS containing 10% FBS at different Au-Fe3 O4 and PLL-Au-Fe3 O4 NP 
concentrations (1, 10 and 100 Mg/ml). The proton spin relaxation time, T2 was measured 
as a function of the NP concentration.
2.5. CYTOTOXICITY OF PLL- Au-Fe3O4 NPs IN BREAST CANCER CELLS
BT-474 and MDA-MB-231 breast cancer cells (ATCC) were cultured at 37°C and 
5% CO 2 in Hybri-Care (ATCC) and RPM I 1640 (Life Technologies), respectively 
supplemented with 10% FBS (Corning) and 1% (100 units/ml) Penicillin-Streptomycin 
(Gibco). Cells in the exponential growth phase were seeded in a 96-well plate at an initial 
density of 10,000 cells/ well and incubated overnight. Different concentrations of PLL- 
Au-Fe3 O4 NPs (0-500 Mg/ml) were added to the cell culture media. After 2 h of 
incubation, the media was removed, and the cells were washed using PBS followed by re­
incubation in cell culture media for additional 72 h. The viable and dead cells were 
measured using a live-dead (calcein AM; CAM  and EthD-1) assay (Invitrogen) and 
calculated according to the manufacturer’s protocol. The cells without any NP treatments 
were used as the control. The percentage cell death was calculated by the following 
equation:
%  cell death= p N P s ~ F b l a n k  x 100
F c o n t r o l  Fb lan k .
(1)
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Where, Fnps is the Ethd-1 fluorescence of the cells treated with PLL-Au-Fe3 O4 NPs, 
Fbiank is the Ethd-1 fluorescence of the cell culture medium alone, and Fcontrol is the Ethd-1 
fluorescence of the cells without any NP treatments. The concentration at which cell death 
was less than 10% was identified as a non-toxic dose.
2.6. INTRACELLULAR UPTAKE OF PLL- Au-Fe3O4 NPs
Cellular uptake of PLL-Au-Fe 3 O4 NPs was observed using a Carl Zeiss Axio 
observer Z1 research microscope system with Apitome.2 optical structuring device. BT- 
474 and MDA-MB-231cells were seeded in 8-well chambers containing 10,000 cells/well 
and grown until 70% confluence. PLL-Au-Fe 3 O4 NPs of 100 .̂g/ml were added to the 
wells, incubated for 2 h, and washed using PBS for 3 times. Live cells were re-incubated 
with media and imaged on a Zeiss microscope using a 63x objective (water) through 
phase contrast. The intracellular uptake of PLL-Au-Fe 3 O4 NPs by BT-474 and M DA- 
MB-231 cells were further examined by TEM at a voltage of 80 kV. Briefly, cells were 
seeded in T25 flasks at a density of 1 x 106 cells/ml. After overnight incubation at 37°C 
and 5% CO 2 , the cells were incubated with 100 ^g/ml PLL-Au-Fe3 O4 NPs. After 
incubation for another 24 h, the medium was carefully removed and cells were washed 
with PBS for 3 times and fixed at 4°C for 1 h using glutaraldehyde (2.5% in PBS). Then 
the cells were further subjected to a sequence of treatments to obtain sections that were 
subsequently mounted onto copper grids before TEM  measurements.
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2.7. PHOTOTHERMAL TREATMENT OF BREAST CANCER CELLS USING 
PLL- Au-Fe3O4 NPs
A series of specimens with different PLL-Au-Fe3O4 NP concentrations (0, 50, 
100, 200, 400 and 800 Mg/ml) were put into quartz cuvettes and irradiated by an 808 nm 
laser for 10 min with 1 W/cm2 power density. An in-situ thermocouple thermometer 
(Cole-Parmer) was used to record the temperature change. To investigate the in v itro  
photothermal ablation of breast cancer cells, BT-474 and MDA-MB-231 cells were 
incubated with 100 Mg/ml of PLL-Au-Fe3O4 NPs in cell culture media for 2 h, washed 
using PBS (3x) to remove the unbound NPs and re-incubated in the corresponding cell 
culture media for 72 h. The cells were exposed to NIR light (808 nm pulse laser of 1 
W/cm2 with a diameter of 6 mm for 10 min) to induce photothermal damage. The 
following control samples were used: cell culture medium, cells without any treatment, 
and the cells treated with PLL-Au-Fe3O4 NPs without any exposure to lasers. After 
exposure to the NIR light, cells were incubated for an additional 72 h at 37°C. Cell 
viability was assessed using CAM and EthD-1 (Invitrogen). To further confirm the in 
v itro  photothermal ablation of breast cancer cells, cytotoxicity following irradiation was 
also performed using MTT viability assay (Invitrogen). Briefly, BT-474 and MDA-MB- 
23 1 cells were seeded in a 96-well plate at a density of 10,000 cells/well. After overnight 
incubation at 37°C and 5% CO2, cells were incubated with PLL-Au-Fe3O4 NPs of 0, 50, 
100, 200, 400 and 800 Mg/ml for 2 h. The medium was replaced with 100 m1 of fresh 
medium. A 10 m1 MTT of 5 mg/ml in PBS was added to the medium. Cells were 
incubated at 37°C for 4 h for labeling cells with MTT. All medium was removed from the 
well except 25 m1. A 50 m1 DMSO was added to each well for dissolving the insoluble
formazan crystals. The absorbance at 540 nm was recorded using a Bio-Tek 
microplate reader (Synergy 2). Mean and standard deviations of two independent 
experiments were reported for each sample.
3. STATISTICAL ANALYSIS
Each experiment was carried out with three independent experiments of at least 
triplicate measurements. The mean differences and standard deviations were evaluated.
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4. RESULTS
4.1. SYNTHESIS AND CHARACTERIZATION OF PLL-Au-Fe3O4 NPs
TEM images revealed that Au-Fe3O4 NPs were uniform and averaged ~55 ± 8.6 
nm in diameter (Figure 1a). The thickness of PLL coating on Au-Fe3O4 was estimated to 
be approximately 9 ± 2.5 nm by analyzing the TEM images (Figure 1b and 1c). SI Table 
1 shows the amount of PLL coating on Au-Fe3O4 . The hydrodynamic dimeter of Au- 
Fe3O4 NPs in water as characterized using DLS showed a wide size distribution of Au- 
Fe3O4 dispersions with more than one particle populations and a high polydispersity 
index (PDI) of 0.856 ± 0.07 (SI Figure 2a). The differences in size between TEM and 
DLS techniques could be explained by NP agglomeration and the presence of small 
aggregates. The PLL coating decreased the PDI of Au-Fe3O4 NPs from 0.856 to 0.539 ±
0.03 (Table 1). The hydrodynamic diameters of NPs after PLL coating eliminated the 
large and small particle aggregates in water, PBS, RPMI 1640 cell culture medium and 
PBS containing 10% FBS indicating a better colloidal stability (SI Figure 2b). The
stability of PLL-Au-Fe3O4 NPs was further probed using a time-resolved video (SI 
Movie File 1). As you can see from this video that Au-Fe3O4 NPs without any coating 
(left hand side tube in the video) precipitate down quickly in water while PLL-Au-Fe3O4 
NPs (right hand side tube) were stably suspended in black emulsion.
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(a) (b) (c)
Figure 1. TEM images showing Au-Fe3O4 NPs. (a) without, and (b) and (c) with PLL 
coating. Scale bar = 50 nm in (a) and (b), and 20 nm in (c). The dark black circles 
indicate Au and the shaded hexagons represent Fe3O4. Arrows in (c) indicate a thin layer
of PLL coating
The Au-Fe3O4 NPs possess a negative surface charge of -7.9 ± 0.8 mV and -12 ± 
7 mV in water and PBS, respectively as determined by zeta potential (Table 1 and Figure 
2a). The zeta potentials of Au-Fe3O4 NPs increased in cell culture medium and PBS with 
10% FBS indicating pronounced differences in the particle surface chemistry caused by 
different solvent compositions. The PLL coated Au-Fe3O4 NPs showed a strong positive 
charge in water and PBS due to the positive amine groups on the polymer backbone 
which confirmed the successful grating of PLL polymer on the surface of NPs (Table 1 
and Figure 2b). This further confirms that the PLL coating made the NPs disperse better 
in aqueous solutions and as a result no agglomeration on storage. Particles that are
175
surface engineered with amine functional groups like PLL has been reported to 
effective release of encapsulated molecules from endosomal compartments.37
Table 1. Characterization of Au-Fe3O4 before and after PLL coating
(a) (b)
R P M I  1 6 4 0  ce l l c u l t u r e  m e d i u m
P B S  +  1 0 %  F B S
Figure 2. Surface zeta potential. (a) Au-Fe3O4, and (b) PLL-Au-Fe3O4 NPs 
in water, PBS, RPMI 1640 cell culture medium and PBS containing 10% FBS. Three 
colored (red, green and blue) lines indicate three replicates from three independent 
experiments. Multiple peaks in Au-Fe3O4 (a) indicate their aggregation behavior that
disappears after PLL coating (b)
The crystal structures of Au-Fe3O4 and PLL-Au-Fe3O4 NPs were recorded by 
the X-ray diffraction (XRD), as shown in Figure 3a. The XRD pattern of Fe3O4 shows 
characteristic peaks at (111), (220), (311), (400), (422), (511) and (400) and (111), (220), 
(220), (311), (222) peaks for Au which is in agreement to the controls of Fe3O4-PDF # 
65-3107 and Au-PDF # 05-0681, respectively. XRD pattern contains no impurity peak 
indicating the high purity of Au and Fe3O4 samples and perfect phase transformation. The 
XRD pattern of PLL-Au-Fe3O4 NPs has similar diffraction peaks as those of Au- 
Fe3O4 NPs with more peak to noise ratio which could be attributed to PLL polymeric 
coating.
To confirm the successful synthesis of NPs, UV-Vis absorption and FT-IR spectra 
were measured. A complete spectra analysis of Au-Fe3O4 NPs shows a broad surface 
plasmon absorption with an absorption maximum at around 710 nm (Xmax) (Figure 3b; 
dotted line).38 The PLL coating showed an absorption shift to lower wavelengths with an 
absorption maximum at 640 nm (Figure 3b; solid line). This explains the enhanced 
dispersion of PLL-Au-Fe3O4 NPs in the aqueous phase by redistributing agglomerated 
Au-Fe3O4 NPs.
FT-IR spectra were used to study the transformation of Au-Fe3O4 and PLL-Au- 
Fe3O4 NP compositions (Figure 3c). As shown in Figure 3c, the strong absorption peak at 
about 590 cm-1 in the FT-IR of Au-Fe3O4 originates from Fe-O stretching of the Fe3O4 
core. The bare Au- Fe3O4 spectrum contains a peak at 1630 cm-1 due to water physiosorbed 
on the iron oxide surface and a broad band around 3400 cm-1 due to surface hydroxyl groups 
(Fe-OH). For PLL-Au-Fe3O4 NPs, new and broad absorption bands were observed in the 
range of 3340 and 3600 cm-1, which were attributed to amine N -H  stretching and O-H
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stretching, respectively. The peaks at 1647 and 1587 cm 1 attributed to to the stretching 
vibration of C=O from the PLL coating.
(a)
Figure 3.Characterization of PLL-Au-Fe3O4 NPs. (a) XRD patterns; (b) Absorption 
spectra (solid line: PLL-Au-Fe3O4 NPs and dotted line: Au-Fe3O4 NPs); (c) FT-IR 
characterization and (d) TGA curves of Au-Fe3O4 and PLL-Au-Fe3O4 NPs
To quantify the amount of PLL on the surface of PLL-Au-Fe3O4 NPs, TGA was
performed (Figure 3d). The PLL coating results in a weight loss of 7.4% between 100 °C
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and 650°C when compared with the uncoated particles (Au-Fe3O4). No change in 
PLL-Au-Fe3O4 mass was observed above 850°C. Combinedly, these findings suggest a 
successful surface functionalization of Au-Fe3O4 NPs by PLL polymer coating.
4.2. T2 MR RELAXIVIITY OF PLL-Au-Fe3O4 NPs AS DETERMINED BY MRI
Saturation magnetization value (Ms) and the T2 relaxation time were analyzed in 
order to evaluate the magnetic properties of Au-Fe3O4 with and without the PLL coating 
(SI Figure 3). Generally, the spin-spin magnetic relaxation of water protons changes in 
the presence of magnetic materials in the solution, such as synthesized Au-Fe3O4 NPs. 
This leads to enhance the magnetic property of the solution. Fe3O4 NPs are generally 
used for MR contrast agents because of their capacity to short the T2 relaxation time of 
their surrounding protons. As can be clearly seen in SI Figure 3, T2 was decreased 
gradually with the increase in NP concentration. The T2 relaxation time of PLL-Au- 
Fe3O4 NPs was higher than that of Au-Fe3O4 NPs due to the fact that the polymer coating 
displaces the water molecules from the vicinity of the Au-Fe3O4 nanocomposite, leading 
to an increase in the MR values.
4.3. CYTOTOXICITY STUDY BY PLL-Au-Fe3O4 NPs AND ITS
INTRACELLULAR UPTAKE
Figure 4a shows the cytotoxicity induced by various concentrations of PLL-Au- 
Fe3O4 NPs in BT-474 and M DA-M B-231 cells is dose-dependent. PLL-Au-Fe3O4 NPs 
did not show much cytotoxicity (< 20% cell death) at a concentration < 100 ^g/ml, and 
hence the concentration was chosen for subsequent studies. To investigate the 
intracellular uptake of the NPs, phase contrast images were used. It can be seen from
Figure 4b and Figure 4c that the PLL-Au-Fe3O4 NPs (black spots as indicated by 
arrows) entered in the cytoplasm of BT-474 and MDA-MB-231 cells. No black clusters 
were found in control cells without any NPs indicating the internalization of NPs by the 
cells. No morphological changes in cellular physiology have been observed when 
compared to control cells demonstrating negligible cytotoxicity by PLL-Au-Fe3O4 NPs. 
The uptake of PLL-Au-Fe3O4 NPs was further evaluated by TEM imaging (SI Figure 4). 
Clearly, cells treated with NPs show a remarkable distribution inside endoplasmic 
vesicles of the cells.
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(a)
Figure 4.Cytotoxicity and cellular uptake of PLL-Au-Fe3O4 NPs. (a) Cytotoxicity of 
PLL-Au-Fe3O4 NPs in BT-474 and M DA-M B-231 cells using live-dead assay at 
increasing NP concentration; Cellular uptake of PLL-Au-Fe3O4 NPs in (b) BT-474 and 
(c) MDA-MB-231 cells. Arrows indicate the NPs inside cells. Cells without any NP 




MDA-MB-231 cells MDA-MB-231: 100 ^g/ml
control; no NPs PLL-Au-Fe30 4
Figure 4.Cytotoxicity and cellular uptake of PLL-Au-Fe3O4 NPs.(a) Cytotoxicity of 
PLL-Au-Fe3O4 NPs in BT-474 and M DA-M B-231 cells using live-dead assay at 
increasing NP concentration; Cellular uptake of PLL-Au-Fe3O4 NPs in (b) BT-474 and 
(c) MDA-MB-231 cells. Arrows indicate the NPs inside cells. Cells without any NP 
treatment (control) did not show the black NP dots inside cells. Scale bar = 10 .̂m (cont.)
4.4. PHOTOTHERMAL EFFECTS BY PLL-Au-Fe3O4 NPs
In order to investigate, the potential of PLL-Au-Fe3O4 as nanothermal ablators, 
suspensions of the NPs in PBS were irradiated using 808 nm light emitted by a laser. The 
photothermal behavior of PLL-Au-Fe3O4 NPs was investigated by a temperature change
versus the NP concentration (Figure 5). Clearly, the NPs were able to induce a 
temperature enhancement in a concentration dependent manner.
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Figure 5. Temperature change of a PBS solution containing PLL-Au-Fe3O4 NPs under 
an 808 nm laser irradiation as a function of different NP concentrations
The temperature of the NP suspension reached 50°C at the PLL-Au-Fe3O4 NP 
concentration of 800 ^g/ml. Laser irradiation of PBS negative control without NPs did 
not show any temperature increase under the same conditions. The results indicate that 
the synthesized PLL-Au-Fe3O4 NPs were able to transform NIR laser into heat under 
laser irradiation. For laser treatment, BT-474 and MDA-MB-231 cells were first 
incubated with PLL-Au-Fe3O4 NPs for 2 h followed by a wash process to remove un­
internalized NPs, laser irradiation for 10 min and then for additional 72 h incubation 
period. In the control groups (cells + laser irradiation in absence of NPs), no significant
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cell death was observed. The cells treated with 100 ^g/ml of PLL-Au-Fe3O4 NPs but 
without laser illumination reached 90 ± 4.7% of cell survival rate compared to those 
treated with PBS control. In contrast, the combination of PLL-Au-Fe3O4 NPs and laser 
treated cells underwent photothermal destruction as shown by both phase contrast and 
cell viability (green live cells) and dead cell (red stain) staining (Figure 6).
BT-474:
Laser; no NPs
Laser + 100 ng/ml MDA-MB-231: 
PLL-Au-Fe30 4 Laser; no NPs




Figure 6. Phase contrast images of PLL-Au-Fe3O4 treatment on cancer cells. Phase 
contrast (row 1) and fluorescence (rows 2 and 3) images of BT-474 and MDA-MB-231 
cells treated with 2 h incubation of PLL-Au-Fe3O4 followed by 10 min laser irradiation 
and 72 h of incubation in the medium. Uninternalized NPs were washed with PBS before 
the imaging. Green fluorescence represents live cells as stained with calcein AM, while 
the red fluorescence represents dead cells as stained with EthD-1. Scale bars are shown
on images
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The groups for PLL-Au-Fe3O4 NPs + 10 min exposure to laser illumination
2
at 1 W/cm showed the inhibition in cell growth by 49 ± 12% in BT-474 cells (Figure 7; 
filled circle) and 60 ± 10% in MDA-MB-231 cells (Figure 7; open circle) suggesting 
significant therapeutic effects following the photothermal treatment. Cells without any 
treatment, with laser treatment alone and with NP groups showed <5% inhibition in cell 
growth. The cytocompatibility of PLL-Au-Fe3O4 NPs was further assessed by MTT cell 
viability assay (SI Figure 5). The quantitative analysis further reveal that the percentage 
of cell viability decreased to 63.5 ± 5.5% and 31.6 ± 3.2% in BT-474 and MDA-MB-231 
cells, respectively at concentrations >10 ^g/ml of NPs following laser irradiation.
Figure 7. Inhibition of cancer cell growth by PLL-Au-Fe3O4 NPs treatment following 
photothermal therapy. Quantitative assay of BT-474 (solid line; filled circle) and MDA- 
MB-231 (dotted line; open circle) cell growth inhibition following photothermal therapy 
in presence of PBS + laser and 100 ^g/ml of PLL-Au-Fe3O4 NPs. The data represent the
average o f three independent experiments
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5. DISCUSSION
A dumbbell shaped Au-Fe3O4 superparamagnetic NPs is synthesized that is 
similar in morphology to multifaceted Janus particles.39,40 The structure (Au-decorated 
Fe3O4) is chosen to provide added advantages of both Au and Fe3O4 functionalities for 
the full utilization of their potential. Several Au dots on the Fe3O4 host ensures that there 
is a maximum number of spots for molecular recognition since Au-terminal acts as 
anchors for targeting agents. Perhaps the most challenging aspect of applying Au-Fe3O4 
NPs involves the colloidal stability and shelf-life, surface functionalization, cellular 
internalization, and biocompatibility. Designing a properly grafted surface is therefore of 
paramount importance. Dextran,41 PEG,42 and silica coating43 have been used 
extensively, however, each method has its benefits and drawbacks and requires trade-offs 
and optimizations. For example, although silica coatings can provide colloidal stability, it 
may also retard R2 relaxation in MRI imaging, as well dampens the superparamagnetic 
moment which reduces hyperthermia efficiency. Reduction in the superparamagnetic 
moment also leads to the necessity for increased dosage of the magnetic NPs. In that 
regards, the Janus-like particle with larger Fe3O4 anchored with several Au dots serves 
the multifaceted purpose of retaining high superparamagnetic moment over larger size35 
as well as optimizing SPR and photothermal effect of Au. Here, we report a simple and 
versatile method to adsorb PLL on bare Au-Fe3O4 dispersed in aqueous solutions. The 
polycationic PLL backbone ensures tight coulomb attachment onto anionic surfaces of 
Au endowing the NP surface with a robust coverage.
This approach can be generalized to many anionic surfaces onto which 
cationic polymers can adhere tightly, such as glass or silica. The results are comparable 
with previous studies on Au nanoshells where polymers (i.e., polyethylene imine; PEI) 
have been used as an intermediate separating layer during the fabrication of Au-Fe3O4 
where the polymer layer prevents the migration of Au shell into the magnetic core by 
connecting between the core and shell structure.44,45 In contrast, we show an outer layer 
of PLL on the surface of Au-Fe3O4 that attribute to the columbic interactions between the 
Au surface and aliphatic monoamines that is clearly responsible for the observed stability 
of Au-Fe3O4 against aggregation in PBS. The TEM images showed the presence of a 
layer of PLL of approximately 9 nm thickness. The PLL coating improved the interaction 
of negatively charged Au-Fe3O4 at the cellular level by the resulting surface charge as 
confirmed by the zeta potential data.
The next step of PLL-Au-Fe3O4 involves cell culture experiments that suggest 
the overall intracellular uptake of the NPs at a non-toxic dose in breast cancer cells. The 
live/dead assay indicates that PLL-Au-Fe3O4 NPs are not cytotoxic in breast cancer cells 
at concentrations <100 ^g/ml (Figure 5). When compared to other cell viability data of 
polymer-coated NPs, our results are comparable to the literature data showing 20% 
reduction in cell viability using similar NP concentrations.45,46 Furthermore, the results 
from the phase contrast imaging microscopy demonstrated the effective internalization of 
the NPs presumably due to the combination of electrostatic interaction with the 
negatively charged glycocalyx on the cell membrane47,48 and the receptor-mediated 
endocytosis v ia  EGCG49-53 The results are in agreement with the previous finding where 
Au NPs functionalized with methoxy-PEG-thiol were internalized by MDA-MB-231
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cells v ia  endocytosis.54,55 Importantly, the observed uptake of PLL-Au-Fe3O4 NPs in 
breast cancer cells associated with low toxicity suggest a potential theranostic use of 
these Au NPs. It is worth noting that PLL-Au-Fe3O4 had higher levels of uptake in 
MDA-MB-231 cells than BT-474 cells. The differences in cell surface protein 
expressions and proteoglycans may attribute to the differential uptake of NPs inside the 
cells.56-58 Importantly, the higher observed uptake of PLL-Au-Fe3O4 in MDA-MB-231 
than BT-474 cells was associated with pronounced toxicity (Figure 5 and 6) suggesting a 
potential theranostic use of these gold nanoparticles.
Multiple studies have demonstrated the heating effect of Au shell NPs. 
Thermal ablation using PEG-coated Au nanoshells with silica cores have been reported to 
induce photothermal morbidity in SK-BR-3 breast cancer cells.59 The treated cells 
revealed lost in cell membrane integrity and cell death that was not observed in the 
controls with laser irradiation or gold nanoshells alone.59 Photothermal destruction was 
effective in reducing colon tumors in mice with a mean survival life of 90 days after the 
treatment.60 We found that at 100 .̂g/ml of PLL-Au-Fe3O4 and 10 min laser exposure, a 
AT of 15±7.6°C was achieved. The current study reveals the effectiveness of using PLL- 
Au-Fe3O4 as a potent MRI-visible photosensitizer during the laser irradiation of cancer 
cells.61-63 The noticeable combination of properties of PLL-Au-Fe3O4 with the local 
application of NIR laser irradiation offers a promising approach for the photothermal 




A multifunctional NP was constructed using the PLL polymer coating on Au- 
Fe3O4 with a mean diameter of ~60 nm that are less prone to aggregation and thus 
suitable for a wide range of biological applications. PLL-Au-Fe3O4 NPs showed good 
colloidal stability, NIR light absorption property, magnetic relaxivity and 
cytocompatibility. Upon exposure to a NIR light, the SPR of Au increased their 
temperature inside the cells. The PLL-Au-Fe3O4 NPs were also demonstrated the 
importance of having a surface of the polymer layer that enhanced MRI contrast. As an 
integrated all-in-one NP platform, the polymeric theranostic agent was shown for 
intracellular uptake and hyperthermal treatments of breast cancer cells for further 
translational therapeutic applications.
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V. ISOLATION AND PURIFICATION OF GLYCOGLYCEROLIPIDS TO 
INDUCE APOPTOSIS IN BREAST CANCER CELLS
ABSTRACT
Monogalactosyldiacylglycerol (MGDG) is the most abundant type of 
glycoglycerolipid found in the plant cell membrane and mostly in the chloroplast 
thylakoid membrane. The amphiphilic nature of MGDG is attractive in pharmaceutical 
fields for interaction with other biological molecules and hence exerting therapeutic anti­
cancer, anti-viral, and anti-inflammatory activities. In this study, we investigated the 
therapeutic efficacy of cyanobacteria derived MGDG to inhibit breast cancer cell growth. 
MGDG was extracted from a cyanobacteria S yn ech o cys tis  sp. PCC 6803 followed by a 
subsequent fractionation by column chromatographic technique. The purity and 
molecular structure of MGDG were analyzed by nuclear magnetic resonance (NMR) 
spectroscopy analysis. The presence of MGDG in the extracted fraction was further 
confirmed and quantified by high-performance liquid chromatography (HPLC). The anti­
proliferation activity of the extracted MGDG molecule was tested against BT-474 and 
MDA-MB-231 breast cancer cell lines. The in vitro study showed that MGDG extracted 
from S yn ech o cys tis  sp. PCC 6803 induced apoptosis in (70 ± 8) % of BT-474 (p<0.001) 
and (58 ± 5) % of MDA-MB-231 cells (p <0.001) using ~60 and 200 ng/ml of 
concentrations, respectively. The half-maximal inhibitory concentration, IC50 of MGDG 
extracted from S yn ech o cys tis  sp. PCC 6803 were (27.2 ± 7.6) and (150 ± 70) ng/ml in 
BT-474 and MDA-MB-231 cell lines, respectively. Quantification of caspase-3/7 activity
showed 2.3 and 2.1-fold (p<0.01) higher protein expressions in the MGDG treated 
BT-474 and MDA-MB-231 cells, respectively than untreated controls conferring to the 
caspase-dependent apoptosis. The MGDG did not show any significant cytotoxic side 
effects in human dermal fibroblasts cells. A commercially available MGDG control did 
not induce any apoptotic cell death in cancer cells substantiating the potential of the 
MGDG extracted from S yn ech o cys tis  sp. PCC 6803 for the treatment of breast cancer 
cells through the apoptosis-mediated pathway.
1. INTRODUCTION
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Glycoglycerolipids (GGLs) are natural products abundantly found in the cell 
membrane of marine algae,1,2 cyanobacteria,3,4 and higher plants,5-9 with one or two 
carbohydrate units, glycerol, and diversified acyl lipid groups.9,10 GGLs are conserved in 
both gram-negative and gram-positive bacteria, i.e ., B a c illu sp u m ilu s ,11 L a c to b a c illu s  
p la n ta ru m ,12 M icro b a c ter iu m  sp.,13 M icro co c cu s  lu teu s ,14 and P h o rm id iu m  ten u e15 with 
highly conserved structures. The amphiphilic nature of GGLs is attractive in 
pharmaceutical fields for interaction with other biological molecules and hence exerting 
therapeutic anti-cancer,16-18 anti-viral,19,20 and anti-inflammatory activities.21,22 GGLs 
potently inhibit angiogenesis,23 cancer cells,16 and solid tumor18,24,25 growth by 
selectively inhibiting the replicative DNA polymerase activity both in  v itro  and in  
vivo.17,18,25 Monogalactosyl diacylglycerol (MGDG), a GGL isolated from spinach, 
combined with gemcitabine anti-cancer drug revealed synergistic effects of inhibitive 
proliferation on human pancreatic cancer cell lines BxPC-3, MiaPaCa2, and PANC-1
through the inhibition of DNA replicative pols alpha and gamma activities, compared 
with MGDG or gemcitabine alone.26 The fractions of GGLs e.g., MGDG, digalactosyl 
diacylglycerol (DGDG), and sulfoquinovosyl diacylglycerol (SQDG) in spinach potently 
affect in  v itro  colon cancer cells, angiogenesis, and solid tumor growth v ia  their 
inhibitory activities of DNA polymerase.18,23-25 Naturally occurring 
sulfoquinovosylglycerolipids show promising anti-proliferative activity toward human 
cancer cells not only by targeting DNA polymerases,27 but also inhibiting the mitotic 
centromere-associated kinesin (MCAK).17 Another interesting feature of these 
compounds is their involvement in cell recognition and signaling which make them 
promising agents in drug delivery systems.28 Several GGLs have been related to the 
activation of natural killer T cells, which is a central event in a variety of immune 
responses including the development of autoimmunity, tolerance, and maintenance in 
defense responses to tumors and infectious agents.29 A series of sulfonic acid-containing 
GGLs isolated from cultured cyanobacteria (blue-green algae) have been discovered as a 
new class of compounds to inhibit the cytopathic effects of the human immunodeficiency 
virus (HIV-1).20 The high potential of GGL therapy strategy has attracted great interest in 
recent years and thus is explored to evaluate its therapeutic efficiency for the treatment of 
breast cancer cells.
We investigated the anti-proliferative efficacy of marine cyanobacterium 
S yn ech o cys tis  sp. derived MGDG molecule on human epidermal growth factor receptor-2 
(HER2)-positive BT-474, MDA-MB-231 triple-negative breast cancer cells, and human 
dermal fibroblasts. MGDG molecule is more abundantly and predominantly present in 
cyanobacterial cell chloroplast membrane than in plant sources. MGDG constitutes
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nearly 60% of the chloroplast lipid in S yn ech o cys tis  sp. cyanobacterial cells. 
S yn ech o cys tis  sp. PCC 6803 was chosen because monogalactosyldiacylglycerol (MGDG) 
from this strain contains 18:3 fatty acid residues making it a more lipophilic molecule 
than other polar MGDG molecules with 16:0 carbon fatty acid residues.30 This 
characteristic of glycoglycerolipids from S yn ech o cys tis  sp. PCC 6803 would catalyze the 
intracellular uptake and high biological activation to induce apoptosis in breast cancer 
cells. Polyunsaturated fatty acids containing 18:3 y- linolenic acid (GLA) showed higher 
apoptosis in various cancer cells (cervical, gastric, and prostate cancers) than normal cells 
both in  v itro  and in  v ivo  by generating reactive oxygen species, suppressing angiogenesis 
v ia  Akt cell signaling pathway and inducing apoptosis.31-34 . The plant-derived MGDG 
molecule abundantly contains 18:3 a- linolenic acid (n-3 ALA) on average at the sn-1 
fatty acid chain. The plant extract MGDG or n-3 ALA, a member of ro-3 fatty acids, and 
its active metabolites have known anti-cancer activity. However, the treatment efficacy is 
limited by the higher dosage requirement for inducing apoptosis and cell death posing 
off-target toxicity to the healthier cells. In contrast, the marine cyanobacteria 
S yn ech o cys tis  sp. derived MGDG molecule predominantly contains 18:3 n-6 GLA at the 
sn-1 fatty acid chain. The n-6 GLA molecule, a member of the ro-6 fatty acids selectively 
inhibits breast tumor cells without affecting the healthy cells35,36. Moreover, the n-6 GLA 
molecule has been shown to sensitize breast cancer cells to antimitotic and endocrine 
therapeutic drugs in  vitro . Hence, the cyanobacteria derived MGDG molecule is of great 
interest in the current study. We separated MGDG with high purity from the total lipid 
extract of S yn ech o cys tis  sp. PCC 6803 cyanobacterial cells. In this study, we 
comparatively investigated the anti-proliferative and apoptosis induction efficacy of the
198
cyanobacterial extract M G D G  with high n-6 GLA content and plant extract n-3 ALA- 
rich pure M G D G  in BT-474 and MDA-MB-231 breast cancer cells.
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2. MATERIALS AND METHODS
2.1. GROWTH KINETICS OF S yn ech o cys tis  sp. PCC 6803
S y n e c h o c y s t i s  sp. PCC 6803 was a kind donation from Dr. Himadri Pakrasi’s 
laboratory at Washington University in St. Louis.9,37"40 The S y n e c h o c y s t i s  sp. was 
cultured in batch cultures of 10 ml solid and 250 ml liquid BG11 media at 30°C and 300 
rpm in a rotary shaker under 30 pmol/m2/s (~2200 Lux) fluorescent lamps 41. 
Fluorescence microscopic images of PCC 6803 and the corresponding spectra analysis 
were captured using a scanning laser inverted confocal microscope (Ti-Eclipse; Nikon). 
For the growth curve analysis, the species was inoculated in a 5 ml liquid BG11 media. 
150 pl aliquots of liquid samples were transferred to a 96 well plate (Corning) at different 
times to measure the growth kinetics of PCC 6803 after adjusting the initial absorbance at 
680 nm, A 680,0= 0.05 at 24 h. BG11 media alone without any inoculum was used as a 
negative control. The maximum absorbance at the wavelength of 680 nm was measured 
using a microplate reader (BioTek). The specific growth rate, a  was computed using 
Equation (3).
^ • ^ 680
d t
=  a N (1)
Where A 6 8 Q  is the absorbance of cells at time, t. By integrating Equation (1) from t = 0 to
t  =  t,
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2.2. TOTAL LIPID EXTRACTION FROM S yn ech o cys tis  Sp. PCC 6803
The total lipid was extracted from the S y n e c h o c y s t i s  sp. using the Bligh and Dyer 
Method 42. Cell pellets from 250 ml of culture were collected at ^68o,t = 3.0 after 120 h, 
centrifuged at 15,000 g for 15 min and suspended in deionized water for two times to 
remove residual medium. One ml of cell suspension was mixed with 3.75 ml of 
chloroform: methanol (1:2, v/v) solution for 15 min using a vortex mixer. After thorough 
mixing, 1.25 ml of chloroform was added and vortexed for 1 min. Two distinctive layers 
were obtained after adding 1.25 ml of water to the mixture. The chloroform layer (lower 
phase) contained all the lipids, and the aqueous methanol layer (upper phase) contained 
the non-lipid fractions. The upper phase was discarded carefully, and the lower phase was 
collected. Chloroform was then evaporated completely under vacuum in a fume hood to 
obtain the total lipid. Total lipid was reconstituted in 1 ml of chloroform and stored in -
20o C.
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2.3. SEPARATION OF MGDG USING COLUMN CHROMATOGRAPHY
Total lipid was fractionated using the normal phase column chromatography 
technique. A handmade column was used for the separation process (SI Figure 1 (a)). 
Silica gel (particle size 10-40 micron) particles were used as a stationary phase. 
Chloroform and acetone were used as mobile phases. A gradient elution method was 
applied for the fractionation (SI Table 1). Samples (A-K) were collected for each 
combination of the eluent and labeled for further detection, structural analysis, and 
quantification (SI Figure 1 (b)).
2.4. IDENTIFICATION OF MGDG USING NMR ANALYSIS
The presence of the MGDG molecule in the eluted fractions was investigated 
using 1H NMR analysis. Each of the eluted fractions was analyzed to investigate the 
presence of MGDG molecule. The plant extract standard MGDG molecule was used as a 
reference. MGDG (> 99% purity, MW: 752.369) was purchased from Avanti Polar 
Lipids Inc. Chloroform-d (CDCh) was chosen both as the reference and the solvent for 
NMR analysis. The NMR peaks have been interpreted from the lipid handbook NMR 
database 43 and the previous studies on structural analysis of plant-derived GGLs 44,45.
2.5. QUANTITATIVE ANALYSIS OF MGDG USING HPLC-UV
The extracted MGDG molecule was both detected and quantified using a HPLC- 
UV system. The following instruments and solvents were used for chromatographic 
analysis. Column: LiChrospher 100 Diol (particle size: 5 |im, column size: 250 *4 mm) 
(Millipore Sigma), guard column: LiChroCart 4-4, mobile phase: chloroform (solvent A),
methanol-water (95:5) (solvent B), detector: UV, injection volume: 20-25 |iL, flow 
rate: 1 ml/min. The MGDG molecule was detected by the UV detector at 240 nm. The 
gradient elution method used in HPLC is shown in SI Table 2 and SI Table 3 46. A 
calibration curve was developed correlating the peak areas against the increasing 
concentrations of plant extract standard MGDG. The peak areas corresponding to the 
known concentrations of standard MGDG are shown in SI Table 4.
2.6. IN V IT R O  THERAPEUTIC EFFICACY
BT-474, MDA-MB-231, and human dermal fibroblast cells (ATCC) were 
cultured in Hybri-care ATCC 46-X medium, RPMI 1640, and fibroblast growth factor 
supplemented basal medium (ATCC), respectively, supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin-streptomycin at 37oC and 5% CO2 . Approximately,
10,000 cells per well were plated in 96-well plates and treated with 0-200 ng/ml doses of 
standard MGDG and extracted MGDG from S yn ech o cys tis  sp. by column 
chromatography technique. To examine the cytotoxicity effects on human dermal 
fibroblasts, the cells were treated with 100 ng/ml of MGDG extracted from S yn ech o cys tis  
sp. and MGDG standard. After 72 h of incubation, cell viability was assessed using MTT 
(3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, MW 414) assay. MTT 
reagent was added to each well to convert into an insoluble formazan from water-soluble 
MTT. After 4 h, sodium dodecyl sulfate (SDS) solution prepared in 0.01 N HCl was 
added to each well to solubilize the formazan. The percentage of live cells proportional to 
the absorbance value of solubilized formazan solution was quantified by measuring the 
absorbance at 570 nm (BioTek Synergy 2). The absorbance value was adjusted by
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subtracting the mean absorbance level of wells containing medium only. Cell viability 
was calculated as a means of six wells containing BT-474, MDA-MB-231, and dermal 
fibroblast cells. The cells treated with PBS were used as live control that was placed in 
every alternative column in the well plate adjacent to corresponding dosage or treatments 
to remove the variability in the number of seeded cells in adjacent wells. The live 
controls were replicated at least six times for each dosage. For dead control, we treated 
the cells with saponin in at least six replicates. The %  cell viability was calculated as 
follows Equation (5):
, ,  . . . . .  -̂ 5 7 0  o f  sample -̂ 5 7 0  o f  medium  . . . . . .
%  cel l  v i a b i l i t y  =  --------- ------- ------------------------------ x 100 (5)
•™5 7 0  o f  live cells ^ 5 7 0  o f  medium
2.7. APOPTOSIS ASSAY
The BT-474 and MDA-MB-231 cells were investigated for the caspase-dependent 
apoptosis mechanism by staining for the cleaved or active form of caspase-3/7 marker 
fluorescence dye. The cells at a density of 10,000 cells/ml were seeded in 96 well plates 
in replicates of at least n=3. The cells were treated with MGDG extracted from 
S yn ech o cys tis  sp. PCC 6803 and MGDG standard and were incubated for 48 and 72 h. 
The cells treated with PBS were used as live control with at least three replicates. After 
incubation, cells were stained with green fluorescent active caspase-3/7 marker 
(Invitrogen). The cells were imaged in the phase contrast field along with green 
fluorescent signals using a Zeiss Apotome 2.0 microscope equipped with a 10X 
objective, 470/40 excitation filter, and 525/50 nm emission filter. To quantify the 
caspase-3/7 protein expression, 50,000 each of BT-474 and MDA-MB-231 cells were 
treated with 100 ng/ml of MGDG. After 48 and 72 h of incubation, cells were washed
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twice using 100 pl of PBS and stained with 5 pM of caspase-3/7 green fluorescence 
apoptosis marker in 100 pl of the respective medium. The cells were incubated for 30-45 
minutes at 37oC. The fluorescence data was detected for 20,000 events/sample and 
acquired using a flow cytometer (BD Accuri C6 plus). The bandpass filters used in the 
flow cytometry were 530/30 and 585/40, respectively. The laser excitation wavelength 
was 488 nm.
2.8. STATISTICAL ANALYSIS
Each experiment was carried out in independent repetitions to have at least 
triplicates valid measurements. The results were reported as mean ± standard deviation 
and analyzed using the Student’s t-tests with two-tailed hypotheses and using the JMP 
statistical software (version 15, SAS Institute). For toxicity analysis, P<0.001 was 
considered as statistically significant and was denoted by ***. For quantification of 
apoptosis assay in flow cytometry, p<0.01 was considered statistically significant and 
was denoted by ***.
3. RESULTS
3.1. S yn ech o cys tis  sp. GROWTH CURVE KINETICS AND MOLECULAR 
STRUCTURE OF MGDG
Figure 1 demonstrates the confocal fluorescence images and fluorescence 
emission spectra analysis of S yn ech o cys tis  sp. PCC 6803, indicating that the 
microorganism grew properly with the highest absorbance spectrum at 680 nm 47,48.
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Figure 1. (a) Time-lapse video microscopic images of S yn ech o cys tis  sp. PCC 6803, and 
(b) its fluorescence emission spectra analysis. Red color indicates the abundance of
photosynthetic pigments
The growth kinetics of S yn ech o cys tis  sp. PCC 6803 was studied to obtain the 
maximum total lipid yield. The growth curve shows that the lag phase extended for 
almost 30 h (Figure 2a). It took the species for six days to reach the stationary phase. The 
specific growth rate, a  was calculated as 0.04 h"1. The doubling time ( t d) was calculated 
as 18.3 h. We extracted the MGDG molecule from the cells at the beginning of the 
stationary phase for maximum yield. Structurally, the MGDG molecule is constructed on 
a glycerol backbone (Figure 2b). The galactose residue is bound to the sn-3 position of 
the glycerol backbone v ia  a P-anomeric linkage. This head group remains conserved 
across the average molecular structures found in plant and cyanobacterial sources. The 
molecule has two long fatty acid chains in the sn-1 and sn-2 position of the backbone.
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The long fatty acid chains show variability in length, double bond position, and 
degree of unsaturation across and within the sources 7 ,9  Typically, 18:1 or 18:3 /16:3 or 
16:0 (sn-1/sn-2) average fatty acid composition is common in plant extract MGDG 45,49. 
In contrast, the fatty acid composition can vary from long-chain composition of 18/16 
(sn-1/sn-2) to a very long chain composition of 34 configurations in S yn ech o cys tis  sp. 
extract MGDG 7,5°. Mostly, the S yn ech o cys tis  sp. PCC 6803 contains the 18:3 GLA 
polyunsaturated fatty acid chain at the sn-1 position and 16:0 palmitic acid saturated fatty 
acid chain at the sn-2 position 7,S1,52.
Figure 2. The growth kinetics of S yn ech o cys tis  sp. and structure of MGDG. (a) Growth 
curve o f S yn ech o cys tis  sp. PCC 6803 wild type strain. The growth was measured in 
terms of absorbance value obtained at 680 nm. (b) Structure of MGDG extracted from 
S yn ech o cys tis  sp. PCC 6803 containing n-6 18:3 y-linolenic acid (n-6 GLA) and 16:0 
palmitic acid at sn-1 and sn-2 fatty acid chains, respectively (upper panel); the most 
abundant structure of plant extracted MGDG standard containing n-3 18:3 a-linolenic 
acid (n-3 ALA) and 16:3 palmitolinolenic acid at sn-1 and sn-2 fatty acid chains,
respectively (lower panel)
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3.2. NMR ANALYSIS CONFIRMS THE SEPARATION OF MGDG FROM 
TOTAL LIPID EXTRACT
MGDG molecule was separated from the total lipid extract of S yn ech o cys tis  sp. 
PCC 6803 using column chromatography. The fractions with each eluent were collected 
separately and analyzed individually by NMR analysis. The MGDG molecule was 
separated with an eluent combination of 40% chloroform and 60% acetone. The fractions 
(H, I, J) were collected with the same eluent combination. The NMR analysis confirms 
the presence of MGDG molecule in fraction I (Figure 3).
Figure 3. Confirmation of the presence of MGDG extracted from S yn ech o cys tis  sp. PCC 
6803 in fraction I. *H NMR analysis of S yn ech o cys tis  sp. extracted fractions H, I, and J 
with 40% chloroform and 60% acetone eluent combination. The NMR spectra of the 
MGDG standard are shown in the lowest panel. The NMR analysis confirms the presence
of MGDG molecule in fraction I
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The set of NMR peaks of fraction I were completely identical to the standard 
MGDG molecule suggesting the separation of MGDG molecule with high purity. The 
structure of MGDG in fraction I was analyzed from the peaks obtained in the NMR 
analysis (Figure 4).
Figure 4. Structural identification of MGDG extracted from S yn ech o cys tis  sp. PCC 6803. 
1H NMR analysis of MGDG extracted from the S yn ech o cys tis  sp. shows that the fraction 
molecule (upper panel) contains all the major structural H components 5 2.8 (diallylic 
methylene), 5 3.6 and 3.8 (Glycosidic H moiety), 5 4.18 (sn-1 H), 5 5.15 (sn-2 H), 5 5.25 
cis A9 moieties present in the standard MGDG molecule (lower panel). The 
cyanobacterial NMR spectra are identical to the NMR spectra of the MGDG standard 
confirming the purity of the extracted MGDG molecule
209
The chemical shift values at 5 4.18, 5.15 represent the sn-1 and sn-2 H atom, 
respectively. The peaks at 5 4.29, 4.55, 4.70, and 4.85 confirm four H atoms of the OH 
group in the carbohydrate sugar present in MGDG. Glycosidic bond in MGDG is 
represented by the chemical shift 5 3.6 and 3.8. A very broad and sharp peak at chemical 
shift 5 5.25 might represent the unsaturated cis A9 fatty acid attached to the sn-1 or sn-2 
position 43. The presence of the unsaturated fatty acids can be confirmed by the diallylic 
methylene functional group at chemical shift 5 2.8. The results are consistent with the 
NMR data of MGDG reported earlier by Marcolongo et. al. and Maeda et. al. 44,45.
3.3. DETECTION AND QUANTIFICATION OF MGDG USING HPLC-UV 
SYSTEM
The S yn ech o cys tis  sp. extracted MGDG molecule was detected and quantified 
using the HPLC coupled with a UV detector. The correlation of area under the peak with 
known concentrations of standard MGDG was observed in HPLC analysis (Figure 5).
The R2 value of the fitted curve was 0.99. After the separation of MGDG from total lipid 
extract in chromatographic fraction I, the fraction was run through the HPLC column for 
quantification. The peak obtained at 6.24 min confirmed the presence of the MGDG 
molecule (Figure 6). The amount of detected MGDG in fraction I was quantified using 
the concentration correlation plot obtained in Figure 5.
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Figure 5. Calibration curve for quantification of MGDG extracted from S yn ech o cys tis  sp. 
PCC 6803. A standard calibration curve was prepared using known concentrations of 
plant extract MGDG molecule and the corresponding peak areas in terms of milli- 
absorbance unit x seconds (mAu.s) in HPLC-UV analysis. The equation obtained for the 
unknown concentration of the MGDG molecule for any known peak area is y= 0.061x
with the R2 value of 0.99
Figure 6. HPLC-UV analysis of MGDG extracted from S yn ech o cys tis  sp. PCC 6803. 
(upper panel) and MGDG standard (lower panel). The MGDG peak was obtained at ~6 
minutes for the MGDG molecule from both of the sources. The peaks obtained at ~2 and 
~7-8 minutes represent the pigments and glucosides peaks eluted with the methanol/
water solvents
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3.4. IN V IT R O  ANTI-PROLIFERATION EFFICACY
To determine the anti-proliferation efficacy in vitro, the dose-response 
cytotoxicity of MGDG extracted S yn ech o cys tis  sp. and MGDG standard was evaluated. 
The anti-proliferation activity of extracted MGDG was compared against the MGDG 
standard in HER2-positive BT-474 (Figure 7a) and MDA-MB-231 triple-negative breast 
cancer cells (Figure 7b). In BT-474 cells, MGDG extracted from S yn ech o cys tis  sp. 
inhibited up to 70% cell proliferation over the concentration range of 0-200 ng/ml 
(•, Figure 7a). The maximum inhibition in BT-474 cells was (70 ± 8) % at 60 ng/ml (p < 
0.001). At higher concentrations (>60 ng/ml), a decrease in %  cell death was observed in 
BT-474 cells indicating cell-dependent drug resistance to MGDG extracted from 
S yn ech o cys tis  sp.53,54 In MDA-MB-231 cell line, for the concentration range of 0-200 
ng/ml, MGDG extracted from S yn ech o cys tis  sp. showed significant cell growth inhibition 
from 0-60% in a dose-dependent manner (•, Figure 7b). The extracted MGDG inhibited 
(58 ± 5) % of MDA-MB-231 breast cancer cells at the concentration of 200 ng/ml (p < 
0.001). The half-maximal inhibitory concentration, IC50 values of MGDG extracted from 
S yn ech o cys tis  sp. are (27.2 ± 7.6) and (150 ± 70) ng/ml in BT-474 and MDA-MB-231 
cells, respectively. In contrast, in both BT-474 and MDA-MB-231 cell lines, standard 
MGDG did not show any statistically significant anti-proliferation activity (<10% cell 
death) compared to untreated positive control within the concentration range of 0-200 
ng/ml (o, Figures 7a and 7b).
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(a)
Figure 7. In v itro  anti-cell proliferation analysis. MGDG extracted from 
Synechocystis sp. PCC 6803 (solid line) and MGDG standard (dotted line) in (a) BT-474 
and (b) MDA-MB-231 cell lines. Mean percentage values are presented from six 
replicates (n=6) for each drug dosage. The MGDG from the Synechocystis sp. inhibits up 
to 70% (p<0.001) and 60% (P<0.001) of BT-474 and MDA-MB-231 cancer cells, 
respectively where MGDG standard does not show any toxicity within the concentration 
range of 0-200 ng/ml. *** indicates the p-value < 0.001 showing a statistical significant 
difference between %  cell death in MGDG extracted from the Synechocystis sp. and 
MGDG standard. (c) MGDG extracted from the Synechocystis sp. does not show any 
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Figure 7. In  v itro  anti-cell proliferation analysis. MGDG extracted from S yn ech o cys tis  sp.
PCC 6803(solid line) and MGDG standard (dotted line) in (a) BT-474 and (b) MDA-MB- 
231 cell lines. Mean percentage values are presented from six replicates (n=6) for each 
drug dosage. The MGDG from the S yn ech o cys tis  sp. inhibits up to 70% (p<0.001) and 
60% (P<0.001) of BT-474 and MDA-MB-231 cancer cells, respectively where MGDG 
standard does not show any toxicity within the concentration range of 0-200 ng/ml. *** 
indicates the p-value < 0.001 showing a statistical significant difference between %  cell 
death in MGDG extracted from the S yn ech o cys tis  sp. and MGDG standard. (c) MGDG 
extracted from the S yn ech o cys tis  sp. does not show any cytotoxic side effects in human 
dermal fibroblasts normal cell line control (cont.)
Although MGDG from S yn ech o cys tis  sp. induced the %  cell death of breast 
cancer cells in a concentration-dependent manner, the cytotoxicity of fibroblast cells 
(normal cell control) was less (<15%) than breast cancer cells after exposure to 100 ng/ml 
of MGDG for 72 h (Figure 7c), indicating that breast cancer cells were more sensitive to 
the MGDG derived from S yn ech o cys tis  sp. than normal cells. Taken together, the results 
revealed that MGDG extracted from S yn ech o cys tis  sp. induced selective apoptotic cell 
death in BT-474 and MDA-MB-231 breast cancer cells with different potency after 72 h 
of incubation, while causing less toxicity in normal fibroblasts.
3.5. S yn ech o cys tis  sp. EXTRACTED MGDG INDUCES CASPASE-DEPENDENT 
APOPTOSIS
To investigate the late phase apoptosis, BT-474 and MDA-MB-231 cells were 
treated with 100 ng/ml of MGDG extracted from S yn ech o cys tis  sp. and MGDG standard 
and stained with green fluorescently labeled caspase-3/7, a well-known apoptotic marker. 
The assay utilizes a nucleic acid binding dye conjugated with a four amino acid peptide, 
DEVD (Asp-Glu-Val-Asp motifs) that is recognized by caspase-3/7 and cleaved, 
enabling the dye to bind with DNA and fluoresce at ~530 nm 55-57 The conjugated dye is 
non-fluorescent until the DEVD peptide is cleaved by active caspase-3/7. After 48 h and 
72 h of treatment, cells treated with MGDG extracted from S yn ech o cys tis  sp. showed 
green fluorescently stained DNA indicating the activation of caspase-3/7 in BT-474 
(Figure 8a) and MDA-MB-231 cells (Figure 8b). The combined phase and fluorescent 
signal images show the overlap of caspase-3/7 positive cells and the unhealthy shrinking 
cells suggesting the initiation of apoptosis. The induction of apoptosis was assessed by 
Western blot technique (SI Figure 3). The Western blot analysis showed that the full-
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length caspase-3 (MW: 32 KDa) expression was reduced in BT-474 and MDA-MB- 
231 cells treated with MGDG from S yn ech o cys tis  sp., while the protein expression did 
not change in cells treated with MGDG standard relative to untreated cell controls. The 
reduced expression of full-length caspase-3 suggests the cleavage of the protein into an 
active form of low molecular weight (17 kDa) active cleaved caspase-3. The cleaved 
caspase-3/7 expression was quantified using flow cytometry. The fold enhancement of 
caspase-3/7 was quantified using flow cytometry analysis (Figures 8c and 8d). We 
observed a statistically significant increase of 1.7±0.04 fold (p<0.01) in caspase-3/7 
concentrations after 48 h and a statistically significant 2.34±0.44 fold (p<0.01) increase 
after 72 h in BT-474 cells treated with MGDG extracted from S yn ech o cys tis  sp. 
compared to untreated cell controls (filled column, Figure 8c). After 72 h, the number of 
apoptotic cells in the extracted MGDG treated cells significantly increased 2.1±0.03 fold 
(p<0.01) in MDA-MB-231 cells (filled column, Figure 8d). MGDG standard did not 
show any significant changes in cleaved caspase-3/7 expressions compared to untreated 
control cells. The obtained scatter plots and histogram data from flow cytometry are 
shown for each treatment in SI Figure 5. These results are in good agreement with 
fluorescent microscopic images indicating the cells being shrunk and round shaped with a 
complete halt in growth of cancer cells. In contrast, after 48 and 72 h of treatment, there 
was no sign of apoptosis in the standard MGDG treated compared to untreated cell 
controls (open column, Figures 8c, and 8d). The untreated cells and the cells treated with 
standard MGDG were compact multilayered colonized and elongated in shape in the case 
of BT-474 and MDA-MB-231 cell lines, respectively, and were observed healthy 
suggesting continuous growth capability.
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Figure 8. In v itro  apoptosis induction. MGDG extracted from the Synechocystis sp. and 
MGDG standard after 48 and 72 h treatments in (a) BT-474, and (b) MDA-MB-231 cells. 
The green fluorescence of apoptotic caspase-3/7 proteins increases in both BT-474 and 
MDA-MB-231 cells treated with MGDG extracted from the Synechocystis sp. The 
combined phase contrast and the fluorescence images show that the cyanobacterial 
extracted MGDG enhances the intensity and density of green fluorescence cells 
indicative of caspase-dependent apoptosis in both cell lines. In contrast, cells treated with 
MGDG standard molecule did not show any sign of apoptosis in either cell line even after 
72 h of treatment. The scale bars represent 100 p,m. Quantification of the active caspase- 
3/7 expression in (c) BT-474, and (d) MDA-MB-231 cells treated with MGDG extracted 
from the Synechocystis sp. and MGDG standard after 48 h and 72 h of treatments. In 
BT-474 cells, the active caspase-3/7 expression was increased by 1.7 (p<0.01) and 2.3 
(p<0.01) fold after 48 h and 72 h treatments, respectively compared to untreated control.
The increase in caspase-3/7 expression was 2.1 (p<0.01) fold after 72 h treatment in 
MDA-MB-231 cells compared to the untreated control. Mean ± standard deviation from 
two independent experiments in at least three replicates (n=6) are presented. *** 
indicates the p-value < 0.01, showing a statistically significant difference compared to
untreated control cells
4. DISCUSSION
MGDG contains fatty acyl groups derived from two fatty acid molecules at sn-1 
and sn-2 position and a polar head at sn-3 position in a 3-carbon glycerol scaffold (Figure 
2b). Fatty acid molecules such as n-6 GLA may exert anti-proliferative effect by
regulating genes and proteins involved in cell cycle and apoptosis, altering the 
cellular composition of fatty acids, and by producing downstream anti-proliferative 
metabolites such as 1-series prostaglandins and free radical molecules from 
cyclooxygenase (COX) catalyzed lipid peroxidation. The potent anti-proliferative activity 
of the MGDG is mostly attributed to the fatty acyl components of the MGDG molecular 
structure.58,59 The structure of the MGDG molecule and the fatty acid content of MGDG 
derived from S yn ech o cys tis  sp. PCC 6803 is well studied. The molecule is rich in 18:3 n- 
6 GLA fatty acids. The fast atom bombardment tandem mass spectrometry (FAB-MS) 
analysis of glycolipids derived from S yn ech o cys tis  sp. PCC 6803 showed 18:3 n-6 GLA, 
18:2, and 18:1 combination of fatty acid chains with a relative abundance of 100, 47 and 
41, respectively at the sn-1 position7. Yuzawa et. al. showed the relative abundance of n- 
6 GLA, 18:2, and 18:1 fatty acid content in wild type S yn ech o cys tis  sp. derived MGDG 
as 30%, 10%, and 5% respectively52. However, the larger fatty acid chains at the sn-1 
position have also been reported recently. The time of flight mass spectrometry (TOF- 
MS) analysis of the same cyanobacterial strain showed the predominance of 34:2 or 
34:3 fatty acid chain at the sn-1 position 50. Wada et. al. showed that the most abundant 
n-6 GLA moiety in S yn ech o cys tis  sp. derived MGDG is subject to desaturation when the 
growth temperature was shifted from 38oC to 22oC 51. In contrast to the variable sn-1 
fatty acid content, the sn-2 position was shown to be conserved mostly with 16: 0 
(palmitic acid) fatty acid chain in S yn ech o cys tis  sp. derived MGDG and was not affected 
with the shifts in temperature 7,51>52.
The MGDG lipid molecule was separated in a normal phase column using 
chloroform and acetone gradient eluent combinations. The column length to diameter
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ratio was ~10. Multiple samples were collected with each eluent combination for 
better purification. We confirmed the presence of MGDG molecule in fraction I using !H 
NMR analysis (Figure 3). Though fraction H, I, and J were eluted with the same mobile 
phase combination of 40% chloroform and 60% acetone, only fraction I contained the 
MGDG molecule. The peaks obtained for a fraction I identical with >99% pure standard 
MGDG molecule suggests the high purity of MGDG molecule in that fraction. The 
diallylic methylene moiety obtained at 5 2.8 in the NMR analysis shown in Figure 4 
confirmed the polyunsaturation in the long fatty acid chain at the sn-1 position. The 
extracted MGDG molecule in fraction I was quantified using the HPLC-UV system. We 
prepared a calibration curve (Figure 5) with known >99% pure standard MGDG molecule 
to quantify the MGDG in each extracted fraction. The peak obtained at retention time 
6.24 min shown in Figure 6, upper panel corresponds to the MGDG molecule in the 
fraction 46. The large peak obtained at retention time 2.36 min is the lipid pigments eluted 
initially by the chloroform. The peak at 7.23 min might be due to the presence of steryl 
glucosides present as a contaminant in the fraction46. Glucosides do not have any known 
effects on the HER2-positive and triple-negative breast cancer cells. The peaks for 
pigments and glucosides were also observed in the standard >99% pure standard MGDG 
chromatogram (Figure 6, lower panel). So, the contaminant should not have any effect in 
this study during the drug formulation used for cytotoxicity analysis. However, the GGL 
molecules are detected with high quality and precision using the evaporative light 
scattering detectors (ELSD) providing with sharp and clear peaks in the 
chrom atogram 46,60,61
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We investigated the in  v itro  anti-proliferation efficacy of cyanobacteria 
derived MGDG molecule in comparison with MGDG molecule from plant source on the 
HER2-positive and triple-negative breast cancer cell lines. We observed significant 
differences in the %  of cancer cell death using MGDG extracted from S yn ech o cys tis  sp. 
versu s  a commercially available MGDG standard. MGDG extracted from 
S yn ech o cys tis  sp. induced apoptosis in (70 ± 8) % of BT-474 and (58 ± 5) % of MDA- 
MB-231 cells at 60 and 200 ng/ml, respectively, while <15% cell death was observed in 
fibroblasts at 100 ng/ml. While the precise mechanism by which each molecule works 
about their cell-killing effect is unknown, it is possible that the presence of 
polyunsaturated y-linolenic acid in the sn-1 position and palmitic acid in the sn-2 position 
of MGDG from S yn ech o cys tis  sp. resulted in the mitochondrial depolarization, 
cytochrome c release, DNA fragmentation and generation of free radicals causing 
specific cell death response in breast cancer cells compared to normal cells.62-66 y- 
linolenic acid has been shown to exhibit anti-proliferative activities specifically in a 
variety of cancer cell lines both in  vitro  and in  vivo. y-linolenic acid inhibited the cell 
growth of four human neuroblastoma cell lines (GOTO, SK-N-DZ, NKP, and NCG) in  
v itro ,67 three human glioma cell lines (MOG, U87, U373) and a rodent glioma cell line 
(C6) in  v itro  and a rat C6 glioma model in  v i v o 68 Glioma regression and apoptosis had 
been reported using both C18 and C20 fatty acids of the n-6 and n-3 series y-linolenic 
acid along with the preservation of normal neural tissue and vasculature in adjacent 
brain.68 y-linolenic acid at a concentration of 150 inhibited Walker 256 cancer cell 
growth both in  v itro  and in  v ivo  causing decrease in mitochondrial membrane potential, 
and increase in cytochrome c release, caspase activation, and DNA fragmentation.63 The
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mitochondrial apoptosis pathway was likely induced by an increase in reactive 
oxygen species (ROS), lipid peroxide production, ATP generation and the deposition of 
large amounts of triacylglycerol in the form of lipid droplets.63,65 A diet containing 5.5% 
y-linolenic acid caused 45% decrease in Walker 256 tumor growth in  v ivo  by reducing 
mitochondrial metabolic activity.62 More interestingly, in v itro , in vivo and clinical study 
data showed that y-linolenic acid has selective anti-proliferative actions in cancer cells 
with little or no side effects on normal cell growth. Polyunsaturated fatty acids including 
y-linolenic acid incubated with human breast, lung, and prostate cancer cells suppressed 
the cancer cell growth exhibiting no adverse effects on normal human fibroblasts or 
normal animal cell lines.69 Intraarterial injection of a lithium salt derivative of y-linolenic 
acid demonstrated its ability to selectively suppress angiogenesis.64 These reports, 
together with our data increases lead to the conclusion that MGDG from 
S yn ech o cys tis  sp. is a promising cancer therapeutic agent with high selectivity of cancer 
cell growth inhibition leading to apoptosis and a decrease in cancer development. Also, 
saturated fatty acid, palmitic acid at the sn-2 position of MGDG from S yn ech o cys tis  sp. 
plays a significant role in the elevation of calcium flux, endoplasmic reticulum stress, 
caspase-3, and caspase-9 activity, and thus inducing apoptosis which is in good 
agreement with previous reports.70-72 Treatment of mouse 3T3-L1 and rat primary 
preadipocytes with palmitic acid induced multiple cell signaling pathways, endoplasmic 
reticulum stress responses, and cell cycle arrest leading to apoptosis.70 Palmitic acid 
induced oxidative stress and DNA damage in rodent-derived insulin-secreting cell line 
RINm5F and primary human fibroblasts.72 Spinach MGDG molecule in combination 
with gemcitabine in  v itro  59and radiation in  v ivo  73 showed enhanced suppression of
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MIAPaCa-2, PANC-1, and BxPC-3 pancreatic cancer cell lines compared to MGDG 
treatment alone. With the in v itro  spinach MGDG treatment alone the IC50 values for the 
mentioned pancreatic cell lines ranged from 18-25 ^M 73,74 MGDG molecule extracted 
from the spinach has been shown to inhibit human replicative and repair DNA 
polymerase enzymes with the IC50 values ranging from 10-200 ^M.59 These results 
illustrate the specificity of the MGDG extracted from S yn ech o cys tis  sp. PCC 6803 to 
breast cancer cells by caspase-dependent apoptotic pathway.
5. CONCLUSION
Fatty acids are of great interest as natural anti-proliferative factors because of 
their selective inhibition of cancer cells. The structure and efficacy of fatty acid 
molecules are variable within and across the sources. We investigated the cancer cell 
inhibition efficacy of plant and cyanobacterial derived MGDG molecule. The marine 
cyanobacteria Synechocystis sp. derived MGDG molecule predominantly rich in n-6 
GLA was separated from the total lipid extract in this study. The molecule was separated 
in a handmade low-cost normal phase silica column with the gradient elution method 
using chloroform and acetone as the mobile phase. We confirmed the presence of MGDG 
molecule in the fraction eluted with 40% chloroform and 60% acetone eluent 
combination. The NMR analysis confirmed the high purity of the separated MGDG 
molecule from the cyanobacterial total lipid extract. The separated MGDG molecule was 
quantified by the HPLC-UV system. The anti-proliferative activity of the cyanobacterial 
MGDG was tested against the MDA-MB-231 breast cancer cell line. The in vitro
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cytotoxicity study showed that MGDG extracted from Synechocystis sp. PCC 6803 
potently inhibited (70 ± 8)% and (58 ± 5)% of BT-474 and MDA-MB-231 cells, 
respectively using 60 and 200 ng/ml of the MGDG. The IC50s of MGDG extracted from 
Synechocystis sp. are (27.2 ± 7.6) and (150 ± 70) ng/ml in BT-474 and MDA-MB-231 
cells, respectively. In contrast, plant extract n-3 ALA-rich MGDG did not have any 
cytotoxic effect in the concentration range of 0-200 ng/ml. It did not show any cytotoxic 
effects in human dermal fibroblasts normal cell controls. Our results support these 
findings showing that the cyanobacteria derived MGDG induces caspase-dependent 
apoptosis pathway to inhibit the HER2-positive BT-474 and triple-negative MDA-MB- 
231 breast cancer cell growth. Further studies involving additional mechansisms of 
actions, intracellular uptake, and robust screening of additional cancer cell lines will 
confirm the potential novel therapeutic efficacy of cyanobacteria derived MGDG 
molecule for a low dosage selective treatment of cancer cells.
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The synthesis and therapeutic efficacy of PTXNR-TTZ ADNs in  v itro  were 
presented which arrested the HER2-positive breast cancer cells in G2/M phase of the cell 
cycle and induced caspase mediated apoptosis. The synthesized ~95 nm in diameter and 
500 nm in length PTXNR particles showed significantly high stability in aqueous phase 
compared to the PTX, suggesting removal of the compromising need for organic carrier 
solvent for intravenous delivery. The in v itro  toxicity analysis showed that the engineered 
drug PTXNR-TTZ was more efficacious than the individual drug treatments with PTX or 
TTZ alone, inhibiting >80% of HER2-positive cell line growth suggesting a synergistic 
effect on the cancer cells. The IC 50 of PTXNR-TTZ on HER2-positive BT-474 breast 
cancer cell line was 106 nM, facilitating lower dose and reduced side effects than the 
individual treatment with PTX and TTZ alone. The Western blot analysis showed that 
PTXNR-TTZ significantly downregulated the anti-apoptotic protein XIAP and induced 
caspase dependent apoptosis pathway in HER2-positive breast cancer cell line. 
Altogether, the investigation might facilitate rational remodeling of conventional 
combination therapy in cancer through ADN that integrates high therapeutic index and 
active targeting capability.
The present work showed that PTXNR-TTZ induced apoptosis in HER2-positive 
breast cancer cell lines following the G2/M cell cycle arrest. The cell cycle is critical for 
normal tissue functioning and also an important regulator of ungoverned cancer cell
progression. Hence, a comprehensive knowledge of cell cycle regulation and its 
regulators is a prior need for better understanding of cancer. The review article presented 
in the dissertation has discussed some of the critical intracellular cell cycle regulating 
signaling pathways such as MAPK/Ras/Raf/ERK, PI3K/Akt. Jak-STAT. The intrinsic 
and extrinsic apoptosis pathways were also discussed. The article showed the molecular 
interplay between the cell proliferation and cell death pathways.
Transcriptional regulation and genetic alterations induced by PTXNR-TTZ was 
investigated in breast cancer cell lines. The objective of the study was to investigate the 
potential role of cell cycle arresting mechanism on the therapeutic efficacy of the 
PTXNR-TTZ treatment in breast cancer cells. PTXNR-TTZ significantly overexpressed 
PRKG1 and NR4A3 genes in HER2-positive cell line. The gene regulatory network 
showed that PTXNR-TTZ might potentially induce intrinsic apoptosis pathway through 
positive regulation of PRKG1- NR4A3 gene expression. PTXNR-TTZ treatment 
upregulated the CDC20 gene expression which plays an oncogenic role in cancer 
progression. The study concluded that hyperactivity of CDC20 and subsequent activation 
of its substrates e.g., APC/C might cause therapeutic inefficacy of PTXNR-TTZ 
treatment in HER2-positive breast cancer cells. Hence, we proposed CDC20 as a 
potential therapeutic target to enhance the treatment response of PTXNR-TTZ. PTXNR- 
TTZ also significantly upregulated a set of tumor promoting inflammatory genes in a 
non-specific triple negative MDA-MB-231 cell line. Taken together, the study 
investigated cell cycle dependent gene regulatory pathways induced by PTXNR-TTZ that 




Additionally, in this work, multifunctional efficacy of a polymer coated 
superparamagnetic nanoparticle therapeutic system was investigated in cancer treatment. 
The work showed the significant enhancement of the metal nanoparticle stability by using 
a biocompatible polymer coating and utilization as a potential nanomedicine platform.
The application of the therapeutic platform integrated both diagnostics and therapeutics 
capability in a single system.
Finally, in v itro  anti-proliferation efficacy of a natural glycoglycerolipid molecule 
MGDG, was investigated for breast cancer treatment. The MGDG molecule rich in ro-6 
y-linolenic fatty acid content was extracted from a cyanobacterial species S yn ech o cystis  
sp. A simple low cost technique was shown in the study to efficiently extract the MGDG 
molecule with high purity. The molecule had better therapeutic efficacy than the 
commercial plant extract molecule and did not show any significant toxicity in normal 
human cell line. Altogether, the study presented a cost effective extraction method and 
anti-proliferation efficacy of a natural source potential anti-cancer molecule.
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3.1. INVESTIGATION OF THERAPEUTIC EFFICACY OF PTXNR-TTZ IN IN  
V IV O  SETTINGS
We have shown the formulation of a combination therapeutic system PTXNR-TTZ 
for targeted HER2-positive breast cancer cell growth inhibition. We thoroughly 
investigated the therapeutic efficacy of PTXNR-TTZ in in v itro  settings. The in vitro  
results showed synergistic cell growth inhibition in HER2-positive breast cancer cell line 
by PTXNR-TTZ treatment. In future, we propose to investigate the therapeutic efficacy of 
PTXNR-TTZ in an in vivo HER2-positive breast cancer model.
• In v ivo  tumor cell growth inhibition: A cell derived xenografts (CDX) model 
with the HER2-positive breast cancer phenotype will be chosen for the in vivo study. For 
example, an established BT-474 cancer cell line transplanted (subcutaneously) nude mice 
model representing the luminal B/HER2-positive subtype of breast cancer is available and 
can be used for investigating the in v ivo  tumor growth inhibition upon intraperitoneal 
injection (i.p.) of PTXNR-TTZ drug. The controls for the investigation will include 1) no 
treatment, 2) PTXNR treatment, 3) TTZ treatment and 4) combination treatment of 
PTXNR+TTZ. The tumor growth can be monitored in every 3 days and normalized to the 
initial tumor volume at the starting point of the treatment.
• In vivo biodistribution study: The PTXNR-TTZ particles will be functionalized 
with a metal binding chelator molecule p-SCN-Bn-DOTA (SBnD) by utilizing the solvent 
accessible the e-lysine amino group of TTZ. The immunoconjugate (TTZ-SBnD) will then 
be radiolabeled with 64Cu isotope to produce a radioactive PTXNR-TTZ-SBnD-64Cu
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complex. For biodistribution analysis, the PTXNR-TTZ-SBnD-64Cu complex will be 
intravenously administered in a subcutaneously engrafted BT-474 tumor bearing mice 
model. The mice will be sacrificed at 2, 6, 12, 24, 48 and 72 h following administration of 
the radioactive complex. The organs will be separated and weighed followed by the 
measurement of the radioactivity. The time dependent measurements for each organ will 
be expressed as a percentage of injected dose per gram (%ID/gram).
3.2. INVESTIGATION OF GENE REGULATION ACTIVITY OF PTXNR-TTZ IN 
IN V IT R O  AND I N  V IV O  PLATFORM
We found that PTXNR-TTZ significantly induced the high mRNA expression of 
NR4A3 and PRKG1 genes in HER2-positive breast cancer cells by analyzing the 
transcriptional data obtained from RNAseq analysis. In subsequent gene regulatory 
network analysis, we showed that the overregulation of NR4A3-PRKG1 axis can 
potentially mediate the intrinsic apoptosis pathway. We have also showed the activation 
of downstream Rho-GTPase signaling pathway in HER2-positive breast cancer cells by 
PTXNR-TTZ treatment. Notably, we found that PTXNR-TTZ significantly upregulates 
the CDC20 gene expression which exerts an oncogenic activity in tumor progression by 
activating APC/CCDC20 complex. We predicted that the targeted inhibition of CDC20 will 
enhance the therapeutic efficacy of PTXNR-TTZ. In future, we propose to verify our 
predictions from RNA sequencing data analysis experimentally in both in  v itro  and in  
v ivo  settings. The gene expression of NR4A3 and PRKG1 and induction of possible 
apoptosis pathway in HER2-positive breast cancer will be investigated in HER2-positive 
cell lines in v itro  and in mouse xenograft model in vivo. Similarly, in v itro  and in vivo
therapeutic efficacy of PTXNR-TTZ will be evaluated upon targeted inhibition of 
CDC20 gene expression. We have outlined our plans in the following points.
• Investigation of PTXNR-TTZ induced NR4A3 mediated apoptosis: The HER2-
positive cell lines BT-474 and SK-BR-3 will be treated with PTXNR-TTZ in vitro. The 
controls will include 1) no treatment 2) PTXNR treatment 3) TTZ treatment 4) 
PTXNR+TTZ treatment. The gene expression of NR4A3 and PRKG1 will be investigated 
using reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) analysis. 
For RT-qPCR analysis, the cells will be lysed followed by the synthesis of cDNA from the 
cell lysates. The synthesized cDNA will then be incorporated with the primers of NR4A3 
and PRKG1 genes along with the DNA polymerase enzymes for subsequent RT-PCR 
amplification reactions. Appropriate commercial kits and manufacturer’s protocols will be 
used for cDNA synthesis and RT-qPCR reactions. For in v itro  apoptosis response study, 
the total protein will be extracted from the HER2-positive breast cancer cell lines. The 
PTXNR-TTZ treated HER2-negative cell line extracted total protein will be used as a 
control sample. The protein expression of NR4A3, PRKG1 and other downstream proteins 
associated with intrinsic apoptosis pathway will be investigated using the Western blot 
analysis. For in vivo analysis, the PTXNR-TTZ drug along with the other appropriate 
controls will be injected in a transplanted xenograft mice model with established HER2- 
positive breast tumor. For selective gene expression analysis, a patient derived xenografts 
(PDX) immune-deficient mice model with established HER2-positive breast cancer is 
more preferable than CDX model due to high similarity and maintenance in the genomic 
signature of the tumor tissue representing the original primary tumor in patient. The tumor 
volume will be monitored and tumor tissue sample will be collected upon significant
236
237
volume remission with PTXNR-TTZ treatment. The total protein will be extracted from 
the tumor tissue for subsequent protein expression analysis using Western blot technique.
• Efficacy of PTXNR-TTZ upon targeted inhibition of CDC20 gene 
expression: The PTXNR-TTZ induced gene expression of CDC20 in HER2-positive 
breast cancer cell lines will be verified by RT-qPCR analysis. To investigate the possible 
role of CDC20 gene overexpression on cell growth CDC20 will be inhibited by a CDC20 
antagonist drug. The CDC20 gene may be knocked down using an appropriate silencing 
RNA (siRNA) molecule as well. The cell viability assays will be conducted following the 
PTXNR-TTZ treatment with the cells 1) before, and 2) after the targeted inhibition of 
CDC20 gene expression. The control treatments will include 1) no treatment, and 2) 
PTXNR+TTZ treatment. The investigation can also be conducted in an immune-deficient 
nude mice PDX model with established HER2-positive breast cancer phenotype. The 
mice will be treated with i.p. injection of CDC20 inhibitor for CDC20 gene inhibition. 
The mice treated with i.p. injection of PTXNR-TTZ along with other mentioned 
appropriate controls before and after the CDC20 inhibition will be monitored every three 
days and normalized to tumor volume at treatment start point.
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Homogenizer
Paclitaxel molecule Paclitaxel Nanorods 
500nm X lOOnm
Figure 1. Synthesis process of PTXNRs. PTXNRs were synthesized using the 
nanoprecipitation method. The figure shows the stability of the paclitaxel molecule and 
PTXNR in aqueous media before and after the synthesis process
T raslu zu m abCD I. PBS . pH  7.4
2 O H  u i ic le o n l i i l ic  s i te
Paclitaxel Nanorod (P1XNR) Paclitaxel-1 rastuzumab (PIXNR-1 1Z)Paclitaxel-imidazole carbamate (PIXNR-CDI)
Figure 2. Schematic diagram of reactions involved for PTXNR functionalization and 
TTZ conjugation on the surface of PTXNRs
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Figure 3. Calibration curve of PTX for quantification of the amount of PTXNRs in 
PTXNR-TTZ particles after conjugation with TTZ. The calibration curve was obtained 
using PTXNRs in PBS at 230 nm absorbance values
Figure 4. Calibration curve of Trastuzumab (TTZ) monoclonal antibody for 
quantification of unconjugated TTZ after conjugation with Paclitaxel nanorods 
(PTXNRs). The calibration curve was obtained using a BCA protein quantification assay
at 562 nm absorbance values
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Figure 5. Calibration curve of BSA  protein for quantification of protein in cell lysates for 
Western blot experiments. The calibration curve was obtained using a BCA  protein 
quantification assay at 562 nm absorbance values
Table 1. Stability analysis of PTXNR and PTXNR-TTZ as a measure of zeta potential 
___________________________value,  ̂(mV)___________________________
Zeta potential, £ (mV)
Sample DI water PBS
PTXNR -32.6± 4.82 -13.4± 2.81
PTXNR-TTZ ' -17.1±3.83 ' -9.5± 0.02 '
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PTXNR-TTZ in DI Water PTXNR-TTZ in PBS
Figure 6. Colloidal suspensions of PTXNR-TTZ in DI water and PBS at 0.6, 1, and 2
mg/ml concentrations
Table 2. Analysis of TTZ conjugation on the surface of PTXNRs
Initial % N R Initial Initial % TTZ Am ount Am ount P T X N R :
PTX form ation PTXNR- TTZ conjugation o f o f TTZ in TTZ
am ount CDI am ount efficiency PTXNR 1 mg o f (w/w)




30 64.98±2.37 1.0 0.10 95.24±1.40 0.8±0.02 0.2±0.02 4.0±0.53
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(a) Untreated
(b) P T X N R
(c) TTZ
(d) P T X N R -T T Z
Figure 7. Flow cytometry data for cell cycle analysis of (a) untreated,
(b) PTXNR, (c) TTZ, and (d) PTXNR-TTZ treated BT-474 cells after 24 h. The side 
scatter (SSC-A) versu s  forward scatter (FSC-A) gating is used to identify BT-474 cells as 
gated by E1. The forward scatter height (FSC-H) versus forward scatter area (FSC-A) 
density plots exclude doublet cells for accurate counting as shown by E2 gating. The 
plots showing FITC-A and PE-A represent live cells and their stained DNA, respectively, 
and gated for DNA analysis using Count versus PE-A plots. The Count versus PE-A plots 
were analyzed using the flow cytometry software to calculate the percentage arrests in 
G0/G1 (first sharp peak), S (flattened areas), and G2/M (second sharp peak) phases
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(a) Untreated
(b) P T X N R
AO2 PTXNR




P T X N R -T T Z
AO 3 TTZ
§  Gate: (G0JG1 in (E2 in (E1 in all))) and
9
Figure 8. Flow cytometry data for cell cycle analysis of (a) untreated,
(b) PTXNR, (c) TTZ, and (d) PTXNR-TTZ treated BT-474 cells after 48 h. The 
histogram of relative DNA content in Count versu s  PE-A plots shows a shift in peaks 
from G0/G1 to G2/M cells in PTXNR and PTXNR-TTZ treated cells compared to
untreated and TTZ treated cells
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(a) Untreated
(b) P T X N R
(c) TTZ
(d) P T X N R -T T Z
Figure 9. Flow cytometry data for cell cycle analysis of (a) untreated,
(b) PTXNR, (c) TTZ, and (d) PTXNR-TTZ treated BT-474 cells after 72h. By the end oi 
the incubation periods, >80% of cells were arrested in G2/M phases after PTXNR and 
PTXNR-TTZ treatments, while untreated and TTZ treated cells showed most cells in
G0/G1
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Figure 2. Hydrodynamic diameters of (a) Au-Fe3O4 NPs and (b) PLL coated Au-Fe3O4 
NPs in water as measured by dynamic light scattering (DLS). Three color codes indicate
three independent DLS measurements
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Figure 3. Magnetic relaxation (MR) characterization of (A and C) Au-Fe3O4 and (B and 
D) PLL-Au-Fe3O4 NPs. A) Spin-spin MR (T2 ms) of bare Au-Fe3O4 NPs was found to 
be 190 ms, whereas, it was B) 280 ms for PLL-Au-Fe3O4 NPs at a given concentration 
of 10 p,g/mL. This change in T2 MR value is the indicative of effective PLL coatings.
Concentration dependent (1-100 p,g/mL) T2 values were obtained in PBS (pH 7.2) 
and in 10% FBS for C) Au-Fe3O4 and D) PLL-Au-Fe3O4 NPs. These results indicated 
that with increase in concentration, the MR properties of these NPs increase and were 




Figure 4. The PLL-Au-Fe3O4 NPs uptake by (a) BT-474 and (b) MDA-MB-231 cells 
after 24 h incubation. Red circles indicate the endosomal vesicles that clearly retain the




Figure 5. MTT cell viability assay of BT-474 (filled circle, solid line) and MDA-MB-231 
(open circle, dotted line) cell viability after treatment with PLL-Au-Fe3O4 NPs under a
650 nm laser irradiation for 10 min
Table 1. The percentage encapsulation efficiency of PLL on Au-Fe3O4 NPs
mg Au-Fe3O4 mg of PLL in PLL-Au-Fe3O4 % PLL encapsulation efficiency
25 0.47 ±0.03 73 ± 3
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Figure 1. Fractionation of total lipid using column chromatography technique.
(a) Fractionation of total lipid in a handmade column. Silica gel (10-40 gm) was used as a
stationary phase. Chloroform and acetone were used as the mobile phase.
(b) The fractionated samples were collected separately by observing the color difference 
of individual lipid class. Eluent 1: fraction A, eluent 2: fraction B, eluent 3: fraction C, D,
E, F, G, eluent 4: fraction H, I, J, eluent 5: fraction K
Table 1. Chromatographic fractionation method of total lipid, A-Chloroform; B-
Acetone
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Eluent A (%) B (%) Volume
(ml)
1 100 0 10
2 90 10 10
3 75 25 10
4 40 60 10
5 0 100 10
Table 2. HPLC column preparation and conditions for detection and quantification of
MGDG
Column LiChrospher 100 Diol 25-4, 5 |im (Normal Phase 
Column)
Detector UV (240 nm)
Mobile phase Solution A: Chloroform, Solution B: Methanol/water 
(95:5 v/v)
Flow rate 1 ml/min





Table 3. HPLC elution method for detection and quantification of MGDG

















Figure 2. Calibration curve of BSA protein for quantification of protein in cell lysates for 
Western blot experiments. The calibration curve was obtained using a BCA protein 
quantification assay at 562 nm absorbance values
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1. WESTERN BLOT ANALYSIS
Western blot analysis was performed to verify the active caspase-3 expression of 
the standard and S y n e c h o c y s t i s  sp. extracted M G D G  treated BT-474 and MDA-MB-231 
cells. Approximately, 106 cells were seeded in 25 cm2 cell culture flasks and treated with 
100 ng/ml standard M G D G  and S y n e c h o c y s t i s  sp. extracted MGDG. After 72 h of 
incubation, the cells were trypsinized for total protein extraction using the 
radioimmunoprecipitation assay (RIPA) lysis buffer. The total protein was quantified 
using the BCA  calibration curve (SI Figure 2). For SDS-PAGE, the samples were 
prepared in 2X Laemmli loading buffer. The samples were denatured at 86oC for 2-3 min 
and loaded on the 16% Novex Tris-Glycine gels (Invitrogen). The gel was run in tris- 
glycine-SDS running buffer at constant 200 V  for 30-40 min. The separated protein bands 
on the gel were transferred to the nitrocellulose membrane using the Power Blotter 
(Invitrogen). The membrane blot was rinsed briefly with tris buffered saline including 1% 
tween-20 (TBST) for 2-3 min and was blocked with 3% bovine serum albumin (BSA) 
protein (Fisher Scientific) at room temperature for 5 h. After blocking, the membrane was 
incubated overnight in the primary antibody caspase-3 (ThermoFisher, Cat. 43-7800) and 
actin (ThermoFisher Cat. MA5-11869) at 4oC with the dilution factor of 1:500 and 
1:3000, respectively. The membrane was washed 3-5 times with TBST buffer for 5 min 
each followed by the incubation with anti-mouse horseradish peroxidase (HRP) 
conjugated secondary antibody (ThermoFisher Cat. A27025). The membrane blot was 
incubated in secondary the antibody for 1 h with the dilution factor of 1:10,000 followed 
by washing with TBST buffer. Finally, the blot was incubated in electro-
chemiluminescent reagent (Super Signal West Dura, ThermoFisher, and Cat. 34075) 




Treatment (Plant) (Syn. Sp.) 
1 0.8 0.55




No MGDG MGDG 
Treatment (Plant) (Syn. sp.)
Cleaved into 
active caspase-3
Figure 3. The Western blot assay confirming the reduced full-length caspase-3 protein 
expressions in BT-474 (left panel) and MDA-MB-231 (right panel) cell lines treated with 
MGDG extracted from S yn ech o cys tis  sp. compared to untreated and MGDG standard 
treated samples. Caspase-3 (32 kDa) is cleaved into lower molecular weight (17kDa) 
active caspase-3/7 that is shown by fluorescence microscopic images and flow cytometry
quantification in Figure 8 of the main texts
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Figure 4. Dead control cells induced by saponin was used in MTT assay
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Figure 5. Quantification of apoptosis assay. For quantification of apoptosis induction the 
BT-474 and MDA-MB-231 cells were treated with standard plant extract MGDG and 
S yn ech o cys tis  sp. extracted MGDG with 100 ng/ml dose. The cleaved caspase-3/7 
fluorescence intensity data were collected using flow cytometry. The scatter plots were 
generated for each treatment showing cleaved caspase-3/7 fluorescence data in x-axis and 
forward scattering (FSC) values in y-axis. A combined histogram was also generated for 
each treatment showing cleaved caspase-3//7 fluorescence intensity distribution in cell 
population. The green, blue and red lines represent the histogram data for untreated, 
MGDG standard treated and S yn ech o cys tis  sp. extracted MGDG treated samples. The 
scatter plots and combined histograms were generated for treatments in BT-474 cell line 
after (a) 48 h and (b) 72 h and in MDA-MB-231 cell line after (c) 48 h and (d) 72 h. In 
BT-474 cell line, the mean cleaved caspase-3/7 fluorescence intensity was shifted by 
1.7±0.04 (p<0.01) and 2.34±0.44 (p<0.01) fold in S yn ech o cys tis  sp. extracted MGDG 
treated cells compared to untreated control cells after 48 h and 72 h of treatment, 
respectively. In MDA-MB-231 cell line, the shift in mean fluorescence intensity was 
0.95±0.01 and 2.1±0.03 fold (p<0.01) in S yn ech o cys tis  sp. treated cells after 48 h and 72 
h, respectively compared to untreated control cells
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